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ABSTRACT 
RAGE is a multi-ligand pattern recognition receptor. RAGE can bind several damage 
associated molecular pattern proteins. RAGE- ligand interaction is pathophysiologically relevant 
to several major diseases including diabetes and certain cancers. RAGE inhibition has been 
reported to reduce morbidity in these disease states. However, to design better RAGE inhibitors 
it is necessary to understand the structural basis behind the RAGE-ligand interaction and 
currently this is not well understood.  This thesis focuses on understanding the interaction of 
RAGE with two of its ligands; AGEs and S100B.  
AGEs are highly heterogeneous and are formed as a result of non-enzymatic glycation. A 
panel of AGEs were characterized in terms of their side chain modifications, thermal stability, secondary 
structure, aggregation and surface charge. These glycation induced changes were then correlated to 
RAGE binding.    
Building on these results the role of AGE-RAGE interaction in pancreatic cancer cell 
proliferation and migration was determined. Ribose modified BSA induced ROS formation, 
which then triggered NF-κB upregulation via RAGE induced ROS signaling. Ribose BSA 
increased pancreatic cell proliferation and migration. Anti-RAGE antibodies and RAGE 
inhibitors prevented AGE induced cellular effects. The role of ribose modified BSA was also 
determined in macrophage activation and pro-inflammatory cytokine release. Rapid 
internalization was observed of the ribose-BSA and confocal imaging revealed the 
internalization of the AGE compound into the lysosomes which lead to the ROS production, NF-
κB activation and pro-inflammatory cytokine release in a RAGE independent signaling 
mechanism. 
Finally, the role of tryptophan residues of the V domain in domain stability and S100B 
binding was determined.  We have generated single, double and triple tryptophan mutants of the 
 iv 
V domain by site directed mutagenesis. The effect of Trp residues in the domain stability could 
not elucidated as no change was observed in the secondary structure of the mutants when 
compared to the wild type suggesting the plasticity of the V-domain. The fluorescence emission 
and life time properties of each Trp residue was determined. Our binding assays of the Trp  
Ala mutants indicate tighter binding of the S100B to the mutants. The S100-RAGE peptide 
structures suggest multi modal interaction of S100B-RAGE interaction. 
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CHAPTER 1: INTRODUCTION 
Receptor for advanced glycation end products 
The Receptor for Advanced Glycation End Products (RAGE) is a multi-ligand cell 
surface receptor of the immunoglobulin super family and was first characterized as the receptor 
for the Advanced Glycation End Products (AGEs)1-3. The RAGE gene is localized on 
chromosome 6 near the HLA locus in humans and mice and is located in the vicinity of MHC III 
complex 4.   RAGE is composed of three immunoglobulin-like regions extracellularly: one “V-
type” or “Variable-type” and two “C-type” or “Constant-type” domains, a short 21- amino acid 
residue transmembrane and 43- amino acid residue cytoplasmic tail 1-3. The 320-amino acid 
residue extracellular domain is crucial for ligand binding and the cytoplasmic tail is critical for 
intracellular signaling. Alternative splicing of mRNA of RAGE leads to additional RAGE 
isoforms including N-truncated forms and C-truncated forms 4-6. RAGE isoforms can be loosely 
classified into three major isoforms; full-length RAGE, secretory RAGE (sRAGE) and dominant 
negative RAGE (DNRAGE)7 (Figure 1.1). Full length RAGE is the most well studied isoform 
and contains all the domains for ligand binding and signaling. The soluble form of RAGE or 
secretory RAGE or sRAGE contains the V domain and the C1 and C2 domains but lacks the 
transmembrane region and the cytoplasmic tail. Due to the absence of the transmembrane and the 
cytoplasmic tail sRAGE is released into the extracellular space, where it can interact with the 
RAGE ligands prior to full length RAGE. As a result, sRAGE  can antagonize full length RAGE 
signaling in vitro and in vivo 8.  sRAGE can be derived from mRNA splicing as described earlier 
and can also be derived from the full length RAGE by protein cleavage9.  The DNRAGE consists 
of all the extracellular domains and the transmembrane region however, it lacks the cytoplasmic 
tail. This is the least understood of the RAGE isoforms. Presumably, like sRAGE, DNRAGE 
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competes with the full length RAGE for ligands and functions as a decoy receptor due to the lack 
of the cytoplasmic tail. Majority of our understanding of the DNRAGE has evolved from 
transfection studies, the over expression of DNRAGE resulted in the decrease of full length 
RAGE activation 10-12. The  expression of DNRAGE has been described in the brain and is 
similar to the expression levels of full length RAGE 13. Various other splice variants of RAGE 
have also been identified. For example, N truncated form of RAGE lacks the N-terminal signal 
sequence and the first V-like extracellular domain (Figure 1.1). This is incapable of binding to 
ligands such as the AGEs 14, 15.    
 
 
 
 
 
 
Figure 1.1. Isoforms of the RAGE receptor.  
Initially, RAGE was discovered as a receptor of AGEs, however, various other ligands 
including the calcium binding S100/calgranulins that accumulate extracellularly at the sites of 
chronic inflammation 15, 16 and the proinflammatory DNA binding HMGB1(amphoterin) which 
is released from necrotic cells 17-20 have also been identified to bind to RAGE. Studies on the 
structural basis of RAGE-ligand interaction revealed that the receptor recognizes specific three 
dimensional structures such as fibrils and β-sheets, rather than any specific amino acid sequence 
21, 22. In Alzheimer’s disease RAGE binds amyloid β-peptide 11, 12 and in systemic amyloidosis 
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RAGE binds to amyloid A 23. Besides these ligands RAGE interacts with surface molecules such 
prions 24 and leukocyte integrins25. Hence, RAGE can be characterized as a multi ligand receptor  
as  it binds to a broad range of unrelated ligands  that accumulate in tissues during inflammation, 
host response, aging and chronic degenerative diseases. Therefore, RAGE is considered as a 
pattern recognition receptor (PRR) and more specifically it recognizes damaged associated 
molecular patterns (PAMPs).  
RAGE-mediated NF- κB signaling 
RAGE-ligand interactions result in activation of proinflammatory signaling pathways. 
RAGE can trigger intra-cellular signaling by both NF-κB dependent and NF-κB independent 
pathways. Classically, RAGE triggered pro-inflammatory signaling has been described by the 
activation of NF-κB 26. RAGE-mediated NF-κB activation has been reported to have a prolonged 
time course suggesting that RAGE can inhibit endogenous auto-regulatory feedback inhibition 
loops 26 . NF-κB activation can upregulate RAGE expression, further activating NF-κB and 
ensuring the amplification and maintenance of the signal 27.  
 
 
 
 
 
 
 
 
 4 
 
 
 
 
 
 
 
 
 
Figure 1.2. RAGE dependent NF-κB signaling.  
The initial step of RAGE mediated NF-κB activation is the degradation of IκBα- NF-κB complex 
(Solid arrow). The activated NF-κB translocates into the nucleus and binds to specific DNA 
sequence. This triggers the expression of pro-inflammatory cytokines, and also the upregulation 
of RAGE. RAGE activation can also trigger the upregulation of NF-κB (Dashed arrow). This is 
critical to inhibit the negative feedback mechanisms triggered by IκBα production. 
RAGE induced activation of NF-κB has been reported to activate various cellular 
signaling cascades 28. Table 1.1 summarizes the different cellular signaling cascades triggered by 
NF- κB. The diverse RAGE signaling is the result of its multi-ligand nature. RAGE signaling is 
also dependent on the cell type.  
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Table 1.1. RAGE induced signaling pathways. 
Cell Type Signaling 
Cascade 
Ligand Reference 
Osteoblasts ERK1/2 AGEs 29 
Myoblasts ERK1/2 S100B  30 
Tubular epithelial 
myofibroblasts 
ERK1/2 AGEs 31 
Smooth muscle cells ERK1/2 AGEs 32 
Monocytes ERK 1/2 AGEs/S100B 33 
Monocytes (Acute 
monocytic leukemia)  
p38 and 
p44/p42 
AGEs 34 
Myoblasts p38 HMGB1 35 
C6 glioma cells p44/p42, p38 
and SAP/JNK 
HMGB1 36 
Neuroblastoma cells JAK/STAT HMGB1 37 
Kidney fibroblasts JAK/STAT AGEs 38 
RAGE expression and physiological function 
RAGE expression depends on the cell type and developmental stage and the expression 
can be both constitutive and induced 17, 39. RAGE is constitutively expressed during embryonic 
development and the expression is down regulated in adult life with the exceptions of lung, skin 
and thyroid 40 41. RAGE expression is expressed at very low levels under physiological 
conditions in most of the cells including endothelial cells, smooth muscle cells, 
monocytes/macrophages, neuronal cells and fibroblasts; however, RAGE expression is induced 
in these cells either on ligand binding or on the activation of transcription factors regulating the 
transcription of RAGE in disease states (reviewed in28).  Transcription of RAGE is under the 
control of various transcription factors including NF-κB, AP-2, SP-1 and NF-IL6 27.  
Physiological role of RAGE in development is poorly understood. RAGE knock out mice 
studies reveal that the RAGE is not essential to life and its deletion does not have any lethal 
effects 42.  RAGE deletion lead to hyper activity and increased sensitivity to auditory stimulus 
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when compared to wild type mice, however, no change was observed in spatial memory or 
anxiety when compared to the wild type 42. Studies have indicated the role of RAGE in neurite 
growth and differentiation. RAGE-HMGB1 or/and RAGE-S100B interactions have been 
reported to play an important role in the promotion of neurite outgrowth and neuronal 
differentiation. HMGB-1 on binding to RAGE regulates cell survival and cell migration17, 37, 43.  
The calcium binding S100B is expressed and released by astrocytes into the CNS. The released 
S100B binds to RAGE in the CNS and contributes to neuronal survival and neurite outgrowth by 
the activation of Cdc42/Rac-dependent signaling triggered by Ras/MAPK dependent NF-κB 
nuclear translocation44. RAGE knockout studies also confirm the role of RAGE in neurite 
outgrowth37.  RAGE also plays important role in pathophysiological processes in the lung 
including modulation of cell spreading, adhesion to ECM components, proliferation, and 
migration 45.        
RAGE and disease 
RAGE plays an important role in the pathophysiology of various diseases. The role of 
RAGE has been implicated in inflammatory conditions 46, 47, diabetic complications 48, 49, 
neurogenerative diseases 50, 51, vascular disease 52, 53, and multiple cancers  54. As described 
earlier, RAGE binds to a wide range of ligands and can trigger diverse signaling in various 
disease states. Most of the RAGE ligands can be characterized as damaged associated molecular 
patterns (DAMPs) which elicit a pro-inflammatory response. The role of RAGE has been 
described in innate immunity at both the early and late stages 25, 55, 56. The blockage of RAGE by 
anti-RAGE antibody or by soluble RAGE (sRAGE) in cells resulted in the suppression of 
experimentally induced autoimmune enphalomyelitis (EAE) in mice 56. In addition, the role of 
RAGE was also established in delayed-type hypersensitivity (DTH) mice model by treating the 
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mice with sRAGE 15. Due to the ability of RAGE to sustain cellular activation, it has the 
potential to function as a master switch to convert a transient pro-inflammatory response, evoked 
by an inflammatory stimulus into sustained cellular dysfunction 22, 26. RAGE biology and 
signaling depends on the ligands which accumulate and interact with RAGE, the signaling also 
depends on the cell type. The role of RAGE is most well described in diabetes and its 
complications. Over expression of RAGE in diabetic mice lead to increase in diabetic 
nephropathy and neuropathy, and a decrease was observed in the RAGE-/- mice. Treatment with 
sRAGE and anti-RAGE antibodies also decreased diabetic neuropathy and nephropathy 57-59. 
Activation of RAGE and AGE-RAGE interaction has also been described in chronic vascular 
dysfunction in diabetic vasculopathy and atherosclerosis 60. In diabetic complications, in addition 
to the long known role of AGE-RAGE interaction 61,  the role of other RAGE ligands have also 
been recently recognized to contribute to its pathology. Increased serum levels of S100A8/A9 in 
type 1 diabetic patients provided the first evidence 62, increased levels of S100A12 were 
observed in type 2 diabetes 63 and increased HMGB1levels were associated with the coronary 
heart disease in type 2 diabetes 64. The role of HMGB1 has been described in the endothelial 
dysfunction in diabetes 65.  This suggests the complex RAGE signaling in diabetic complications. 
In Alzheimer’s disease RAGE plays an important role in the transportation of 
pathophysiologically relevant concentrations of amyloid-β peptide into the CNS 66. Treatment of 
transgenic rodent models with sRAGE or anti-RAGE antibodies suppressed RAGE associated 
abnormalities 67, 68 and reduced the amyloid-β peptide transport across the blood-brain barrier66. 
RAGE blocker, FPS-ZM1 also effectively controlled the progression of Aβ-mediated brain 
disorder and may have the potential to be a disease-modifying agent for Alzheimer’s disease 69.  
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RAGE also plays an important role in the disease progression of multiple cancers. The 
role of AGE-RAGE interaction in cancer cell growth was first described in renal carcinoma 
cells70. The role of RAGE and its ligands including AGEs, HMGB1 and S100 proteins have been 
implicated in multiple cancers such as colon cancer 71, prostate cancer 72, oral squamous 
carcinoma 73,  breast cancer 74, hepatocellular carcinoma75,  gastric cancer76, pancreatic cancer 77 
and others 54. Molecular mechanism concerning the activation and function of RAGE during 
malignant progression and neoplastic transformation is scarce, however various in vitro studies 
and in vivo reports in mouse xenograft models support a direct link of RAGE activation with 
survival, proliferation, migration and invasion of tumor cells78 79. Therapeutic inhibition of 
RAGE by using anti-RAGE antibodies have been reported to inhibit RAGE mediated cancer 
progression in in vivo mice xenograft models. For example, anti-RAGE antibodies reduced 
growth of RAGE overexpressing tumors in the mice xenograft model of melanoma 80 81. 
Interestingly treatment with anti-RAGE antibody also significantly enhanced the efficacy of 
dacarbazine resulting in reducing the growth rate in RAGE overexpressing tumors cells 80.  
Recently, a RAGE antagonistic peptide was designed and used to block RAGE-S100P 
interaction in pancreatic cancer and a reduction in tumor growth was observed 81. These results 
suggest RAGE as an important therapeutic target in the treatment of various cancers.  
RAGE inhibition is an important strategy for the treatment due to its role in various 
disease states. However, due to the multi ligand nature of RAGE and its complex signaling it is 
highly difficult to design and develop RAGE inhibitors. The structural basis behind the RAGE-
ligand interaction is still not clearly understood. RAGE has three extracellular domains and the 
ligands can bind to any of the three domains. Even though we know on which domain of RAGE 
some of the ligands bind, the exact binding regions on the receptor is not known.  
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The overall goal of my Ph.D. is to obtain a better understanding of the role of the 
interaction of RAGE-ligand interaction which would provide the basis for the development of  
efficient RAGE inhibitors. More specifically, the interaction of RAGE with AGE compounds 
and S100B is addressed in this thesis.  
The first three chapters of the thesis focus on AGE compounds and the fourth chapter on 
S100B. The first chapter focuses on understanding the glycation induced biochemical and 
biophysical changes on serum albumin and their interaction with RAGE. The second chapter 
studies the role of AGE-RAGE interaction in pancreatic cancer cell proliferation. The 
inflammatory role of AGE compounds, more specifically the role of AGE compounds in 
macrophage activation is described in chapter in three. The final chapter focuses on 
understanding the structural basis of RAGE-S100B interaction. The role of tryptophan residues 
in the V domain of RAGE has been determined in domain stability and S100B binding.   
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CHAPTER 2: GLYCATION, ADVANCED GLYCATION END PRODUCTS (AGES) 
AND THEIR INTERACTION WITH RECEPTOR FOR ADVANCED GLYCATION 
END PRODUCTS (RAGE) 
Introduction 
Non-Enzymatic glycation and AGE compound formation 
The non-enzymatic glycation reaction (Maillard reaction) between nucleophilic groups in 
biomolecules and reactive carbonyl groups leads to complex modification of proteins and other 
biomolecules 82 (Figure 2.1). Among the physiologically occurring reactive glycation reagents 
are the reducing carbohydrates, in particular glucose and ribose and their phosphorylated 
derivatives, but also short chain aldehydes (oxo- and hydroxy aldehydes) such as glyceraldehyde, 
methyglyoxal and glycolaldehyde, which are formed as intermediates during metabolic reactions 
and lipid peroxidation 83. The initial step of protein glycation (Schiff base formation) is 
reversible but can slowly proceed to the formation of more stable Amadori products and through 
subsequent rearrangements, elimination, fragmentation and oxidation reactions to chemically 
stable products. These so called advanced glycation end products (AGE) are highly diverse and 
introduce novel side chain modifications including chromophores, fluorophores and intra- and 
intermolecular crosslinks into proteins 84. A single glycation reagent can lead to multiple 
chemically distinct modifications at different amino acid side chains within a single protein 
molecule 85. Glycation occurs most frequently at the N-terminal amino group and the side chains 
of arginine and lysine residues. Glycation may also occur on cysteine, histidine, and tryptophan 
side chains 86. The covalent chemical modification of serum proteins is likely to alter their 
normal physiological function. At least two dozen AGE modification have been identified in 
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biological samples. When multiple glycation reagents are present very complex and 
heterogeneous mixtures result (Figure 2.2).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1. Possible mechanism for the formation of AGE compounds.  
(The Figure is reproduced from 87).  
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Figure 2.2. The chemical structures of common AGE modifications.  
(The Figure 2.2 is reproduced from 87. FFI: 2-(2-furoyl)-4(5)-furanyl-1H-imidazole; AFGP: 1-
alkyl-2-formyl-3,4-diglycosyl pyrrole; CML: N-ε-carboxy-methyl-lysine; CEL: N-ε-carboxy-
ethyl-lysine; GOLD: glyoxal-lysine dimer; MOLD: methyl-glyoxal-lysine dimer).  
AGE compounds and disease 
Increased glycation of serum proteins is well documented in diabetic patients 88-90, but 
also be found in patients with other conditions such as cardio-vascular disease 88-90, arthritis 91, 92, 
kidney failure 93, or liver cirrhosis 94. Advanced glycation end products have been also been 
observed in various tissues under pathological conditions such as atherosclerotic plaques 95, sites 
of inflammation or neurodegeneration 96 and cancer tumors 97. They also accumulate in proteins 
with long half-life such as collagen of the skin and cartilage 98 or crystalline in the eye-lens 99. It 
has been hypothesized that diabetic complications are causatively linked to the formation of 
advanced glycation end products 100. For example, diabetic patients show increased 
concentrations of glycated and AGE-modified hemoglobin (HbA1c) compared to 
normoglycemic individuals. HbA1c levels are clinically used as reliable reporter on long-term 
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blood glucose levels 101 and are positively correlated with diabetic complications such as 
microvascular damage, nephropathy and retinopathy 102-105. In fact, Soluble AGE compounds in 
the circulation and extracellular fluids have been demonstrated to be useful as prognostic and 
diagnostic biomarkers for diabetes related complications 106. It is important to note that protein 
glycation in diabetic patients is not limited to modification by glucose but also involves other 
reactive aldehydic intermediates (described earlier), which are chemically much more reactive 
than glucose and are rapidly bound by proteins 107, 108. Metabolic intermediates such as glyoxal, 
methylglyoxal and 3-deoxyglucosone are formed as metabolic by-products and are formed at an 
accelerated rate in diabetic patients 109-111. They accumulate at elevated rates in tissues under 
oxidative stress, at sites of inflammation, or under conditions involving reduced renal function 
109, 112-114.  
An important question is whether AGE compounds are causatively involved in disease 
development and progression, or whether AGE compounds are simply by-products of metabolic 
reactions without significant biological activity. There seems to be a consensus that AGE 
compounds are biologically active and promote various cellular processes including 
inflammation 115, tumor growth 116 and neurodegeneration 51. However, considering the large 
number of possible AGE modifications in many different proteins it becomes important to 
investigate whether all AGE modifications are equally significant form a pathophysiological 
standpoint. It might be that certain glycation reactions yield AGE compounds with toxic 
properties (sometimes called TAGE, toxic-AGE), while other may be benign 117. The present 
research focuses on soluble AGE compounds that may exert their biological activities through 
activation of AGE-specific cell surface receptors. 
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AGE-specific cell surface receptors 
We chose serum albumin as a model protein for glycation because serum albumin 
undergoes significant glycation in diabetic patients, has been studied as a substrate for glycation 
118, 119 and because AGE-BSA is frequently used in biomedical research studies as a 
representative example for AGE compounds. Bovine and human serum albumins are highly 
homologous and both forms of protein are expected to respond identically to glycation.  
AGE products in the circulation or extracellular space can interact with two types of cell 
surface receptors 120. Clearance and scavenger receptors are predominantly involved in AGE 
capture, removal and degradation 121. This group of receptors includes type I (SR-AI) and type II 
(SCARA2) macrophage scavenger receptors 122, CD-36 123, FEEL-1 and -2 124, scavenger 
receptor proteins SR-BI and SR-BII 125 and the lectin-like oxidized low-density lipoprotein 
receptor 1 (Lox-1) 126. The other type of AGE-receptors initiates specific cellular signaling 
events in response to AGE exposure. The receptor for advanced glycation endproducts (RAGE) 
is the best characterized AGE-signaling receptor and generally considered to be the medically 
most relevant AGE receptor 127. The cellular signaling pathways activated by AGE binding to 
RAGE have been studied in various cell types and generally lead to the formation of oxidative 
stress and reactive oxygen species that can promote AGE formation, activation of the Nf-κB 
transcription factor, induction of pro-inflammatory gene expression and release of inflammatory 
cytokines and chemokines 128, 129.  
The other cell surface receptor with AGE signaling potential is the “AGE-receptor 
complex” and consists of three proteins AGE-R1 (OST-48), AGE-R2 (80-K-H) and AGE-R3. 
AGE-R3 is also known as galectin-3 (LGALS3) and is responsible for AGE binding 130. AGE 
binding to galectin-3 is less well studied, but there are several reports that suggest that the AGE-
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receptor complex and galectin-3 are indeed involved in diabetes related complications and 
mediate biological effects of AGE in the eye 131, vascular endothelium 132, kidney 133 and 
liver 134. 
All AGE binding receptors are pattern recognition receptors and recognize any molecule 
that displays a particular molecular signature. The molecular pattern in AGE compounds that is 
recognized by RAGE or galectin-3 is currently not known. However, it would be important to 
distinguish AGE compounds that activate RAGE from those that are not able to initiate RAGE 
signaling. This would allow to develop diagnostic tests for AGE compounds with detrimental 
health effects and to design novel drugs that could specifically target the AGE-RAGE axis in 
important pathologies. 
Serum albumin, drug binding and glycation 
Serum albumin is the major drug binding protein in plasma and greatly influences the 
pharmacokinetics of drugs that bind to it. Consequently, changes in the capacity of serum 
albumin to bind drug molecules can have profound effects on the free drug concentration and can 
consequently affect both toxicity and therapeutic efficacy. The binding of many drug molecules 
to whole plasma, isolated plasma proteins and in particular serum albumin has been studied in 
great detail 135-137.  Biophysical studies investigating drug binding to serum albumin use both the 
human and the closely related bovine protein as a valid substitute 138, 139. These studies have 
identified two major drug binding sites (Sudlow I and II) and at least four additional secondary 
drug binding sites in serum albumin 140-142. Surprisingly little is known about the effects of 
chemical modification by glycation of serum albumin on its drug binding properties. 
Diabetic patients have notoriously elevated levels of glycated blood proteins. In this 
patient group levels of albumin glycation average ~ 25% of total serum albumin and can exceed 
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glycation levels of 40 or 50% in individual cases 88-90. These patients often show additional co-
morbidities and receive multiple medications with different plasma protein binding properties. 
Therefore, a better understanding of albumin glycation and its effects on drug binding is 
clinically relevant in patients with increased glycation of serum proteins. 
The binding of many drug molecules to whole plasma, isolated plasma proteins and in 
particular serum albumin has been studied in great detail 137, 143, 144. Biophysical studies 
investigating drug binding to serum albumin use both the human and the closely related bovine 
protein as a valid substitute 139. These studies have identified two major drug binding sites 
(Sudlow I and II) and at least four additional secondary drug binding sites in serum albumin 140 
145. 
The binding of several drug molecules to glycated serum albumin has been investigated 
146-148 149, but no consensus mechanism that would allow prediction of changes in binding affinity 
for particular drugs has emerged yet. Our studies combine structural and thermodynamic 
experiments to gain a better understanding of the relationship between glycation induced 
structural changes in albumin and its drug binding properties. 
We chose diclofenac as a representative example of small acid drug molecules with high 
plasma protein binding. Diclofenac (Figure 2.3) binds to two sites on serum albumin with Ka = 
105 to 104 M-1 affinities, depending on the methodology used to measure binding affinities and 
the composition of the buffer system used in the experiments 150-153.  Diclofenac can interact via 
ionic and hydrophobic interactions with drug binding sites on proteins 154, 155. Samples modified 
with low concentrations of glycation reagents were used for the diclofenac binding study as the 
glycation conditions are very close to physiological conditions.  
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Figure 2.3. Chemical structure of the non-steroidal anti-inflammatory drug diclofenac. 
Problems associated with AGE compound research 
A fundamental problem in AGE related research is the complexity and heterogenicity of 
AGE samples, which make the analytical characterization very difficult. Biomedical researchers 
use AGE-compounds derived under a variety of conditions, modified with different glycation 
reagents and generated with very high concentrations of glycation reagent, which lead to 
complete modification of reactive amino acids and likely to denaturation of the protein. For 
example, AGE-compounds have been generated using highly reactive aldehydes, such as 
methylglyoxal and glyceraldehyde at 100 mM, or glucose and ribose at 1 M concentration 156, 157. 
Whether the resulting AGE compounds are good models of physiological relevant AGE has not 
been shown and results from different studies are difficult to compare when AGE compounds 
have not been characterized.  
With this in mind, a panel of AGE-modified serum albumin samples was generated under 
conditions that used lower concentrations of glycation reagents than commonly reported in AGE 
related studies. These compounds are referred to as “moderately glycated”. To achieve moderate 
glycation, near physiological concentrations of glycation reagents were used. For example, we 
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used a low glucose concentration of 20 mM, a concentration that can be observed in diabetic 
patients. Indeed, blood glucose concentrations as high as 100 mM have been reported in certain 
diabetic patients 158. The true physiological concentrations of many of the reactive aldehydes are 
difficult to estimate because of their high reactivity 159. Also, blood concentrations of glycation 
reagents are not reflective of localized concentration within tissues or individual cells, which can 
be much higher. The reagent concentrations used by us for the glycation reactions (mostly 1 and 
5 mM) were significantly lower than the reagent concentrations used in many previously 
published studies.  
The goal of this study was to determine how each of these different glycation reagents 
affected the physical and chemical properties of the protein, and to correlate these changes in the 
protein to 1) RAGE interaction and cancer cell proliferation 2) to diclofenac binding.   
This study was initiated to characterize glycation induced biophysical and biochemical 
changes in serum albumin and to correlate these changes to the degree of glycation in general 
and the different glycation reagents in particular. The direct binding of the panel of AGE 
modified serum albumin samples to two known AGE receptor proteins: the receptor for 
advanced glycation endproducts (RAGE) and galectin-3 (AGE receptor complex protein 3) was 
measured in vitro. Finally, the role of AGE-compounds derived from different glycation reagents 
in cancer cell proliferation was determined in a melanoma cell line called WM115. We finally 
investigate with spectroscopic and calorimetric methods, how glycation of serum albumin 
modifies its interactions with diclofenac.  
Materials and Methods 
Reagents were of molecular biology or ACS purity grade and purchased through Fischer 
Scientific or VWR. Bovine serum albumin (BSA), fraction V, was purchased from Amresco. 
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Antibodies were purchased from R&D Systems. An assay kit for the quantitative determination 
of fructosamine modified serum proteins was purchased from Diazyme (Poway, CA). Molecular 
biology reagents and enzymes were purchased from New England Biolabs (Ipswich, MA), 
OriGene (Rockville, MD) and Fermentas (ThermoFisher). Chromatography media for protein 
purification were purchased from GE Healthcare. Reagents and media for cell culture were from 
Life Technologies Cooperation (Invitrogen). 
Preparation of glycated serum albumin 
BSA (fraction V, was purchased from Amresco) was glycated following the procedure 
published by Schmitt et al. 160-162. The protein was dissolved 500 mM sodium phosphate buffer, 
1mM EDTA and 1mM sodium azide, pH 8 at a final concentration of 20-40 mg/ml. Glycation 
agents were added to the final concentrations indicated in Table 2.1and sterile filtered using a 0.2 
micron syringe filter. The solutions were sealed in sterile (autoclaved) glass vials and incubated 
at 37 C for 21 days. The CML modified serum albumin was generated following the procedure 
described by Ahmed et al. 163. The Schiff base was formed using 2.3mM and 23mM in the low 
and high modified CML samples respectively and 55mM of sodium cyanoborohydride was used 
to reduce the Schiff base formed between lysine and glyoxylic acid. The samples were incubated 
at 37 C for 24 hrs. After the incubation periods the samples were dialyzed twice against 200 
volumes of PBS (8mM KH2PO4, 42mM Na2HPO4 and 150mM NaCl) at 4 C. Protein 
concentration of the samples were measured by Pierce-BCA protein assay calibrated with 
commercial BSA standards. The samples were then aliquoted into 1.5 mL freezing tubes and 
were stored at -80C. A single batch of bovine serum albumin (biotechnology grade) was used 
for all glycation experiments. As an additional control for non-glycated BSA, we used ethanol 
precipitated BSA (fraction V), which showed a single Tm in thermal unfolding studies, typical 
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for non-fatty acid containing albumin (DF-BSA). Both BSA preparations were purchased from 
Amresco, USA. BSA incubated at 37 °C for 21 days was used as the third control.  
 
 
Figure 2.4. Chemical structures of the glycation reagents used to modify bovine serum albumin 
for this study.  
Rib: ribose; Glc glucose; Dia diacetyl (2, 3-butanedione); Ace acetoin (3-hydroxybutanone); Gla 
glycolaldehyde (2-hydroxyacetaldehyde); Gly glyceraldehyde (2, 3-dihydroxypropanal); GA 
glyoxylic acid (oxoethanoic acid); MG methylglyoxal (2-oxopropanal). 
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Table 2.1. Concentrations of the different glycation reagents used. 
Sample Name Glycation 
Reagent 
Concentration 
(mM) 
BSA-fresh none n/a 
Glc-L BSA glucose 20  
Glc-H BSA glucose 200 
Glc-vH BSA glucose 500 
GA-L BSA glyoxylic acid 1 
GA-H BSA glyoxylic acid 10 
Ace-L BSA acetoin 1 
Ace-H BSA acetoin 5 
Dia-L BSA diacetyl 1 
Dia-H BSA diacetyl 5 
Gly-L BSA glyceraldehyde 1 
Gly-H BSA glyceraldehyde 5 
Gla-L BSA glycolaldehyde 1 
Gla-H BSA glycolaldehyde 5 
MG-L BSA methylglyoxal 1 
MG-H BSA methylglyoxal 5 
Rib-L BSA ribose 20 
Rib-H BSA ribose 200 
Rib-vH BSA ribose 500 
CML-L BSA glyoxylic acid 
NaBH3CN 
2.3 
55 
CML-H BSA glyoxylic acid 
NaBH3CN 
23 
55  
UV/Vis and fluorescence spectroscopy  
UV/Vis spectra were recorded on an Agilent 8543 diode array spectrophotometer using a 
quartz cuvette with a path length of 10 mm. The protein samples were normalized based on their 
concentrations determined by the BCA assay. The glycated serum samples were diluted in the 
PBS (8mM KH2PO4, 42mM Na2HPO4 and 150mM NaCl) buffer. Fluorescence emission spectra 
were recorded on a Horiba Jobin Yvon FluoroMax-4P spectrofluorometer. A quartz cuvette with 
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600 µL volume and a reduced pathlength of 5 mm was used for all fluorescence experiments and 
the slit size of 3nm was used for the excitation and emission filters.  
Amino acid analysis 
Amino acid analyses were performed by the Molecular Structure Facility at the 
University of California, Davis. Proteins were hydrolyzed in liquid phase with 6 N HCl/1% 
phenol at 110 °C for 24 hrs. Samples were analyzed on a Hitachi L8800 amino acid analyzer 
using a sodium citrate buffer system and post-column ninhydrin modification. Norleucin was 
used as internal standard. 
Lysine side chain modification 
Modified lysine side chain modifications were determined using fluorescamine (Acros 
Organics), which forms a highly fluorescent reaction product with amino groups 164, 165. 
Commercial BSA standards (Pierce Thermo Scientific) (0-1000 mg/ml in PBS) were used to 
obtain the standard curve. The assay was performed in a 96 well plate. 50 µl of 10.8 mM of 
fluorescamine dissolved in acetone was added to each well and 150 µl of the standard/sample 
were added. The samples were incubated for a minute and the fluorescence was measured using 
a SpectroMaxM5 plate reader from Molecular Devices with an excitation wavelength set to 390 
nm and emission recorded at 490 nm.  
Arginine side chain modification  
Arginine side chain modifications were monitored by determining free arginine side 
chains with 9,10-phenanthrenequinone (PAQ) 166 which forms a strongly fluorescent compound 
167. The fluorescence was measured in a SpectroMax M5 plate reader (Molecular Devices) using 
a 96 well plate. Briefly, 50 μl protein sample (1 mg/ml) was mixed with 25 µl of 2 M NaOH and 
150 μl of 9,10-phenanthrenequinone (150 μM in EtOH). The mixture was incubated at 60 °C for 
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3 h. 100 μl of the mixture was then mixed with 100 μl of 1.2 N hydrochloric acid and incubated 
at room temperature in the dark for fluorophore formation for 1 h. Fluorescence of modified 
arginine side chains was measured with an excitation wavelength of 312 nm and an emission 
wavelength 395nm.   
Fructosamine content estimation 
Fructosamine content was determined using the “Glycated Serum Protein Assay” kit 
from Diazyme, Poway, California. This assay uses Diazyme's specific fructosaminase™, a 
microorganism originated amadoriase. In the first step the AGE modified protein is digested with 
proteinase K into low molecular weight glycated peptides. In the second, fructosaminase 
degrades the Amadori products catalytically and generates glucosone and hydrogen peroxide. 
The hydrogen peroxide is quantified colorimetrically by a Trinder end-point reaction by 
measuring the absorbance at 546nm. Briefly, 200uL of reagent 1 was added in a 96 well plate, 
10ul of the AGE compound (1mg/mL final concentration), calibrator or control was added and 
the blank absorbance was recorded at 546nm. Five different dilutions of the calibrator were used. 
The plate was then incubated at 37 °C for 5 min. 50ul of reagent 2 was added and the increase in 
absorbance was recorded at 546nm after incubation at 37 °C for 5 min. The calibration curve was 
plotted using the calibrator absorbance values and the fructosamine content was obtained for the 
AGE samples.       
Carboxymethyl lysine estimation 
The carboxymethyl lysine (CML) content in the AGE samples was estimated by ELISA 
using an anti-CML antibody (R&D Systems, IgG2B MAB 3247) and an alkaline phosphatase 
labeled secondary antibody. 100 µL of 100 µg/mL protein was used for the assay. The samples 
were coated on a high binding capacity ELISA plate overnight at room temperature. The samples 
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were then blocked with 3% BSA at 37 ºC for 2 hours. The anti-CML antibody was added for one 
hour and then washed with PBS/0.05% tween for 5 times. The secondary antibody was added for 
an hour and then washed with PBS/0.05% tween for 5 times. The alkaline phosphatase substrate 
p-nitrophenol phosphate (1mg/mL) was added and was incubated at 37 ºC. The absorbance was 
measured in an ELX800 multiwell plate reader (BioTek, Winooski, VT) with a 405 nm filter at 
different time points.      
Carbonyl content estimation 
The carbonyl content of glycated serum albumin was measured using the 2,4-
dinitrophenylhydrazine method 168. Briefly, 0.2 mL of 4 to 5 mg/ml protein were mixed with 0.8 
mL of 0.1% dinitrophenylhydrazine in 2.5 M hydrochloric acid and incubated at room 
temperature for 1.5 hours. Then, 1 mL of 20 % trichloroacetic acid was used to precipitate the 
protein followed by centrifugation. The pellet was resuspended and washed with 10 % 
trichloroacetic acid. The pellet was then washed twice with ethyl acetate: ethanol (1: 1). The 
final pellet was resuspended in 0.5 mL of 6 M guanidium chloride and the absorbance was 
measure at 370 nm. To calculate the carbonyl content of the AGE modified proteins an 
extinction coefficient of 22 mM-1 cm-1 for dinitrophenylhydrazone was used. 
Differential scanning calorimetry 
Thermal stability of glycated BSA was monitored by differential scanning calorimetry 
(DSC) using a  Nano DSC (TA Instruments, New Castle, DE) with 0.3 ml micro-volume cell. 
The protein was diluted in PBS to a final concentration of 70 µM. The samples were degassed 
for 10 minutes at 4 ºC. The sample was loaded into the sample cell and PBS was loaded into the 
reference cell. Temperature scans were carried out from 10 ºC to 100 ºC at a heating rate of 1 
ºC/min under 3 atm. PBS was loaded into both the sample and reference cell to obtain the 
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baseline. DSC curves were analyzed using the Nano Analyze Software v2.1.9 provided by the 
instrument manufacturer. Baseline curve was subtracted and two state scaled model was used to 
obtain the Tm and enthalpy of unfolding.  
For the diclofenac binding studies, the final concentrations of protein and diclofenac were 
45 µM and 1 mM, respectively. The protein was premixed with the drug in PBS and was 
incubated for 2 min at room temperature and 300 µl of this mixture was loaded into the sample 
cell. These concentrations were chosen based on the observed signal strength (changes in heat 
capacity) and to allow >90 % saturation of diclofenac binding sites on most of the glycated forms 
of serum albumin. All samples were degassed thoroughly under vacuum for 10 minutes at 4°C. 
A scan rate of 1ºC/min was used and the scans were carried out from 10°C to 95°C. The Tm and 
enthalpy of unfolding ΔH of the protein were estimated using the Nano Analyze Software v2.3.6 
provided by the instrument manufacturer as described before. 
Circular dichroism spectroscopy 
Circular dichroism spectra were recorded on a Jasco J815 spectropolarimeter equipped 
with a PFD-425S Peltier cell holder. A constant concentration of 1.3 µM (300 µl) protein in PBS 
was used for all measurements. The samples were scanned from 200 nm to 350 nm and multiple 
(3 scans) scans were averaged. The scans were carried out at 20 °C with an integration time of 1 
sec and a scanning rate of 50 nm/min. Temperature scans were carried between 10 °C to 90 °C 
with a scan rate of 1 °C/min and the wavelength was set to 222 nm to observe the change in 
alpha helical content. A cuvette of 2 mm path length was used for the CD scans. CD-spectra 
were deconvoluted after baseline correction( PBS was used to record the baseline) using spectral 
data ranging from 200 to 260 nm using the CD-pro software package/ Dichroweb software 169, 170 
171 using the CONTIN algorithm. 
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For the drug binding experiments, the protein and drug were premixed to achieve final 
concentrations of 45 µM and 1 mM, respectively (premixed in PBS as described earlier). This 
protein—drug ratio was identical to the conditions used in DSC experiments.  The samples were 
scanned from 200 nm to 280 nm in a quartz cuvette of 1 mm path length with an integration time 
of 1 sec and a scanning rate of 50nm/min and multiple CD scans were averaged. The temperature 
was kept constant at 20°C. Spectra were deconvoluted using spectral data ranging from 200 to 
260 nm using the Dichroweb software using the CONTIN algorithm as described earlier. 
Aggregation and surface charge analysis by HPLC 
A BioLogic DuoFlow F10 chemically inert HPLC system (Biorad) was used for 
chromatographic analysis. Size exclusion separations of the AGE samples were carried out using 
a Zorbax GF-250, 4.6 x250 mm gel filtration column with 4 µm particles and 150 Å pore 
diameter (Agilent Technologies), 50 µL of 1.5 mg/mL protein samples were injected using a 50 
uL static loop. The isocratic phase consisted of 50 mM potassium phosphate, 150 mM sodium 
chloride, pH 7.4 and the flow rate was set at 300 µl/min. Protein elution was detected by 280 nm 
UV absorbance at 1 second intervals. The peaks in the elution profile were integrated and all 
samples were measured in triplicates.  
Anion-exchange chromatography using a UNO-Q1 anion-exchange column (Biorad) was 
utilized to analyze differences in the surface charge of glycated serum albumin. A binary buffer 
system was used to generate a linear salt gradient. Buffer A contained 20 mM Tris pH 8.2, buffer 
B contained 20 mM Tris, 1 M NaCl, pH 8.2. 50 µL of 1.5 mg/mL protein was used. All samples 
were analyzed three times. 
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Dynamic light scattering (DLS) and fluorescence spectrometry 
Dynamic light scattering was used to determine the average particle size and size 
distribution of all protein samples using a Zetasizer Nano-ZS 90 (Malvern, UK) dynamic light 
scattering instrument. The protein concentration was 10 mg/ml for all samples in 50mM 
phosphate, 150mM NaCl, pH 7.4 (PBS) and samples were filtered through a 0.2 micron syringe 
filter. Data were recorded for two independent experiments and analyzed for hydrodynamic 
particle diameter and sample polydispersity using the software provided by the instrument 
manufacturer. 
Isothermal calorimetry (ITC) 
Isothermal titration calorimetry measurements were performed using a Nano ITC 
instrument (TA Instruments, USA). A microcell with a volume of 190 µL was used to study the 
binding of diclofenac to glycated BSA. All solutions were prepared in PBS and degassed using a 
dedicated, stirred vacuum station for 10 minutes at 4°C. The protein concentration was 110 µM 
while the concentration of the titrated drug was 5 mM. Concentrations were chosen based on the 
observed binding affinities for each sample from preliminary experiments to achieve binding 
saturation for optimal analysis of binding titration curves. The drug was titrated into the protein 
solution in 25 injections of 2 µl using the 50 µl auto-pipette with a constant stir rate of 400 rpm. 
Each injection had a duration of 2 sec with an interval of 400 sec. The heats of the dilutions of 
the drug were determined by titrating 5mM drug into PBS. After subtracting the heats of 
dilutions data were analyzed using the Nano analyze software® v2.3.6 provided by the 
instrument manufacturer. We used a model assuming a set of identical, independent binding sites 
to obtain the thermodynamic parameters.  
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Recombinant RAGE-VC1 expression and purification 
The plasmid pET15b_RAGE-VC1 encoded RAGE residues 23-243 with an additional N-
terminal 6xHis-tag. The protein was expressed in Shuffle T7 Express cells NEB C3029 cells 
(New England Biolabs). The plasmid (1 µL) was inserted into electro-competent Shuffle T7 
Express cells (100 µL) by electroporation at 1600V. The cells were expanded in L.B. media 
containing the selection antibiotic ampicillin. The cells were grown in 400mL media in 2L 
culture flasks at 37 °C with continuous shaking at 220 rpm. The cells were induced with 100mM 
IPTG after they have reached an OD600 of 0.6. After induction the temperature was reduced to 27 
°C, the cells were grown overnight and harvested by centrifugation at 4000rpm. The cells from 4 
liter culture were suspended in a buffer containing 50mM Tris, 20mM Imidazole, 300mM NaCl, 
pH-8.0 and frozen at -20 °C.       
For purification, the cells expressing RAGE-VC1 were thawed on ice and sonicated with 
a power of 15 with the sonicator (Misonix XL-2000). The cell debris was separated by 
centrifugation at 12000 rpm at 4 °C and the supernatant was collected. The protein was purified 
from the supernatant by a two-step process. First, using a pre-packed HisTrap HP column (GE 
Healthcare) the His-tagged RAGE VC1 was purified. The bound RAGE-VC1 was eluted using 
50mM Tris, 200mM Imidazole, 300mM NaCl, pH-8.0. Protein elution was detected by 280 nm 
UV absorbance at 1 second intervals. The eluted protein was collected and diluted (1:1) using 
10mM Na-acetate buffer, pH 5.5. We then used the pre packed HiTrap SP FF column (GE 
healthcare 17-5054-01) which contains the cation sulfopropyl to separate out the DNA bound to 
the protein.  The bound protein was eluted from the column using a linear gradient of NaCl from 
0M to 1M in the 10mM Na-acatate buffer, pH 5.5. The eluted protein was collected, 
concentrated by ultra-filtration using regenerated cellulose 10 Kda MWCO membrane 
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(Millipore), aliquoted and stored at -80 °C. The purity of the protein was estimated by sodium 
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and showed a single band of 
the expected molecular weight when stained with colloidal Coomassie Blue (Figure 2.5). 11.3 
mg of RAGE VC1 was obtained from 4 liters culture. The protein could be concentrated up to 10 
mg/mL in the presence of 800mM NaCl.   
 
 
 
 
 
 
 
 
 
 
Figure 2.5. SDS-PAGE of purified RAGE VC1 domain. 
Galectin-3 CRD expression and purification 
The carbohydrate recognition domain (CRD) residues 112-250 of galectin-3 was cloned 
into the pEX-N-His PrecisionShuttle bacterial expression vector from OriGene. The protein was 
expressed in BL21 (DE3) cells. The conditions used for the expression of galectin-3 were exactly 
similar to the RAGE-VC1 expression.  
The expressed protein was purified by a single step metal chelate affinity 
chromatography using a HisTrap HP column (GE Healthcare) and 200 mM imidazole for elution 
as described earlier.  The protein was dialyzed twice against 200 volumes of 10mM Tris, pH 7.5, 
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concentrated and characterized by UV/VIS spectroscopy and SDS-PAGE. Only a single band of 
the expected molecular weight was detected after Coomassie Blue staining of the gel (Figure 
2.6). We obtain about 12.5 mg of the gal3-CRD from 4 liters culture. However, the protein could 
be concentrated to more than 1.3 mg/mL.  
 
 
 
 
 
 
 
 
 
Figure 2.6. SDS-PAGE of purified RAGE Gal-3 CRD domain.  
Pull-down of glycated BSA by RAGE-VC1 and galectin-3 CRD  
Binding between glycated BSA and its potential receptor proteins was determined by 
affinity pull down assay. The AGE-BSA samples and AGE-receptors were mixed in solution and 
the complex was pulled down using an affinity resin binding to the 6His-tag attached to RAGE-
VC1 and galectin-3, respectively.  The assay was carried out in a micro-spin column, 50 µL Ni2+ 
charged Profinity IMAC resin (Biorad) was loaded on to the column. The resin was equilibrated 
using 50mM Tris, pH 7.4. Equal molar amounts of AGE-BSA and His6xs-RAGE-VC1or 6xHis-
galectin-3, respectively, (25 µM 50mM Tris, pH 7.4) were mixed and allowed to incubate for 10 
min on ice. The samples (100uL final volume) were then loaded onto a micro-column of and 
allowed to bind to the resin for 5 min. The resin column was washed up to 10 times with 10 
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column volumes of 50 mM Tris at pH 7.4. Flow through fractions were collected. After the final 
wash, proteins retained on the solid resin and in wash fractions were analyzed by SDS-PAGE. 
The samples were boiled in a reducing buffer with 4% BME before loading on the gel. 
Interaction of Rib-vH BSA with RAGE-VC1 or Galectin-3 by fluorescence polarization 
Fluorescence polarization was measured on a FluoroMax® (Horiba Jvon Yvon) 
spectrofluorometer equipped with a Glan-Thompson polarizing prism. A quartz cuvette with 
reduced path length of 5 mm was used for all experiments. The internal fluorescence of rib-vH 
BSA was used for this assay. An excitation wavelength of 350nm and an emission of 500nm 
were used. The slit size of the excitation and emission filters was set to 4nm. The proteins were 
dialyzed against 200 volumes of 50mM Tris, pH 7.4 overnight at 4 °C. 600 µl of 1 µM solution 
of AGE product in 50mM Tris, pH 7.4 was titrated by incremental addition of RAGE-VC1 or 
galectin-3. The polarization values were measured after each addition with an equilibration time 
of 2 min at room temperature, the increase in sample volume at the end point of the titration was 
less than 3%.  The fluorescence polarization values were plotted against RAGE-VC1/galectin-3 
concentration and the binding affinities (dissociation constants Kd) were calculated by fitting the 
data obtained to a modified quadratic equation (Eq 1) using kaleidograph software (synergy 
software). This equation was described by Anderson et al. (1988) 172 for a ‘one-binding-site 
model’.  
F=Fo+(ΔFmax/[Po])* [([Po]+[C]+Kd)-[([Po]+[C]+Kd)2-(4*[C]*[Po])]1/2]/2  (2.1) 
ΔFmax= is the total change in polarization 
Fo = is the initial polarization value 
Po= is the total concentration of RAGE/galectin-3 
C= is the concentration of the AGE compound after every addition 
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Cellular proliferation assay 
We used the human melanoma cell line WM-115, stably transfected with RAGE in our 
assay. The cells were maintained in Opti-MEM (Invitrogen) supplemented with 4 % FBS in the 
presence of penicillin, streptomycin and 1mg/ml G418 at 37 °C and 5 % CO2. For cell 
proliferation assays, the cells were detached with 0.25 % trypsin and seeded (4x104 cells per 
well) in 24 well plates in Opti-MEM supplemented with 4 % FBS, penicillin, streptomycin and 
G418. After 24 h incubation, the different preparations of glycated BSA were added to the wells 
at a final concentration of 230µg/ml and the plates were incubated for another 24 h. Alamar Blue 
(resazurin) was then added to the wells (1/10th the total volume of the well) and the plates were 
further incubated for 3-4 h at 37 °C. The reduced form of Alamar Blue was detected by 
fluorescence spectroscopy (excitation: 540 nm; emission: 590 nm) using a Spectramax M5 plate 
reader. Wells containing only cell culture medium, but no cells, were used for fluorescence 
background correction. Three proliferation experiments were performed using four wells for 
each experimental condition. 
Results and Discussions 
UV/Vis spectroscopy 
We assessed the effect of eight glycation reagents (Figures 2.3 and 2.4) on the 
modification of lysine and arginine side chains in serum albumin (Table 2.2). Glycation of BSA 
with glucose and ribose were performed at three different concentrations. The lowest 
concentration of 20 mM was chosen based on pathophysiologically relevant blood glucose 
concentration observed in patients with uncontrolled diabetes. The highest concentration of 500 
mM is frequently described in the literature for the in-vitro preparation of AGE-modified 
proteins for glycation related studies. We included these high concentrations of modifying ribose 
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and glucose into our study to allow comparison to literature data.  The concentrations of the 
other glycation reagents were chosen to be 1-5 mM to account for their increased chemical 
reactivity. These concentrations exceed concentrations observed in the blood; however, the true 
concentration of these reactive carbonyl compounds in specific tissues or inside individual cells 
under pathological conditions is uncertain 159. Methylglyoxal, glyoxylic acid, glyceraldehyde and 
glycolaldehyde are metabolic intermediates; acetoin and diacetyl are products of liver 
metabolism 173.  Acetoin and diacetyl are also formed during fermentation and found in many 
foods 174, or intentionally added as flavoring agents to impose a butter-like aroma. Diacetyl has 
been linked to obliterative brochiolitis in workers exposed to the compound 175. 
Visual inspection and high-speed centrifugation of AGE-modified BSA samples at the 
end of the 21 days glycation period and after dialysis did not indicate any significant formation 
of protein precipitation in any of the glycated samples. This shows that BSA can undergo 
prolonged glycation without significant loss of solubility (10–40 mg/ml). 
The “Maillard” reaction is also known as “browning reaction” because it leads to 
compounds that absorb in the visible region of the spectrum, resulting in a brown coloration of 
the products. We recorded the UV/VIS spectra of all glycated serum albumin samples to 
distinguish glycation reagents that do result in colored advanced glycation end products from 
those that do not generate chromophores absorbing light in the near UV and visible region. 
Characteristic spectroscopic features of advanced glycation end products formed by specific 
reagents may be useful to identify specific AGE compounds. UV/VIS absorbance traces are 
nearly identical for nonmodified BSA and CML- and glyoxylic acid modified BSA, indicating 
that no new chromophores with absorbances above 250 nm have been introduced into the protein 
structures. 
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BSA modified with lower concentrations of most glycation reagent also remained 
colorless to the eye, except for samples modified with ribose or diacetyl, which appear light 
yellow in color. The Figure 2.8 shows the UV/VIS absorbance spectra of BSA modified with 
low concentrations of modifying reagents. Spectral traces for Glc-L and Ace-L are nearly 
superimposable with non-modified BSA-fresh. Modifications in samples MG-L BSA, Glc-L 
BSA, or Gla-L BSA do not change absorbance in the visible region (>380 nm), but indicated the 
formation of novel chromophores which absorb in the region between 260-370 nm. 
 Diacetyl glycated BSA (Dia-L BSA) clearly showed a novel chromophore with a well-
developed absorbance maximum at 327 nm. In contrast, ribose modified samples (Rib-L BSA) 
also showed strong absorbance between 300-370 nm, but the absorbance profile is broad and 
featureless, without clear peaks or troughs between 300 to 500 nm. We also noticed variations in 
the region around 280 nm, which, in non-modified proteins, is caused by UV absorbance by 
phenylalanine, tyrosine and tryptophan residues. Decreased molar absorbance in the 280 nm 
region may indicate modification of tryptophan residues, while increases in molar absorbance 
indicate formation of novel chromophores absorbing in this region of the spectrum. Figure 2.7 
shows the UV/VIS absorbance profiles of AGE-BSA produced with high concentrations of 
glycation reagents.  The spectral properties or Rib-H and Rib-vH BSA showed broad 
absorbances between 300-500 nm, with a clear shoulder or second peak around 302 nm. Diacetyl 
(Dia-H BSA), glycoaldehyde (Gla-H BSA) and methylglyoxal (MG-H BSA) modified BSA 
show similar absorbance between 300-400 nm, possibly indicating formation of identical or 
similar chromophores. These latter samples can be distinguished spectroscopically form samples 
modified with glucose (Glc-H BSA, Glc-vH BSA) or glyceraldehyde (Gly-H BSA). Acetoin 
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glycated serum albumin contains only minimal quantities of novel chromophores absorbing 
above 300 nm. 
Our data demonstrate that there are significant differences in the extent of UV/Vis 
absorbance caused by individual glycation reagents. However, UV/Vis absorbance spectra of 
glycated protein samples provide only very limited information about the extent and the nature of 
the glycation modification. 
 
 
 
 
 
 
 
Figure 2.7. UV absorbance spectra of BSA glycated with high concentrations of glycation 
reagents.  
Increased concentration of glycation reagent leads to formation of novel chromophores in in 
most samples, except for acetoin and glyoxylic acid.  
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Figure 2.8.  UV absorbance spectra of BSA glycated with low concentrations of glycation 
reagent.  
Diacetyl and ribose modified samples are clearly distinguishable from the other samples by their 
increased absorbance between 300 and 350 nm.  
Fluorescence spectroscopy  
The fluorescence properties of the AGE-BSA samples were investigated. Many AGE 
compounds are fluorescent and their fluorescence is often used as a measure for AGE content in 
tissues such as skin 176, cartilage 177 and the eye lens 178.  
We expected that the different glycation reagents lead to the formation of chromophores 
with distinguishable fluorescence properties. Fluorescence spectra were collected at 285 nm, 340 
nm, 375 nm, 400 nm, 475nm and 525 nm excitation wavelengths. The emission scans of the 340 
nm excitation wavelength are shown in Figure 2.9.  Proteins that had not undergone a browning 
reaction showed fluorescence emission spectra nearly identical the non-modified BSA. The 
emission spectra of CML and glyoxylic acid modified BSA could be attributed solely to the 
fluorescence of the tryptophan residues. This observation is expected, since UV/VIS absorbance 
is a prerequisite for fluorescence. 
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Protein modification with acetoin (Ace-H BSA), diacetyl (Dia-H) and CML modification 
did not result in significant formation of fluorophores in the protein. All other glycation reagents 
did generate novel fluorophores. At the chosen excitation wavelength of 340 nm we observed 
fluorescence emission maxima between 391 nm (Gly-H BSA) and 432 nm (Dia-H BSA). The 
fluorescence intensities varied greatly between samples. The strongest fluorescence was 
observed for the ribose modified sample (Rib-vH BSA), which was over three-fold stronger than 
the fluorescence emitted from glucose modified albumin (Glc-vH BSA). Glyceraldehyde and 
glycolaldehyde modification also led to formation of strong fluorophores, whereas the 
fluorescence intensity of methylglyoxal modified BSA (MG-H BSA, 5 mM methylglyoxal) was 
comparable to the highly glucose modified sample (Glc-vH BSA, 500 mM glucose). However, 
the peaks of the emissions were clearly separated by 27 nm (Emmax MG-H: 399 nm, Emmax Glc-
vH: 426 nm).  
The samples were excited at 285 nm to determine the effect of glycation on Trp 
fluorescence.  We do not see a huge shift in the fluorescence maxima of the AGE samples except 
in the methyl glycoxal (MG-H) and the ribose (rib-H, rib-vH) modified samples. In the rib-vH 
BSA the emission maxima was at 426nm, this suggests the modification Trp residues in the 
ribose modified samples. In the MG-H BSA sample two distinct peaks were observed which had 
their emission maxima at 332nm and 378nm respectively. This suggests the formation of a novel 
fluorophore. We also observe a drop in the emission intensities. We suspect this could be the 
result of an environmental change in the environment surrounding the Trp residues due to 
unfolding of the protein due to glycation. Trp fluorescence is highly dependent on the 
surrounding environment (This aspect is described in detail in chapter 5).  
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When the samples were excited at 375nm an emission maxima was observed at around 
445nm in the rib-vH BSA sample. The MG, Gly and Gal modified samples also showed an 
emission maxima at around 445 nm however, the intensity was much lesser when compared to 
the Rib-vH BSA sample.   
The spectroscopic characterization demonstrates that the reaction products of serum 
albumin glycation depend on the glycation reagent used. Depending on the chemical structure 
and reactivity of the glycation reagent, novel chromophores and fluorophores are formed. For 
example, while glucose and ribose are chemically closely related, they differ greatly in their 
ability to glycate proteins as reflected by chromophore and fluorophore formation.  In addition, 
the spectral features of glycated albumins demonstrate the chromophores / fluorophores 
introduced by glucose, ribose and the other reactive aldehydes are chemically not identical. It 
appears that refined fluorescence spectroscopic methods may be suitable to distinguish between 
glycation end products derived from different glycation reagents. This would be valuable for the 
analysis of AGE compounds and may offer the possibility to identify the glycation reagent 
responsible for glycation under physiological conditions. 
Glycation in general primarily involves the modification of lysine and arginine residues. 
It has been reported that the modification of arginine residues by compounds such as 
methylglyoxal leads to formation of hydroimidazolones, tetrahydropyrimidine and 
argpyrimidine. Crosslinkage between modified arginine and lysine side chains leads to 
pentosidine 179. Of these compounds, only argpyrimidine and pentosidine are fluorescent 180. 
Argpyrimidine shows high absorbance between 320 and 335 nm and a fluorescence emission 
maximum around 400 nm 178. Pentosidine also absorbs between 325 and 335 nm, but has an 
emission maximum at 375–385 nm 178. Analysis of the fluorescence emission spectra suggests 
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that pentosidine and argpyrimidine have been formed, but also indicate that additional 
fluorophores are present. These fluorophores produce maximum emission at 435 nm when 
excited at 365 nm, which has been previously reported for AGE-proteins 160. The changes in 
fluorescence emission profiles with changes of the excitation wavelengths indicate that multiple 
fluorophores with overlapping absorbance and emission spectra exist in the samples. Despite the 
fact that the fluorescence properties of AGE modified protein have been investigated for almost 
two decades, very few of the fluorescent compounds present in AGE proteins have been 
identified unambiguously.  
 
 
 
 
 
 
 
 
Figure 2.9. Fluorescence emission spectra of glycated BSA at an excitation wavelength of 340 
nm.  
Ribose, glyceraldehyde and glycolaldehyde glycation leads to strongly fluorescent compounds. 
Gycation with methylglyoxal and even high concentration of glucose (500 mM) leads to 
moderate fluorescence. No significant fluorescence was observed in acetoin and glyoxylic acid 
modified samples.  
 40 
Amino acid side chain glycation  
The degree of amino acid modification was assessed with several complimentary 
methods. Standard amino acid analysis uses strong acidic conditions for amide bond hydrolysis. 
These conditions are likely to destroy many glycation and advanced glycation endproducts. 
Therefore, amino acid analysis can only determine a subset of amino acid modifications that are 
acid resistant, such as CML, argpyrimidine and other advanced glycation endproducts. We 
performed amino acid analysis on only the BSA samples derivatized with glucose (200 mM), 
glyoxylic acid (10 mM), methylglyoxal (5 mM) and CML (23 mM) concentrations of modifiers 
and on non-modified, aged BSA. BSA contains 59 lysine residues and 23 arginine residues. It 
was found that approximately 15% of arginine residues were modified in the methylglyoxal 
modified sample and approximately 15% of lysine residues in the CML-H preparations. The 
lysine and arginine contents detected for glyoxylic acid and glucose modified samples were 
found to be N95% (Table 2.2). To get a more precise assessment, the modification of arginine 
and lysine side chains was assessed using the 9,10-phenanthrenequinone and fluorescamine 
assays, respectively. The mild conditions of these assays, when compared to standard amino acid 
analysis, allowed us to determine hydrolysis sensitive glycation-modifications in the samples. 
We also measured the formation of the early glycation product fructosamine and the advanced 
glycation end product carboxymethyl lysine (CML) as described earlier.   
As expected, for a given glycation reagent, the extent of side chain modification 
increased with increasing reagent concentration. However, a substantial portion of arginine and 
lysine residues remained un-modified even at high reagent concentrations. This demonstrates 
that glycation does not proceed to completion and suggests that modification of amino acids may 
occur preferentially on the protein surface or specific glycation “hot-spots”. A similar conclusion 
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has been drawn by Barnaby et al. after they studied albumin glycation by mass-spectrometry 85, 
181, 182. 
Table 2.2 summarizes the amino acid modifications in the all the different glycated 
samples. There are profound differences between the glycation reagents in terms of overall 
reactivity, as well as in their selectivity for either lysine or arginine modification. For example, 
glucose is a relatively unreactive glycation reagent when compared to ribose, or any of the other 
compounds tested. The differences in reactivity between glucose and ribose arise from the higher 
stability of the closed ring form (hemiacetal) for glucose, when compared to ribose 183. 
Interestingly, the reactivity of ribose towards lysine side chains allows for almost complete 
modification of lysine (96 %), whereas arginine side chains are only moderately modified (15 
%). High percentage of modified lysine residues were also observed in the rib-L BSA sample 
(48.7%). 58.7% and 24.4% of the lysine and arginine residues were found to be modified in the 
glc-vH BSA sample respectively. Fructosamine was only detected in glucose modified albumin. 
The glc-vH BSA sample has a fructosamine content of 27 mol/mol of protein. Fructosamine was 
not observed in any other sample. Fructosamine modification seems to be the dominant lysine 
side chain modification in glucose modified samples, which is in agreement with previously 
reported findings184.  The carboxymethyl lysine was found in ribose glycated albumin but not in 
glucose glycated albumin. These differences in composition between glucose and ribose glycated 
proteins may have implications for their biological activities.  
Methylglyoxal, glyceraldehyde, glycoaldehyde and diacetyl showed similar reactivities 
towards arginine and lysine and lead to substantial modification (>40%) at 5 mM reagent 
concentration. We detected CML only in glyceraldehyde and glycoaldehyde modified samples, 
but not in methylglyoxal or diacetyl modified samples (5%). The reactivity of glyoxylic acid is 
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generally minimal; hence we do not observe substantial modification of lysine and arginine 
residues (> 5%). The initial formation of the Schiff-base between the protein and the glyoxylic 
acid is nearly completely reversible in the absence of an additional reducing reagent and the high 
oxidation state of the carboxyl group prevents Amadori rearrangement. However, in the presence 
of sodium cyanoborohydride as reducing reagent (used in the CML modified BSA), the 
formation of CML on lysine residues occurs, while arginine residues remain unaltered. 18% and 
32% of the lysine residues were modified in the CML-L and CML-H BSA samples respectively.  
Acetoin, which is chemically related to diacetyl by reduction of one of the keto groups, is 
significantly less reactive when compared to diacetyl or the other reactive aldehydes. Arginine 
residues appear not to be modified by acetoin and the modification of lysine residues by this 
reagent is only modest. 
Finally, we measured the carbonyl content using the dinitrophenylhydrazine method, 
which involves exposure of the protein to strong acidic conditions, which, as mentioned above, 
can lead to destruction of glycation and AGE-products. The CML samples did not contain 
detectable carbonyl groups. Glc-BSA and rib-BSA samples did contain detectable levels of 
carbonyl groups and the carbonyl content increased with the concentration of glucose and ribose. 
Higher carbonyl content was observed in the rib-BSA samples. The glc-vH BSA sample had a 
carbonyl content of 0.71 mol/mol and the rib-vH BSA had a carbonyl content of 1.90 mol/mol.   
High carbonyl content was also observes in the Dia-H, Gly-H, Gla-H and the MG-H BSA 
samples. In general, the detected carbonyl content was approximately one carbonyl group per 
BSA molecule (Table 1.2). Carbonyl content was minimal in GA-BSA samples. 
Our observations regarding amino acid side chain modification by glycation are 
consistent with previous reports in the literature and underline that AGE formation depends 
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qualitatively and quantitatively on the glycation reagent. It also underscores that AGE 
compounds formed at low or moderate concentrations of glycation reagent are only partially 
glycated, leaving a substantial percentage of arginine and lysine side chain unmodified.  
Table 2.2. Summary of amino acid side chain modifications, CML, fructosamine and carbonyl 
content. n.d., none detected. 
Sample 
Name 
Lysine 
Modified 
% 
Arginine 
Modified 
% 
Content 
CML 
mol/mol 
Content 
Fructosamine 
mol/mol 
Content 
Carbonyl 
mol/mol 
BSA-fresh 0 ± 0 0 ± 0 n.d. n.d. 0.02 ± 0.01 
Glc-L BSA 8.2 ± 3.5 3.7 ± 1.2 n.d. 1.8 ± 0.5 0.15 ± 0.02 
Glc-H BSA 22.0 ± 2.6 14.0 ± 3.1 n.d. 21.8 ± 1.5 0.71 ± 0.04 
Glc-vH BSA 58.7 ± 2.3 24.4 ± 2.5 n.d. 27.0 ± 4.7 1.04 ± 0.06 
GA-L BSA 5.0 ± 2.0 3.7 ± 1.5 n.d. n.d. 0.10 ± 0.02 
GA-H BSA 10.0 ± 3.0 4.3 ± 1.5 n.d. n.d. 0.10 ± 0.01 
Ace-L BSA 10.7 ± 3.1 5.0 ± 1.0 n.d. n.d. 0.15 ± 0.03 
Ace-H BSA 17.0 ± 4.3 6.6 ± 1.5 n.d. n.d. 0.42 ± 0.03 
Dia-L BSA 13.0 ± 2.0 11.0 ± 2.6 n.d. n.d. 0.36 ± 0.04 
Dia-H BSA 40.2 ± 5.5 38.3 ± 1.5 n.d. n.d. 1.20 ± 0.08 
Gly-L BSA 19.7 ± 2.5 9.0 ± 2.6 n.d. n.d. 0.29 ± 0.02 
Gly-H BSA 42.0 ± 1.7 38.3 ± 2.2 5.9 ± 0.1 n.d. 1.18 ± 0.03 
Gla-L BSA 19.3 ± 3.1 12.3 ± 2.5 n.d. n.d. 0.38 ± 0.03 
Gla-H BSA 45.3 ± 4.2 40.3 ± 2.1 5.7 ± 0.2 n.d. 1.38 ± 0.03 
MG-L BSA 19.5 ± 2.2 13.0 ± 2.0 n.d. n.d. 0.35 ± 0.03 
MG-H BSA 44.7 ± 2.5 39.3 ± 6.0 n.d. n.d. 1.30 ± 0.03 
Rib-L BSA 48.7 ± 0.8 12.3 ± 2.1 7.5 ± 0.3 n.d. 0.72 ± 0.03 
Rib-H BSA 89.5 ± 0.5 13.7 ± 2.3 10.3 ± 1.2 n.d. 1.78 ± 0.04 
Rib-vH BSA 96.0 ± 0.7 15.0 ± 2.6 13.8 ± 0.7 n.d. 1.90 ± 0.04 
CML-L BSA 18.0 ± 9.0 8 ± 2.0 18.1 ± 1.2 n.d. 0.02 ± 0.01 
CML-H BSA 32.0 ± 9.0 10.0 ± 4.0 31.5 ± 1.6 n.d. 0.02 ± 0.01 
Changes in secondary structure resulting from glycation and AGE formation 
Extensive modification of lysine and arginine residues in proteins can be expected to 
disturb the secondary and tertiary structure of the protein. We used circular dichroism (CD) 
spectrometry for secondary structure analysis and Figure 2.10 shows the CD-traces of selected 
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glycated BSA samples at 20ºC.  Table 2.3 summarizes the results of CD based secondary 
structure deconvolution. Native BSA has a high degree of α-helical secondary structure (63%) 
and very little β-sheet content (5%). These values are very similar to values reported in the 
literature (67% helix, 10% turn, 23% unordered) 185. We observed that glycation indeed altered 
the secondary structure of the protein. There was a general decline in α-helical content as result 
of glycation and the content of β-sheet increases, for example, 4-fold from 5 % to 20 % for BSA 
modified with glyceraldehyde (Gly-H BSA) or ribose (Rib-vH BSA). However, the structure of 
the protein does not collapse into a random coil state. It rather seems to approach a molten 
globule state, in which residual secondary and tertiary structure is retained by the protein. 
Plotting the change in α-helical and β-sheet secondary structure as a function of the extent of 
lysine residue modification revealed an approximately linear correlation (Figure 2.11). 
 
 
 
 
 
 
 
 
Figure 2.10. Circular dichroism spectral data of selected glycated BSA samples demonstrate the 
gradual loss in secondary structure, and particularly in α-helical content upon glycation.  
Fresh BSA is shown in red and demonstrates highest α-helical content. 
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Figure 2.11. Blotting the extent of lysine side chain modification in glycated samples against the 
relative content of α-helical and β-sheet secondary structure in the corresponding samples reveals 
a linear correlation.  
The red dots show the increase in β-sheet relative to increased lysine modifications. The blue 
squares show the decrease in α-helical content as function of lysine modification. The sample at 
the out left represents non-modified BSA, the sample at the outer most right corresponds BSA 
glycated with 500mM ribose.   
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Table 2.3. Analysis of secondary structure distribution in glycated BSA samples based on the 
deconvolution of circular dichroism (CD) spectra. 
Sample Temperature  
(0C) 
Alpha 
Helices 
 (%) 
Beta Sheets  
(%) 
Turns  
(%) 
Unordered  
(%) 
BSA-fresh 20 63 5 12 20 
Glc-L BSA 20 43 10 22 25 
Glc-H BSA 20 36 11 24 29 
Glc-vH BSA 20 32 19 10 39 
GA-L BSA 20 40 13 19 28 
GA-H BSA 20 40 11 23 26 
Ace-L BA 20 41 15 16 28 
Ace-H BSA 20 34 17 17 32 
Dia-L-BSA 20 44 16 9 31 
Dia-H BSA 20 33 20 10 37 
Gly-L BSA 20 50 10 11 29 
Gly-H-BSA 20 40 13 11 36 
Gla-L BSA 20 48 9 11 32 
Gla-H BSA 20 30 20 10 40 
MG-L BSA 20 46 14 14 26 
MG-H BSA 20 36 15 11 38 
Rib-L BSA 20 33 20 9 38 
Rib-H BSA 20 32 20 9 39 
Rib-vH BSA 20 25 21 9 45 
Glycation induced protein oligomerization 
Glycation of BSA also did not result in the formation of large protein aggregates that 
would form visible precipitates or cause significant UV/VIS scattering. However, glycation has 
been reported to lead to protein cross-linkage and induce the formation of amyloid-like 
aggregates in some cases 157, 186. In order to determine the effect of glycation on protein 
oligomerization and cross linking, the extent of non-monomeric protein was estimated by high-
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performance size exclusion chromatography. Monomeric and non-monomeric protein could be 
clearly distinguished from each other. However, the non-monomeric content could not be 
separated sufficiently to distinguish between dimers, trimers and higher order oligomers. 
Therefore, only a single value for “non-monomeric” proteins reported in Figure 2.12. Freshly 
dissolved BSA showed consistently a low level (6.1 ± 0.4%) of non-monomeric material. 
Glycation with 20 mM glucose had no effect on oligomerization and even glycation with 500 
mM glucose only led to a minimal increase in protein oligomers to 7.6 + 0.4 %. In contrast to 
glucose, ribose caused very significant oligomerization of BSA molecules, resulting in 23.3 % 
non-monomeric material at 20 mM ribose and 38.4 % at 500 mM ribose.  Glycolaldehyde also 
showed high oligomerization potential, resulting in 11.5 % of non-monomeric material at 1 mM 
and 28.8 % at 5 mM glycoaldehyde in the glycation reaction. Significant oligomerization was 
also observed in samples glycated with 5 mM of methylglyoxal (11.5 %) and glyceraldehyde 
(10.7 %). It is important to note that these oligomeric proteins are still highly soluble and 
probably consist of cross-linked dimers, trimers and tetramers. These data demonstrate that 
ribose and glycolaldehyde have significant potential to cause inter-protein cross linkage of 
albumin, whereas glucose does not effectively drive cross-linkage of the same protein.  
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Figure 2.12. Percentage of non-monomeric content in glycated BSA samples. 
Highest percentage of non-monomeric content was observed in the rib-vH BSA sample.  
Effect of glycation on surface charge 
Glycation occurs preferentially on lysine and arginine residues and eliminates the 
positive charge located at these side chain groups. To gain insight into the changes in surface 
charge changes upon glycation with various agents, high performance ion exchange 
chromatography was used and the retention of the glycated protein on the charged 
chromatographic matrix during elution with a linear salt gradient was analyzed. The peak shape 
of the eluted material provides information about sample heterogenicity. Sharp, symmetric peaks 
indicate little heterogenicity, while broad and non-symmetric peaks indicate increased 
heterogenicity in sample composition. The elution profiles for selected AGE-modified samples 
are shown in Figure 2.13. We noticed significant peak asymmetry for all samples. The elution 
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profile of non-modified BSA indicated that some heterogenicity existed in the sample. The 
natural glycosylation and some oligomerization caused the heterogenicity observed in non-
glycated BSA can be speculated. For all glycated samples increased retention on the 
chromatography matrix was observed, indicating a decrease in positive surface charge. As 
expected, the samples showing the highest degree of lysine and arginine side chain modification 
show the greatest change in surface charge.  Glycation generally increases sample heterogenicity, 
most prominently for glycolaldehyde and ribose. Reagents that showed little glycation reactivity, 
such as acetoin and glyoxylic acid, showed only minimal effects. BSA glycated with 500 mM 
glucose showed a decrease in positive surface charge and relatively little sample heterogenicity. 
Isoelectric focusing was also used to estimate that the isoelectric point of BSA modified with 
500 mM ribose is approximately 1 pH unit lower than the isoelectric point of non-glycated BSA. 
The reduction in isoelectric point of glycated proteins may affect protein - protein and 
protein - lipid membrane interactions. However, to significantly change the surface charge of 
BSA, many residues have to be modified by glycation. It thus appears more likely that the 
glycation of specific residues on the protein surface will affect protein function, for example by 
changing an α-helical segment into a β-sheet or by disrupting hydrogen bonding networks 
involving lysine and arginine residues.   
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Figure 2.13. HPLC elution traces of glycated BSA during anion exchange chromatography.  
The lowest trace corresponds to non-modified BSA. A peak elution peak shift to the right (later 
elution times) indicates increased retention on the column due to decreased positive surface 
charge of the molecules. Broadening and asymmetry in the peaks demonstrates sample 
heterogenicity as result of glycation. The small peak at 160 sec is related to gradient switching.  
Effect of glycation on thermal unfolding 
Since we confirmed that glycation altered the secondary structure and reduced the 
positive surface charge of serum albumin, we hypothesized that glycation would also influence 
the thermal stability and unfolding of the proteins. Circular dichroism (CD) spectrometry and 
differential scanning calorimetry (DSC) was used to characterize the thermal unfolding of 
glycated BSA. 
The change in α-helical secondary structure content in glycated BSA samples as a 
function of increasing temperature was measured. The molar ellipticity at 223 nm is a good 
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indicator of α-helical content in protein samples and was continuously recorded between 20 ºC 
and 90 ºC (Figure 2.14). Unmodified BSA showed a gradual decrease in mean molar residual 
ellipticity up to about 60 ºC, corresponding to a reduction of α-helical structure from 63% to 54 
%. At that temperature a transition occurred and accelerated protein unfolding set in, reducing 
the α-helical content to 38 % at 80 ºC. All glycated samples showed a lower α-helical content 
than non-modified BSA over the entire temperature range. Despite the reduced α-helical content, 
an unfolding transition could be observed for most samples, except for samples modified with 
200 mM and 500 mM ribose (Rib-H-BSA, Rib-vH-BSA).  The lack of an unfolding transition 
suggests that the protein either forms a highly heterogeneous population of partially unfolded 
structures or a folding state that approximates a molten globule. In both cases, the protein has 
access to many unfolding intermediates, which are energetically similar and thus lead to “slow 
melting”, rather than a sharp and defined unfolding event. 
To gain more detailed insights in the structural transitions during heating the CD-spectra 
was recorded at 20 ºC, 50 ºC, 60 ºC, 70 ºC and 80 ºC and determined the relative secondary 
structure composition at each temperature. Unmodified BSA showed a high α-helical content of 
63%, low β-sheet content (5%), 12% turns and 20% unordered structures at 20 ºC, as previously 
reported in the literature 185. Elevating the temperature to 80 ºC reduced the α-helical content to 
38% and increased the β-sheet content to 12%.  
All glycated samples showed significantly decreased α-helical and increased β-sheet 
structure at all temperatures when compared to non-modified BSA. There are significant 
similarities between the glycation reagents in terms of their effect on secondary structure. For 
example, samples modified with 1 mM of glycation reagent generally retain between 40 -50% α-
helices and 9 - 16 % β-sheet structures at 20 ºC. At 80 ºC the differences between glycated 
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samples are more pronounced. Glyceraldehyde (Gly-L) modified BSA shows only 15 % β-sheet, 
whereas the methylglyoxal (MG-L) samples possess 24% β-sheet. Higher concentration of 
modifying reagent exaggerates the loss of α-helices, leaving only 30 – 40% α-helices, and 13-20 
% β-sheet at 20 ºC.  
As seen with our other analytical methods, ribose caused the most pronounced change in 
the secondary structure. BSA modified with 20 mM ribose (Rib-L BSA) had an α-helical content 
of only 33%, and BSA modified with 500 mM ribose (Rib-vH BSA) showed the least α-helical 
content of all samples with 25%. Ribose modification also showed a high β-sheet content (21%). 
The general effect of glycation on the secondary structure of BSA can be summarized as 
decreasing the α-helical content and increasing the β-sheet. Our results are in agreement with 
previous studies, which describe that glycation causes the disruption of α-helical conformation 
187. Also, the effect of glycation seems to induce secondary structure changes similar to the 
changes observed during thermal unfolding of non-modified BSA. Interestingly, thermal 
unfolding of BSA has been reported to lead to formation of aggregates and amyloid like 
structures 185, 186. As pointed out above, we observed a significant degree of non-monomeric 
material in ribose and glycolaldehyde modified samples. Therefore, we have β-sheet enriched 
soluble oligomers in these samples, which may be similar to soluble oligomers reported for the 
prion protein or amyloid-beta peptide 188. This could be significant, because the hypothesis has 
been put forward that the neuronal toxicity of misfolded prion protein and amyloid beta peptide 
is associated with soluble oligomers, rather than insoluble aggregates, deposits or plaques 189, 190. 
Next thermal unfolding of glycated BSA by differential scanning Calorimetry was 
investigated. DSC provides thermodynamic parameters of the unfolding process, in particular the 
transition midpoint (Tm) and enthalpy ∆H and entropy ∆S of the unfolding process.  
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Non modified BSA showed two thermal transition peaks, as previously reported 191. The 
first partially unfolding transition is reversible, whereas the second transition is irreversible, but 
does not lead to complete unfolding of the ordered structure 192. The midpoint temperature of the 
thermal melting curve (Tm) and the associated change in enthalpy of the unfolding process (∆H 
Tm) were determined using a two state model (Table 2.4). The Tm1 of the unmodified BSA was 
found to be 62.3 ± 0.1°C and Tm2 was 79.3 ± 0.2 °C. These values are higher than the ones 
reported previously 191, 193, but can be explained by the differences in the buffer systems.  
The majority of samples showed two thermal transition peaks similar to unmodified 
BSA. The shapes of the thermograms were broadened for most samples, indicating increased 
heterogenicity in the protein population (Figure 2.15). However, only a single transition could be 
discerned for samples modified with glucose (Glc-vH), ribose (Rib-L), diaceteyl (Dia-H), 
glyceraldehyde (Gly-H), glycolaldehyde (Gla-H) and methylglyoxal (MG-H) (Table 1.4). 
Thermograms obtained for highly ribose modified samples could not be analyzed.  
The determined transition temperatures Tm and changes in enthalpy ∆H for the folding 
transition were shifted to higher temperatures and lower enthalpies for most samples (Table 2.4). 
This indicates increased conformational heterogenicity as result of glycation, reduced thermal 
stability and a decrease in ordered structure in the protein. As observed with the other analytical 
methods, higher concentrations of modifying reagents and higher levels of side chain 
modification lead to reduced thermal stability. However, one has to keep in mind that the thermal 
unfolding of BSA and its glycated derivatives does not lead to complete structure dissolution, but 
rather to a β-sheet rich molten globule state. Our CD analysis has shown that this molten globule 
state is structurally different for different glycation modification. 
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Figure 2.14. Thermal unfolding of glycated BSA samples followed by circular dichroism.  
Changes in the molar residual ellipticity at 223 nm was followed as a function of temperature 
and are indicative of the relative decrease in α-helical content in the samples.  
 
 
 
 
 
 
 
 
 
Figure 2.15. Differential scanning calorimetry thermograms for selected glycated samples. 
The trace for non-modified BSA is shown in red. Glycation greatly influences thermal unfolding 
behavior of the samples. Samples glycated by ribose do not show defined, DSC detectable 
thermal unfolding.  
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Table 2.4. Differential scanning calorimerty derived thermal transition mid temperatures (Tm) 
and the associated enthalpies (∆H) and entropies (∆S) of thermal unfolding of AGE-BSA 
samples. 
These parameters could not be calculated for rib-H BSA and 500mM rib BSA samples as they 
did not show any defined peak. 
Sample 
Tm1 
(0C) 
∆HTm1 
(kJ/mol) 
∆Sm1 
(kJ/mol * K) 
Tm2 
0C) 
∆HTm2 
(kJ/mol) 
∆Sm2 
BSA-fresh 
62.3 ± 0.1 492 ± 4 1.47 ± 0.02 79.3 ± 0.2 838 ± 12 
2.38 ± 
0.05 
Glc-L BSA 
64.1 ± 0.2 382 ± 7 1.13 ± 0.03 84.2 ± 0.3 860 ± 8 
2.40 ± 
0.03 
Glc-H BSA 
66.4 ± 0.1 403 ± 8 1.19 ± 0.03 81.8 ± 0.3 612 ± 7 
1.72 ± 
0.02 
Glc-vH BSA 65.4 ± 0.2 418 ± 3 1.23 ± 0.01 - -  
GA-L BSA 
63.0 ± 0.1 460 ± 8 1.37 ± 0.03 82 ± 0.4 630 ± 6 
1.77 ± 
0.02 
GA-H BSA 
65.0 ± 0.3 410 ± 6 1.21 ± 0.03 84.3 ± 0.2 872 ± 7 
2.44 ± 
0.03 
Ace-L BSA 
63.5 ± 0.2 420 ± 11 1.25 ± 0.05 80.1 ± 0.2 848 ± 6 
2.40 ± 
0.02 
Ace-H BSA 
65.5 ± 0.2 442 ± 8 1.30 ± 0.03 82.3 ± 0.1 797 ± 7 
2.24 ± 
0.03 
Dia-L BSA 
65.9 ± 0.1 418 ± 4 1.23 ± 0.02 82.5 ± 0.1 767 ± 5 
2.16 ± 
0.02 
Dia -H BSA 74.3 ± 0.3 295 ± 7 0.85 ± 0.03 - -  
Gly-L BSA 
66.0 ± 0.1 436 ± 8 1.28 ± 0.03 82.2 ± 0.1 850 ± 2 
2.39 ± 
0.02 
Gly-H BSA 74.2 ± 0.1 320 ± 1 0.92 ± 0.01 - -  
Gla-L BSA 
64.1 ± 0.1 414 ± 2 1.23 ± 0.01 82.8 ± 0.2 746 ± 6 
2.10 ± 
0.02 
Gla-H BSA 74.2 ± 0.2 300 ± 4 0.86 ± 0.02 - -  
MG-L BSA 
66.3 ± 0.1 420 ± 2 1.23 ± 0.01 82.6 ± 0.4 856 ± 3 
2.41 ± 
0.01 
MG-H BSA 75.1 ± 0.1 287 ± 7 0.82 ± 0.03 - -  
Rib-L BSA 72.2 ± 0.1 349 ± 3 1.01 ± 0.01 - -  
Rib-H BSA - -  - -  
Rib-vH BSA - -  - -  
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Binding of glycated BSA to the AGE-receptor proteins: RAGE and Galectin-3 
It has long been proposed that glycated and AGE modified proteins exert biological 
effects on target tissues by interaction with specific cell-surface AGE receptor proteins 130, 194-196. 
Therefore, the in-vitro binding of our panel of AGE-modified protein samples to two known 
AGE receptors: RAGE and galectin-3 was studied. RAGE is an immunoglobulin-like multi-
ligand and pattern recognition receptor 197, which not only binds AGE compounds, but also S100 
proteins 198, amyloid peptides 199, amphoterin 17, and double stranded DNA 200. Galectin-3 is a 
component of the AGE-receptor complex and member of the lectin protein family with affinity 
for β-galactosides 201, but galectin-3 also has high binding affinity for AGE 202.  
Initially, pull-down assays between glycated BSA samples and immobilized RAGE-VC1 
domain and galectin-3, respectively were performed. These binding experiments indicated that 
most glycated BSA samples did not bind to either galectin-3 or RAGE with high affinity. 
However, the ribose modified samples did bind tightly to both RAGE and galectin-3, 
respectively. Our pull down assay involves intensive washing of the isolated protein-protein 
complex and weak binding will not be detected. To estimate the sensitivity of our pull-down 
experiments, S100B was used as a positive control protein. S100B binding to RAGE has been 
well characterized by us 203, 204 and is in the low to sub-micromolar range. S100B binding to 
RAGE could be detected in our experimental set-up, suggesting that the binding affinity of 
ribose modified BSA is in a similar range, whereas the binding affinity of our other glyacted 
samples is likely to be lower (Kd > 50 µM).  
To further define the binding of RAGE and galectin-3 to AGE-modified proteins in a 
more quantitative manner, a fluorescence polarization based assay was developed. The intrinsic 
fluorescence of our AGE modified protein samples was used, which allowed us to avoid any 
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additional reporter label or immobilization of the proteins. The interaction of the two protein 
components directly and label free in solution was measured. The binding affinities for the 
protein-protein interactions in solution could also be calculated by this polarization assay. 
Typical titration binding curves of AGE-BSA to RAGE-VC1 are shown in Figure 2.16. We 
estimate that we are able to detect binding affinities lower than 50 µM in our experimental set-
up.  
The results of the polarization assays are in agreement with those of the pull down assay. 
Binding to RAGE was observed only with the rib-H BSA and 500mM rib BSA (Table 2.5). The 
binding experiments with galectin-3 confirmed binding of all ribose modified samples bound 
more tightly to galectin-3 than to RAGE. None of the other glycated samples showed binding 
affinity below Kd < ~50 µM to either RAGE or galectin-3 in vitro. This includes glucose 
modified modified BSA, which is frequently used in glycation related research studies. However, 
there is an ongoing controversy about which type of AGE compounds can bind to RAGE. For 
example, several authors have reported independently, that CML-modified BSA does not interact 
with RAGE in cell based assays 205-208. Whereas others report CML-modified proteins to be bind 
to RAGE and to activate cellular signaling 209, 210. There is general agreement in the literature 
that ribose glycated proteins do bind to RAGE. Discrepancies between in-vitro and in-vivo 
binding studies may be explained by the intrinsic differences between the experimental systems. 
The spatial arrangement of AGE-receptors on the cell surface, and possibly the recruitment of 
co-receptors, can significantly influence ligand binding.  
Our studies are the first to measure the binding of a panel of moderately glycated BSA to 
RAGE and galectin-3 in vitro in solution with monomeric RAGE-VC1 and galectin-3. Under 
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these conditions, only ribose derived AGE compounds bound with high affinity to either RAGE 
or galectin-3. 
 
 
 
 
 
 
 
Figure 2.16. Binding curves of ribose modified BSA to RAGE-VC1 (solid squares) and galectin3 
(solid dots).  
Binding of BSA modified with 20 mM ribose (Rib-L) is shown in green, samples modified with 
200 mM ribose (Rib-H) are shown in blue and samples modified with 500 mM ribose (Rib-vH) 
are shown in blue. The intrinsic fluorescence of ribose glycated BSA was used to follow changes 
in fluorescence polarization upon binding to RAGE or galectin-3.  
Table 2.5. Binding affinities between AGE-BSA samples and RAGE and galectin-3, 
respectively.  
Binding affinities were calculated based on data from fluorescence polarization titrations. The Kd 
values shown as >50 µM indicate that these compounds do not bind with affinities below 50 µM 
to either RAGE or galectin-3. 
Sample Kd 
AGE-RAGE 
(µM) 
Kd 
AGE-
galectin (µM) 
Dia-H BSA > 50  > 50  
Gly-H BSA > 50  > 50  
Gla-H BSA > 50  > 50  
MG-H BSA > 50 > 50 
Rib-L BSA > 50 17.0 ± 0.4 
Rib-H BSA 9.1 ± 0.3 2.4 ± 0.6 
Rib-vH BSA 2.0 ± 0.8 0.9 ± 0.1 
Glc-vH BSA > 50 > 50 
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Effects of glycated BSA on cell proliferation  
Our binding assays indicated that most of our AGE samples did not bind tightly to 
RAGE. However, lack of tight binding in vitro does not preclude biological activity in more 
complex biological assays. 
Therefore, the effects of AGE on cellular proliferation in a model system using the 
WM115 primary human melanoma cell line was studied. RAGE overexpression in melanoma 
tumors has been previously reported 211. The WM115 cell line naturally expresses galectin-3 and 
was further modified to stably express RAGE. Our research group has characterized this cell line 
in detail and demonstrated that RAGE overexpression increases cell motility and tumor growth 
in a mouse model 212. We therefore believe that our cell based model is suitable to test whether 
different AGE preparations affect cellular behavior.  
Twelve of our AGE–modified BSA samples was studied for their cell mediated effects. 
Figure 2.17 summarizes the results of our proliferation assay and indicates that most glycated 
samples increased cellular proliferation when compared to non-modified BSA. Glyoxylic acid 
modified BSA (GA-H-BSA) had no significant effect on cell proliferation. GA-H-BSA was also 
the least glycated sample in our panel based on lysine and arginine modification (Table 2.2). All 
other glycated BSA samples increased proliferation to varying degrees. Ribose modification was 
most effective in enhancing proliferation, whereas AGE-BSA derived from equal concentrations 
of glucose were much less effective. In fact, AGE-BSA derived from 20 mM ribose (Rib-L-
BSA) increased cell proliferation more effectively than AGE-BSA obtained by glycation with 
500 mM glucose. Comparing the three ribose modified protein samples showed enhanced 
proliferation with increased degree of glycation. The observed increase in cellular proliferation 
was correlated with the biophysical characterized properties of the samples. A linear correlation 
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was observed between enhancement of cell proliferation and extend of lysine modification (R = 
0.92) (Figure 1.18), as well as with β-sheet content (R = 0.83) (Figure 2.18) and the percentage 
of non-monomeric material (R = 0.79) (Figure 2.18). There was no correlation with the degree of 
arginine modification (R = 0.39). However, the extent of amino acid side chain modification of 
glycated BSA alone is not sufficient to predict efficacy as proliferation enhancer in our system. 
For example, acetoin modified (Ace-H-BSA) and glyceraldehyde modified (Gly-H-BSA) 
samples showed similar proliferation activity, but varied greatly in the extent of lysine and 
arginine modification (Table 2.2) and spectroscopic properties. This demonstrates that not only 
the extent of modification, but also the chemical nature of the glycation reagent and the structure 
of newly formed side chain modifications is important for the biological activity of glycation and 
AGE compounds.  
 
 
 
 
 
 
 
 
 
Figure 2.17. Cellular proliferation was assessed by measuring the fluorescence of reduced 
resazurin (Alamar blue).  
The measured proliferation signal is proportional to the number of cells and their metabolic 
activity. All samples tested increased proliferation when compared to non-modified BSA. 
Methylglyoxal and ribose modified samples were the most effective proliferation enhancers. **p 
< 0.001;*p < 0.01; #p < 0.05, NS not significant. The assay was performed three times 
independently, a representative example is shown in which each sample was analyzed in four 
independent assay plate wells. 
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Figure 2.18. The cellular proliferation enhancement by AGE-modified BSA samples could be 
correlated with biophysical properties such as the extent of lysine side chain modification (top), 
b-sheet secondary structure content (middle) and the degree of non-monomeric in the sample 
(bottom).  
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Figure 2.19. AGE induced cellular proliferation of the WM115 mock transfected cells 
These cells do not over express RAGE.  
Thermodynamic characterization of diclofenac binding to glycated-BSA by isothermal 
titration calorimetry (ITC) 
The interaction and the thermodynamic characteristics between diclofenac and glycated 
BSA was measured by Isothermal titration calorimetry. The low glycated samples were used for 
the study as the glycation conditions are very close to physiological conditions. The changes in 
Gibbs free energy ΔG and of the entropic parameter ΔS were calculated based on experimentally 
determined changes of the enthalpy ΔH and the affinity constant Ka. The stoichiometry of the 
drug – albumin interaction was derived directly from the fitting of experimental data. The 
parameters for the complete thermodynamic description of the interaction between diclofenac 
and glycated forms of BSA are summarized in table 2.6. Two experimental ITC traces and the 
fitting of the data are shown in Figure 2.20.  
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To fit the data several models were explored to fit the titration curves and found that all 
data could be fitted well using a model assuming a set of identical, independent binding sites. 
More complex models accounting for multiple binding sites with different affinities or 
cooperativity did not yield better fits 213. Our experiments showed that the addition of diclofenac 
to glycated, as well as to native BSA, resulted in an exothermic interaction with well-developed 
heat peaks (Figure 2.21). For non-glycated, defatted BSA, both, the enthalpic DH and entropic 
components -TΔS were negative and contributed positively to the negative Gibbs energy ΔG.  
For non-defatted BSA the entropic component -TΔS was close to zero and the binding was 
almost exclusively driven by the change in ΔH. Surprisingly, the diclofenac binding properties 
for the CML-L-BSA modified samples were very similar to the properties of the non-modified 
protein. The diclofenac binding to CML-L-BSA was driven by the negative change in ΔH of -22 
kJ mol-1 K-1 and only a small contribution of -TΔS of -1.77 kJ mol-1. For all other glycated BSA 
samples the entropic components –TΔS were opposing the enthalpic ΔH components 
contributions by +4 to +45 kJ mol-1 K-1. 
Figure 2.20 shows the relative magnitude of ΔG, ΔH and –TΔS for diclofenac binding to 
glycated BSA. The Gibbs free energy ΔG changes only little, while values for ΔH and -TΔS 
increase with glycation. The interpretation of these data on the molecular level is not 
unambiguous, but could be interpreted to indicate that increased ΔH contributions from 
hydrophobic interactions are off-set by entropic factors, possibly resulting from reduced 
flexibility in the protein after drug binding. 
The binding affinity for diclofenac to non-glycated BSA was determined to be Ka 2.4x10
4  
M-1 (Kd = 42 µM) which is in agreement with literature values 
150, 152, 153. In general, glycation of 
albumin resulted in reduced binding affinities for diclofenac. The extent by which the binding of 
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the drug to the protein was weakened depended on the glycation reagent and was reduced 
maximally by six-fold from Ka 2.4x10
4 M-1 to Ka 4x10
3 M-1 (Kd 42 to 250 µM) for modifications 
with ribose, glycolaldehyde and diacetyl. For the other glycation reagents the decrease in binding 
affinity was less pronounced.  
The data also suggest that glycation not only modulated binding affinity, but also altered 
the number of apparent diclofenac binding sites (Table 2.6). Non-glycated BSA possess two 
diclofenac binding sites and glycation with the majority of the tested reagents (Ace, Dia Gly, 
Gla, MG) reduced the number of binding sites by about 25% to a nominal number of 1.5 binding 
sites.  A much more pronounced loss of binding sites was detected for ribose modified BSA 
(Rib-L-BSA), where almost two thirds of the drug binding capacity was lost and only 0.8 
nominal binding sites remained. Interestingly, the opposite effect was seen for glycation with 
glucose (Glc-L-BSA), which increased the number of diclofenac binding sites to 2.7 and with 
CML-modified albumin (CML-L-BSA), with a 75% increase in binding capacity to 3.5 binding 
sites. 
Our ITC experiments demonstrated that the nature of the glycation reagents determined 
the binding properties for diclofenac. Glycation decreased binding affinity for all samples 
analyzed but could either increase or decrease the number of drug binding sites, depending of the 
glycation reagent used. This leads to situations in which decreased binding affinity can be 
compensated by increased binding stoichiometry, thus not altering the binding capacity 
significantly. It can also have the opposite effect in which the drug binding capacity is reduced 
because of lower binding affinity and concomitant loss of binding sites. We estimated the 
diclofenac binding capacity of glycated serum albumin samples using: 

Kd *n*[Alb] 
Alb DCF 
[DCF]        (2.2) 
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Figure 2.22 shows the ratio between albumin bound diclofenac (Alb-DCF) and unbound, 
free diclofenac (DCF).  An invariant serum albumin concentration [Alb] of 600 mM (4g/dL) 
based on the physiological albumin concentration and a concentration for diclofenac below 10 
mM based on therapeutic peak serum concentrations 214, 215 was assumed. This analysis showed 
that the diclofenac binding capacity dropped significantly upon glycation for some glycation 
reagents. Correspondingly, the free drug concentration increased from 3% for non-glycated BSA 
and CML-L-BSA (Glc-L-BSA) to ~10% for glucose modified BSA and 50% for ribose modified 
BSA (Rib-L-BSA).  
Table 2.6. Thermodynamic parameters for the interaction between glycated serum albumin and 
diclofenac determined by ITC.  
Sample Ka  
(M-1) 
n H  
(kJ mol-1) 
G  
(kJ mol-1) 
-TS  
(kJ mol-1K-
1) 
DF-BSA 
(24.9 + 4.5) x 
103 
2.04 + 0.16 -18.9 + 0.4 -25.05 + 0.46 -6.14 + 0.83 
BSA 
(24.2 + 2.8) x 
103 
2.07 + 0.03 -24.3 + 0.2 -25.00 + 0.29 -0.72 +  
0.47 
Glc-L BSA 
(6.0 + 0.5) x 
103 
2.69 + 0.18 -25.5 + 2.0 -21.53 + 0.24 3.97 + 1.71 
Ace-L BSA 
(12.3 + 0.9) x 
103 
1.61 + 0.11 -28.9 + 0.4 -23.32 + 0.19 5.54 + 0.23 
Dia-L BSA 
(4.4 + 0.1) x 
103 
1.47 + 0.01 -49.3 + 1.0 -20.80 + 0.04 28.54 + 0.96 
Gly-L BSA 
(5.6 + 0.4) x 
103 
1.46 + 0.01 -43.1 + 0.8 -21.37 + 0.17 21.72 + 0.92 
Gla-L BSA 
(3.8 + 0.7) x 
103 
 1.55 + 0.01 -54.6 + 5.9 -20.38 + 0.45 34.24 + 6.34 
MG-L BSA 
(7.0+ 1.3) x 
103 
1.57 + 0.05 -34.8 + 3.6 -21.93 + 0.46 12.89 + 4.11 
Rib-L BSA 
(4.7 + 0.3) x 
103 
0.76 + 0.16 -65.9 + 7.6 -20.94 + 0.15 44.91 + 7.41 
CML-L 
BSA 
(14.6 + 2.4) x 
103 
3.48 + 0.23 -22.0 + 2.1 -23.73 + 0.41 -1.77 + 2.53 
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Figure 2.20. Representative ITC titrations profiles and corresponding fits two glycated forms of 
BSA.  
The top panels show the raw heats measured during each injection of diclofenac into a solution 
of CML-L-BSA and Ace-L-BSA respectively. The lower panels show fit (red line) of the 
experimental data (blue dots) using a model for multiple independent binding sites.  
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Figure 2.21. Contribution of ΔH (red shaded bars) and –TΔS (green shaded bars) to the change in 
free Gibbs energy ΔG (blue solid bars).  
 
 
 
 
 
 
 
 
 
 
Figure 2.22. The relative distribution in % between diclofenac (DCF) protein bound to different 
forms of glycated bovine serum albumin (solid blue) and non-bound, free diclofenac (shaded 
red).  
Estimations are based on binding affinities and stoichiometries determined in this study, and 
assumed concentration of 0.6 mM serum albumin in serum and a total DCF concentration below 
10 mM. Non-glycated BSA has high DCF binding capacity, leaving only 3% unbound. Glycation 
generally reduces DCF binding capacity. 
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Binding of diclofenac to glycated BSA stabilizes the protein 
Our ITC data we shown that the number of diclofenac binding sites and the binding 
affinity was altered by glycation and we wanted to obtain additional insight in the mechanism of 
diclofenac binding to glycated BSA. Differential scanning calorimetry (DSC) was used to 
investigate the consequences of diclofenac binding on the stability of glycated BSA against 
thermal unfolding. DSC provides information about the thermal properties of molecules and can 
directly measure enthalpies associated with thermal transitions 216, 217. Complete thermodynamic 
characterization of protein unfolding requires that the process is reversible. If a thermal transition 
is irreversible, then the midpoints of the thermal transition(s) Tm and the overall shape of the 
thermogram are of interest. 
The thermal unfolding of BSA occurs in multiple transitions in a temperature range 
between 50 °C to above 90 °C and significant changes in heat capacity (Cp). The thermal 
unfolding of serum albumin is irreversible, thus limiting the thermal analysis to the unfolding of 
the protein only. The thermal stability of BSA is also known to be sensitive to the presence of 
bound fatty acids and the buffer composition 193, 218. Near physiological phosphate buffered 
saline (PBS) was used for all experiments. The protein concentration in all DSC experiments was 
45 mM and a 22-fold molar excess of diclofenac (1 mM) ensured high occupancy of diclofenac 
binding site on glycated based on the binding affinities determined by ITC. 
Non-defatted BSA shows two transition peaks in the DSC profile, whereas defatted BSA 
shows only a single transition peak 191, 219. A first transition occurs at Tm 62.8 ºC, followed by a 
second transition at Tm 80.9 ºC (Table 2.7 and Figure 2.23). The estimated enthalpies of 
unfolding associated with these transitions are 380 and 824 kJ mol-1 K-1. In the presence of 
diclofenac a very significant a significant stabilization of the protein against heat induced 
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unfolding was observed and the first Tm1 increased by almost 13 ºC from 62.8 to 75.7 ºC, and 
the second Tm2 by almost 3 ºC to 83.7ºC. The associated enthalpies also increase dramatically to 
622 kJ mol-1 K-1 and 1672 kJ mol-1 K-1. The increase in Tm clearly and the increased enthalpy 
changes ΔH showed that diclofenac bound to BSA and increased the energy necessary to disrupt 
non-covalent, intra-molecular interactions to unfold the drug-BSA complex.  
Our DSC data for the unfolding of defatted BSA (DF-BSA, Tm of 61.8 ºC and ΔH of 451 
kJ mol-1 K-1) and for the diclofenac-DF-BSA complex (Tm 76.1ºC, ΔH to 701 kJ mol-1 K-1) 
confirmed previously reported data by Sharma et al. 153. 
The increases in thermal stability upon diclofenac binding were similarly impressive for 
the glycated samples. Increases in Tm1 between 10 ºC and 15 ºCare observed, except for ribose 
modified BSA, which shows only a marginal increase in thermal stability upon drug binding by 
3.8 ºC. Table 2.7 summarizes the calculated Tm and ΔH values for all samples analyzed and 
Figure 2.23 shows DSC thermograms for glycated BSA in the presence and absence of 
diclofenac. Comparing the thermograms clearly shows the shift of the unfolding transition to 
higher temperatures. Additional peaks and shoulders in thermograms also indicate changes in 
unfolding mechanism between samples and upon diclofenac binding. This is indicative of 
different binding modes of diclofenac to the differentially glycated serum albumin samples. 
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Figure 2.23. DSC traces of glycated BSA in absence (dashed blue lines) and the presence of 
diclofenac (solid red lines). Binding of diclofenac to all samples caused a significant shift of the 
thermal transition midpoint Tm to higher temperatures.  
 
 
 
 
 71 
Table 2.7. Thermal stability and unfolding characteristics of glycated serum albumin in the 
absence and presence of diclofenac (DCF) as determined by DSC.  
Diclofenac binding to albumin leads to a significant increase in thermal stability for all samples 
analyzed. Thermal transition midpoint temperatures Tm increased by 10 - 15 °C and DH values 
for the unfolding process increased as well. Compare to Figure 3 for differences in thermogram 
profile. 
 Sample DCF Tm1 
( °C ) 
 H1 
(kJ mol-1 K-1) 
Tm2 
( °C ) 
 H2 
(kJ mol-1 K-1) 
DF-BSA 1 mM 76.1 ± 0.1 701 ± 2 - - 
DF-BSA -- 61.8 ± 1.0 452 ± 5 - - 
BSA 1 mM 75.7 + 0.3 623 + 14 83.7 + 0.1 1672 + 28 
BSA -- 62.8 + 0.2 379 + 2 80.9 + 0.8 825 + 13 
Glc-L BSA 1 mM 74.0 ± 0.5 573 ± 29 84.1 + 0.2 1155 ± 75 
Glc-L BSA -- 64.1 ± 0.2 382 ± 7 84.2 ± 0.3 860 ± 8 
Ace-L BSA 1 mM 75.0 ± 0.4 682 ± 38 84.0 ± 0.1 1216 ± 43 
Ace-L BSA -- 63.5 ± 0.2 420 ± 11 80.1 ± 0.2 848 ± 6 
But-L BSA 1 mM 79.3 ± 0.3 399 ± 25 - - 
But-L BSA -- 65.9 ± 0.1 418 ± 4 82.5 ± 0.1 767 ± 5 
Gly-L BSA 1 mM 79.2 ± 0.1 433 ± 1 - - 
Gly-L BSA -- 66.0 ± 0.1 436 ± 8 82.2 ± 0.1 850 ± 2 
Gal-L BSA 1 mM 79.0 ± 0.1 383 ± 2 - - 
Gal-L BSA -- 64.1 ± 0.1 414 ± 2 82.8 ± 0.2 746 ± 6 
MG-L BSA 1 mM 79.0 ± 0.3 431 ± 8 - - 
MG-L BSA -- 66.3 ± 0.1 420 ± 2 82.6 ± 0.4 856 ± 3 
Rib-L BSA 1 mM 76.0 ± 0.4 296 ± 4 - - 
Rib-L BSA -- 72.2 ± 0.1 349 ± 3 - - 
CML-L 
BSA 
1 mM 75.8 ± 0.1 698 ± 12 83.6 ± 0.1 1196 ± 7 
CML-L 
BSA 
-- 62.9 ± 0.4 514 ± 13 79.8 ± 0.2 759 ± 22 
Effect of diclofenac binding on secondary structure 
The structural characteristics of diclofenac binding to glycated BSA was determined by 
circular dichroism spectrometry. The effect of different glycation reagents on the secondary 
structure of serum albumin was described earlier and we observe that glycation affects the 
secondary structure of serum albumin by breaking α-helices and increasing the β-sheet content 
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and the number of poorly ordered residues118, 187. This process leads to partial loss of native 
structure of the protein, but does cause extensive unfolding. We expanded this study and 
investigated if the binding of diclofenac to glycated BSA would further alter the secondary 
structure composition. 
We found that binding of diclofenac to non-glycated serum albumin caused only minor 
alterations in secondary structure compositions, that were not statistically significant in the 
student t-test (p>0.05) (Figure 2.24). This result was expected and demonstrated that the natively 
folded serum albumin does not alter its secondary structure upon drug binding to an extent that 
can be detected by CD. Surprisingly, we found similar structural stability for the glycated forms 
of serum albumin. Statistical analysis of the secondary structure composition for glycated serum 
albumin samples in the presence and absence of a 22-fold molar excess of diclofenac did not 
indicate any significant changes in secondary structure. There was only one exception in which 
diclofenac binding had a significantly (p = 0.008) effect on secondary structure. The ribose 
glycated sample did show a reduction of poorly ordered residues from 37.6 to 34.0 % upon 
diclofenac binding. Based on 583 amino acid residues in mature BSA, we calculated that 
approximately 20 residues changed from a disordered conformation and adopted an α-helical (~9 
residues), β-sheet (~6 residues) or turn conformation (~5 residues).  
Our CD-data showed that while glycation altered the secondary structure of serum 
albumin for all glycated forms, the binding of diclofenac did not further affect the secondary 
structure compositions to a significant level. A notable except was the ribose modified BSA 
sample. The ribose glycation did disturb the native secondary structure the most, showed the 
least thermal stabilization in DSC experiments and had retained the lowest diclofenac binding 
cap 
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Figure 2.24. Circular dichroism (CD) analysis of glycated serum albumin samples for secondary 
structure composition and changes in secondary structure composition in the presence a 
saturating excess of diclofenac.  
Binding of diclofenac did not significantly change the secondary structure of albumin. Top: 
representative CD traces of BSA, CML-L-BSA, MG-L-BSA and Rib-L-BSA in the absence 
(solid lines) and presence (dashed lines) of diclofenac. Bottom: Distribution of secondary 
structure elements in glycated samples of serum albumin. Glycation reduces a-helical (black) 
content and increases the content of residues in b-sheet (green), turn (blue) and unordered 
conformation. 
Dynamic light scattering studies 
Here we expended these studies using dynamic light scattering as an analytical method 
that provides insights into particle size and size distribution within a particle population. 
Literature data report a hydrodynamic diameter for non-glycated bovine serum albumin between 
3.3 – 4.3 nm depending on pH and buffer composition 221, 222. We measured a Z-average radius 
of 4.4 nm for non-glycated BSA under our experimental conditions. The majority of glycation 
reagents did only cause minimal increases in average particle size, indicating that intermolecular 
cross linkage between protein chains was not extensive. The only exception was found in 
samples modified with ribose. In these samples the average particle radius doubled suggesting 
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that multiple albumin chains had been cross-linked. Minor cross-linkage was detected based in 
increased particle size (5.05 - 5.25 nm) for glycation with diacetyl and glcolaldehyde, 
respectively. Our data from DLS experiments are in excellent agreement with previous results 
from analytical size exclusion chromatography. 
Table 2.8. Dynamic light scattering was used to characterize protein aggregation and to 
determine the Z-average size and polydispersity of the samples. 
Sample 
Name 
Z-Average 
Radius 
(nm) 
Polydispersity 
Index 
BSA 4.41+ 0.01 0.28 + 0.01 
Glc-L-BSA 4.51 + 0.01 0.21 + 0.01 
Glc-H BSA 9.18±0.11 0.17±0.000 
Glc-vH BSA 10.83±0.33 0.30±0.01 
Ace-L BSA 4.65 + 0.01 0.29 + 0.01 
Ace-H BSA 9.91±0.08 0.33±0.002 
Dia-L BSA 5.06 + 0.01 0.35 + 0.01 
Dia-H BSA 9.91±0.19 0.29±0.004 
Gly-L BSA 4.67 + 0.07 0.25 + 0.01 
Gly-H BSA 10.22±0.16 0.26±0.003 
Gla-L BSA 5.25 + 0.19 0.29 + 0.01 
Gla-H BSA 16.18±0.33 0.22±0.001 
MG-L BSA 4.75 + 0.03 0.28 + 0.01 
MG-H BSA 9.54±0.16 0.22±0.001 
Rib-L BSA 8.64 + 0.03 0.37 + 0.01 
Rib-H BSA 19.83±0.82 0.24±0.004 
Rib-vH BSA 19.19±0.08 0.24±0.001 
CML-LBSA 4.22 + 0.03 0.25 + 0.01 
CML-H BSA 9.19±0.22 0.30±0.02 
 
Conclusions 
Protein glycation and AGE formation are physiologically relevant processes and 
excessive AGE formation has been clearly correlated with severe health problems as described 
earlier. Consequently, there is much interest in assessing the effects of AGE products at the 
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molecular and cellular levels. In vitro produced AGE products are very frequently synthesized 
under conditions that lead to levels of excessive modification and are unlikely to occur under 
(patho) physiological conditions. Also, different investigators employ various reagents to 
produce AGE proteins, further complicating interpretation and comparisons between studies. 
It was our goal to produce serum albumin with moderate modification levels similar to 
physiological conditions and to analytically characterize its properties. We therefore used low 
modifier concentrations and equally important limited the time of modification to three weeks, 
which is the half-life of serum albumin.  
Glycation and subsequent formation of intermediate and advanced glycation end products 
was qualitatively and quantitatively characterized. Chemical reactivity and concentration of the 
glycation reagent determined the extent of side chain modification. For example, glucose was a 
relatively poor glycation reagent when compared to ribose or reactive aldehydes such as 
methylglyoxal or glyceraldehyde. This may have implications for the hypothesis that the 
elevated AGE levels observed in diabetic patients are directly derived from increased blood 
glucose. Chemically distinct side chain modifications are introduced into glycated albumin 
depending on the glycation reagent. This was demonstrated by the differences in absorbance and 
fluorescence spectroscopic properties between the different glycation products produced in the 
study. Spectroscopic analysis techniques may become useful in characterizing biological AGE 
compounds and deducing the glycation reagent involved in AGE formation. We confirmed by 
circular dichroism spectrometry that glycation of BSA, which is a largely α-helical protein, led to 
the breakage of α-helices and increased formation of β-sheet secondary structures. At the same 
time, glycation destabilized the overall protein fold and increased flexibility of the protein. 
However, even high levels of glycation did not unfold BSA completely, but rather led to the 
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formation of a heterogeneous population of molten globule like conformations. The fact that 
BSA remains soluble even in a highly glycated state may not be a general feature of glycation. 
Few reports in the literature suggest that high levels of glycation induced protein aggregation 223, 
224. This suggests that the highly glycated AGE compounds can exist in a soluble form and bind 
to AGE signaling receptors such as RAGE and galectin-3 to trigger signaling. In vitro binding 
studies between AGE-BSA and RAGE or galectin-3 revealed that binding of most compounds to 
the AGE-receptors is weaker than our detection limit (Kd  ~ 50 µM). However, ribose glycated 
protein bound tightly to RAGE (2.0 µM), as well as to galectin-3 (2.0 µM). Interestingly, the 
binding affinity (Kd) increased with the extent of glycation, which suggests a qualitative 
difference between the samples. It may be possible that higher glycation generates more potential 
binding sites for RAGE or galectin-3 in the protein surface, or that oligomerization clusters more 
binding epitopes. In both scenarios, avidity effectively increases the apparent macroscopic 
binding affinity. 
The biological activity of our glycated samples was determined in a cell based 
proliferation assay. The observed increase in cell proliferation could be correlated with the extent 
of lysine residue modification, β-sheet content and oligomerization state of the glycated protein. 
However, other factors, most probably the chemical structure of the formed AGE modifications 
on the protein surface are important too. The observation that AGE compounds exert biological 
activity at concentrations (3.5 µM) well below their in-vitro determined binding affinities (Kd > 
50µM) may be explained by multiple hypotheses. It is conceivable that RAGE or galectin-3 
receptors form larger clusters on the cell surface, thus effectively increasing binding affinity by 
avidity. In fact, RAGE has been shown to form dimers in the plasma membrane 225. 
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Alternatively, RAGE or galectin-3 may associate with additional co-receptors on the cell surface, 
which could increase binding affinity for glycated proteins. 
Building upon our studies on the structural changes in albumin upon glycation we finally 
investigated the role of glycation in drug binding of serum albumin. We hypothesized that 
glycation of serum albumin affects drug binding in a manner that is specific to individual 
glycation reagents. 
Our investigation shows that glycation does significantly alter the thermodynamics and 
the mechanism of diclofenac binding to serum albumin. Glycation reduces the binding affinity 
by up to six-fold, alters the number of diclofenac binding sites from 2 to between 0.8 to 3.5 
binding sites per albumin molecules, depending on the nature of the glycation. The relative 
enthalpic and entropic contributions of the protein—drug interaction are greatly altered, while 
the differences in Gibbs free energy changes ΔG remained relatively small (~ 5 kJ mol-1) 
between samples. 
The data demonstrate that increased serum protein glycation reduces the diclofenac 
binding capacity to an extent that could be pharmacologically relevant in patients with high 
levels of serum albumin glycation. The modification of drug binding properties also depends on 
the chemical nature of the glycation reagent and thus on the physiological source of the reactive 
carbonyl compound causing glycation. 
In summary, our study demonstrates significant differences between different glycation 
reagents in their ability to alter the biophysical properties of serum albumin and to generate 
biologically active AGE-compounds. It also underlines the importance of choosing the most 
appropriate glycation reagent when AGE compounds are being prepared for biological studies. 
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Our findings should accelerate our understanding of the biological role of AGE compounds in 
disease development and progression. 
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CHAPTER 3: THE ROLE OF AGE COMPOUNDS AND THEIR INTERACTION WITH 
RAGE IN PANCREATIC CANCER CELL PROLIFERATION AND MIGRATION 
Introduction 
Pancreatic cancer  
Pancreatic adenocarcinoma is one of the most devastating malignant diseases and is 
responsible for more than 227,000 deaths each year in the world 226. It is the fourth leading cause 
of cancer related deaths in the US with an estimated 34,000 deaths every year 227. Pancreatic 
cancer is characterized by very poor prognosis due to the absence of specific early symptoms 228, 
229. Consequently, the median survival rate is about 5-6 months in conventional therapies and the 
5-year overall survival rate is less than 5% 228. The etiology of pancreatic cancer is poorly 
understood and the disease is characterized by high metastatic rates. The low survival rates are 
primarily due to the fact that the pancreatic cancer tumors exhibit very few symptoms and 
progress very rapidly and when detected are at an advanced stage and only 10% being operable 
230.  Hence, the early detection and diagnosis of the disease is essential to improve outcomes. 
However, the lack of prognostic markers hampers the early detection of the disease. Pancreatic 
cancer is also genetically complex which adds to the difficulty in treating the disease. Several 
key genes including the KRAS, TP53, SMAD4 and CDKN2A are mutated which in turn effect 
signaling pathways such as KRAS signaling, apoptosis and hedgehog signaling231, 232 hence 
making the treatment of the disease difficult. Presently, the most effective therapy for the 
treatment of pancreatic cancer is by palliative chemotherapy of FOLFIRINOX (folinic acid, 5-
fluorouracil, irinotecan and oxaliplatin) and gemcitabine/nab-paclitaxel 233. However, to ensure 
the best treatment for patients and to reduce the mortality it is important to further identify new 
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targets and treatment strategies. We focus on the role of the receptor for advanced glycation end 
products (RAGE) as a target in the treatment of pancreatic cancer.     
RAGE and its ligands in pancreatic cancer 
As described earlier RAGE is a member of the Ig protein super family and is a pro-
inflammatory receptor. RAGE and its ligands, which are secreted from the cancer cells and 
leukocytes, such as high-mobility group box 1 (HMGB1) and S100 proteins facilitate the 
maintenance of a chronic inflammatory state which leads to the development and progression of 
several cancers and also promotes metastases 36, 234. The role of RAGE in tumor growth and 
metastasis has been described in pancreatic cancer 81, 235, 236. RAGE has been described to be 
permissive for the early pancreatic neoplasia which leads to pancreatic cancer 237. The role of 
RAGE-HMGB1 interaction in sustaining autophagy and limiting pancreatic cancer cell apoptosis 
during chemotherapy and oxidative stress has been described in vivo and in vitro 235, 236.  
Recently, the role of RAGE in enhancing neutrophil extracellular traps (NETs) formation in 
autophagy mediated pathways has been described in pancreatic cancer 238.  The other ligand of 
RAGE which is well studied in pancreatic cancer is S100P.  S100P promotes pancreatic cancer 
growth, survival and invasion and is a novel therapeutic target for pancreatic cancer 239, 240. 
S100P-RAGE interaction has been described to be essential in the S100P mediated effects in 
pancreatic cancer. Inhibition of S100P-RAGE prevented S100P induced pancreatic cancer 
growth 81. All these studies establish RAGE as an important target for the treatment of pancreatic 
cancer. However, RAGE signaling is highly complex the role of other RAGE ligands such as the 
AGE compounds has not been studied in pancreatic cancer. The role of AGE-RAGE interaction 
in pancreatic cancer cell survival, proliferation and migration has not been reported. As 
described in chapter1, AGEs are highly heterogeneous in nature and the structural basis behind 
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the toxic AGE compounds is not understood currently. This study was undertaken to elucidate 
the role of AGE compounds in pancreatic cancer cell proliferation and migration and to identify 
the role of AGE-RAGE interaction in the AGE mediated cellular effects. Targeting the AGE-
RAGE axis is an effective strategy to prevent AGE mediated cellular effects. Several approaches 
have been used to inhibit RAGE-ligand interaction like truncated form of the receptor (sRAGE) 
36, RAGE blocking antibodies 241, ligand derived peptides 81, 242 and several other chemical 
inhibitors have also been described to have RAGE inhibiting effects 243 69.  The ultimate goal of 
the study was to pharmacologically inhibit AGE-RAGE interaction to prevent AGE mediated 
effects in pancreatic cancer.  
Pancreatic cancer and glycation 
Glycation and AGE compounds formation is not very well understood in the context of 
tumor biology and cancer disease progression. In malignant tumors there is a shift in metabolism 
away from oxidative phosphorylation to aerobic glycolysis 244. This results in increased glucose 
uptake into the tumor. This effect is called Warburg effect and is a hallmark of cancer 245. This 
increased glucose flux coupled with hypoxic conditions in the tumor can lead to significant 
increase in glycation and the formation of AGE compounds. The formation of AGE compounds 
and the presence of certain AGE compounds such as CML and argpyrimidine have been 
identified in cancer tissues such as adenocarcinomas of the colon and leiomyosarcomas, 
squamous cell carcinomas of the larynx and adenocarcinomas of the breast 97. The mitogenic 
effect and migratory potential of AGE compounds have also been demonstrated in breast 246, 
lung 247 and oral 248 cancer cell lines. The role of glucose modified AGE compounds has been 
described to stimulate the growth of human pancreatic cancer cells by promoting DNA synthesis 
249. The AGE compounds are highly heterogeneous in nature and our knowledge on the AGE 
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compounds formed in tumors and their effects in tumor growth is limited. It is not clear if only 
certain AGE compounds play an important role in the tumor progression while the others are 
benign. Reports suggest that glyceraldehyde derived AGE compounds and methyl glyoxal 
derived AGE compounds play a role in increased tumor cell proliferation and migration 246, 247 
while the AGE compounds derived from glucose were reported to be benign 247. However, there 
is no consensus on the toxic AGE compounds (TAGE) and it is unclear if there is a certain 
modification or a structural feature of the AGE compounds responsible for their activity. We 
previously characterized an entire panel of AGE compounds (Chapter 2) and this study was 
initiated to correlate the glycation induced structural changes in this AGE compounds to their 
activity, more specifically their mitogenic and proliferative effect in pancreatic cancer cell lines. 
The AGE compounds trigger signaling through several surface receptors such as RAGE and 
AGE receptor complex, as described in chapter 2. RAGE is the most well studied signaling 
receptor for the AGE compounds.   
Pancreatic cancer patients are frequently characterized by hyperglycemia 250, 251. About 
85% of the patients diagnosed with pancreatic cancer are found to have impaired glucose 
tolerance or frank diabetes 250, 251. Reports also suggest the onset of diabetes 2-3 years preceding 
the diagnosis of pancreatic cancer (T3cDM) 252. A recent report suggests the role of glucose 
mediated hypoxia to promote cell proliferation and migration in pancreatic cancer 253. These 
increased hypoxic conditions could cause the accelerated formation of AGE-compound 
generation and accumulation at the tumor site. However, the role of AGE-compound 
accumulation has not been described in pancreatic cancer and requires further investigation.  
We hypothesized that AGE-RAGE interaction triggers cellular signaling which leads 
cancer cell proliferation and migration. 
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 Glycation induced changes in the protein leading to their toxicity were elucidated more 
specifically, the role of glycation induced protein oligomerization will be studied. The 
significance of AGE-RAGE interaction, the signaling pathways and role of RAGE inhibition in 
pancreatic cancer cell proliferation were determined. Three pancreatic cancer cells with 
differential RAGE expression were selected for the study; PANC-1, MIA PaCa-2 and BxPC-3 
cells.  PANC-1 and MIA Paca-2 have a high RAGE expression when compared to BxPC-3 cells 
254. The PANC-1 and MIA PaCa-2 cells contain a KRAS mutation  at the 12 Asp and 12 Cys 
respectively whereas the BxPC-3 cells do not have the KRAS mutation 255.   
Materials and Methods 
Reagents were of molecular biology or ACS purity grade and purchased through Fischer 
Scientific or VWR. Bovine serum albumin (BSA), fraction V, was purchased from Amresco. 
Antibodies for western blotting were purchased from Cell Signaling Technologies. Molecular 
biology reagents and enzymes were purchased from New England Biolabs, Life Technologies, 
OriGene and Fermentas. Chromatography media for protein purification were purchased from 
GE Healthcare. Reagents and media for cell culture were from ATCC. 
AGE compound preparation 
Described in chapter 2. 
Isolation of Rib-vH BSA oligomers and formation of BSA oligomers 
The Rib-vH BSA oligomers were separated by size exclusion chromatography using a 
HiPrep 16/60 Sephacryl S-100 HR column (GE Healthcare) with a bed volume of 120 mL. The 
column was equilibrated with phosphate buffered saline with a flow rate of 300 uL/min. Rib-vH 
BSA was diluted to a concentration of 3 mg/mL and 2 mL of this was loaded on to the column 
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with a flow rate of 300 µL/min. 10 mL fractions were collected throughout the run and the 
elution was observed by the UV detector trace.     
BSA oligomers were generated by carboxyl-to-amine cross linking using water soluble 
cross linker, EDC (1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride) and N-
hydroxysuccinimide (NHS) to form an amide bonds. Briefly, 1 mL of 1 mg/mL solution of BSA 
was prepared in 100 mM MES and 100 mM NaCl, pH 6.0. Final concentrations of 20mM EDC 
and 5mM NHS were added to the protein. The reaction was carried out at RT for 2 hours. The 
reaction was quenched by adding 100 mM ethanolamine solution (Solution prepared in D.I 
water) for 30 min. The protein solution was then dialyzed against 1000 volumes of PBS, pH 7.4 
at 4 °C. The oligomers were separated by size exclusion chromatography using a HiPrep 16/60 
Sephacryl S-100 HR column (GE Healthcare) with a bed volume of 120 mL. 
Cell lines used in the study 
The role of glycation and AGE compounds in pancreatic cancer cell proliferation was 
elucidated in two human pancreatic cancer cell lines. Pancreatic cancer cell lines PANC-1, MIA 
PaCa-2 and BxPC-3 were purchased from ATCC. PANC-1 cells were cultured in DMEM media 
with 10% FBS and MIA PaCa-2 cells in DMEM media with 10% FBS and 2.5% horse serum. 
BxPC-3 cells were cultured in the RPMI-1640 medium containing 10%FBS. The DMEM media, 
FBS and horse serum were obtained from ATCC. The cells were maintained in a sterile 
incubator at 37 °C with 5% CO2.   
Cell proliferation by alamar blue assay 
To determine the mitogenic effect of Rib-vH BSA we measured cell proliferation by a 
fluorogenic oxidation-reduction indicator “Resazurin”. The non-fluorescent resazurin undergoes 
reduction in the reducing environment of the cells to form resorufin which exhibits 
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absorption/emission maxima at around 575 nm and 585 nm respectively. Briefly, 5000 cells were 
seeded in a cell culture 96 well plate and allowed to adhere overnight at 37 °C. The media was 
then replaced with fresh DMEM media with reduced serum of 2%. The cells were then treated 
with Rib-vH BSA (1mg/ml) for 24 hours at 37 °C. After the required time period, 10% of the 
total well volume was added with resazurin (0.1 mg/mL in D.I water and sterile filtered) and the 
plate was incubated at 37 °C the emission maxima was measured at 585 nm using the 
SpectraMax M5®  plate reader. For RAGE inhibition 25 µg/mL of anti-RAGE antibody (2A11) 
or 10 µM of RAGE inhibiting peptide (RAP) were used.    
Cell proliferation by Ki-67 staining  
Rib-vH BSA induced cellular proliferation was also determined using the Ki-67 staining. 
10,000 cells were seeded in an ibidi 60µ dish ™. The cells were incubated at 37 °C overnight. 
The media was then replaced with fresh DMEM media with reduced serum of 2%. The cells 
were then treated with Rib-vH BSA (1mg/ml) for 24 hrs at 37 °C. The media was aspirated and 
the cells were washed with PBS twice. The cells were then fixed with 100% methanol at -20 °C 
for 10 minutes. The cells were then washed with PBS and blocked with 5% BSA in PBS 
containing 0.1% triton X-100. Anti Ki-67 (ab15580) was diluted (1:100 dilution) in 2% BSA in 
PBS containing 0.1% TritonTM   X-100. The cells were incubated with the antibody at 4 °C 
overnight and washed with PBS after the incubation. 1:200 dilution of the Alexa Fluor® 647 
conjugated anti-rabbit secondary antibody (Jackson Labs: 711-605-152) was added and 
incubated for 1 hour at RT. The cells were washed with PBS and then imaged using the Zeiss 
AxioObserver Z1, fully motorized inverted scope with LSM700 laser scanning head attachment.   
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Colony formation assay  
50,000 cells per well were seeded in a 6 well cell culture plate and were incubated at 37 
°C till they reached about 60% confluency. The cells were then treated with Rib-vH BSA to a 
final concentration of 1 mg/mL and then incubated at 37 °C for 48 hrs. After the incubation the 
cells were scrapped out using a sterile cell scrapper, resuspended in fresh media and counted 
using the haemocytometer.  1000 cells were seeded per well in a new 6 well cell culture plate. 
The cells were incubated at 37 °C for 10 days. The cells were grown in DMEM media containing 
10% FBS without any Rib-vH BSA treatment. After the incubation the media was aspirated, 
cells were washed twice with ice cold PBS and fixed with ice cold methanol: acetone (1:1) for 10 
minutes on ice. The fixed cells were then washed twice with PBS and stained with crystal violet 
solution for 10 minutes at RT. The wells were then washed with running tap water and air dried. 
The wells were imaged and the colonies formed were counted using ImageJ software.  
Cell migration assay 
To determine the AGE induced migration of pancreatic cancer cells 8.0 µM cell inserts 
were used (translucent, greiner bio-one). Briefly, the cells were scrapped using a sterile cell 
scrapper from a 75 cm2 flask once the cells were 80% confluent. The cells were resuspended in 
serum free media and counted using a haemocytometer. 50,000 cells in serum free DMEM media 
were seeded in to each cell insert the cells were then treated with 1 mg/mL of rib-vH BSA. The 
cell insert was then placed in a 24 well plate. The well contained media with 10% FBS as the 
chemoattractant. The cells were allowed to migrate for 24 hours at 37 °C. Equal number of cells 
were also seeded in the well containing DMEM media with 10% FBS without the insert as a 
control. After 24 hours the non-migrated cells in the cell insert were removed with a sterile cell 
swab. Resazurin was added in the well (10% of the total well volume) containing the DMEM 
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media with 10% FBS and the insert was placed back into the well and incubated at 37 °C for 24 
hours. The percentage of cells migrated were determined by measuring the fluorescence as 
described above.  
Reactive oxygen species (ROS) formation 
AGE induced ROS formation was determined by a cell-permeable non-fluorescent ROS 
probe 2, 7-dichlorodihydrofluorescein diacetate. This compound is de-esterified intracellularly 
and on oxidation by ROS turns in to 2, 7- dichlorofluorescein which is highly fluorescent. 25,000 
cells per well were seeded in a 96 well plate and incubated at 37 °C overnight. The media was 
aspirated and the cells were washed twice with PBS and were loaded with 5 µM per well of 2, 7 
Dichlorofluorescein diacetate and incubated at 37 °C for 30 minutes. The cells were then treated 
with the AGE compound (1 mg/mL) at 37 °C. Fluorescence emission was measured at 535 nm 
with an excitation wavelength of 500 nm using the SpectraMax M5 plate reader.           
Super oxide generation  
Dihydroethidium was used to determine the super oxide generation.  25,000 cells/well 
were seeded in a 96 well plate and incubated at 37 °C overnight. The cells were loaded with 10 
µM dihydroethidium and were incubated at 37 °C for 30 minutes. The loaded cells were treated 
with 1mg/mL of Rib-vH BSA at 37 °C. The oxyethidium fluorescence was monitored with an 
excitation wavelength of 500 nm and an emission maximum of 590 nm at different time points to 
determine the super oxide production. The cells treated with 1mg/mL of BSA and the untreated 
cells were used as the controls.   
Nitric oxide generation 
The effect of AGE compounds on nitric oxide production was evaluated by Griess 
reaction. Griess reaction measures the formation of the nitric oxide by measuring the nitrite ion 
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which is a stable breakdown product of nitric oxide. 25,000 cells per well were seeded in a 96 
well plate and were incubated at 37 °C overnight for the cells to adhere. The media was then 
aspirated and replenished with serum free media. The cells were then treated with 1 mg/mL AGE 
compound and incubated at 37 °C for 24 hours. from each well 50 µl of the cell supernatant was 
collected and transferred to a fresh 96 well plate, 50 µL of Sulfanilamide solution also called as 
solution 1(10 mg/mL solution in 5% phosphoric acid) was added in each well and incubated at 
RT in dark for 10 minutes and finally 50 µl of N-1-napthylethylenediamine dihydrochloride 
(NED) (1mg/mL of NED in D.I. water) solution was added and incubated in dark for 10 minutes 
at RT. The absorbance of the Azo compound formed was measured at 570 nm. Serial dilutions of 
sodium nitrite were made and the nitrite content was determined and a calibration curve was 
obtained. The exact nitrate content of the cells was measured using this standard curve. 
NF-κB activity assay 
Rib-vH BSA induced NFκB activity was determined by transient transfection of NFκB 
cis-reporting plasmid (Stratagene #219077) into the pancreatic cancer cell lines. Briefly, 100,000 
cells/well were seeded in a 6 well plate and were incubated at 37 °C overnight. The NFκB 
reporter plasmid was transfected using Lipofectamine® 2000. For each well 2.5 µg of the 
plasmid was mixed with 8 µL of Lipofectamine® 2000 in 200 µL of serum free DMEM medium 
and was incubated for 30 minutes at RT. Before transfecting the cells, the media was aspirated 
and was replaced with serum free DMEM. The transfected cells were incubated at 37 °C 
overnight. After incubation the media was aspirated and was replaced with DMEM media 
containing 2% serum and the cells were treated with 1mg/mL Rib-vH BSA for 24 hours at 37 
°C. After 24 hours the cells were washed twice with sterile PBS, pH 7.4 and then 400 µL of the 
supplied 1X cell lysis buffer was added in each well and incubated for 15 minutes at RT. 5 µL of 
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this cell lysate was added to 100 µL of luciferase substrate and the luminescence was measured 
using a Berthhold tube luminometer.  To determine the role of ROS induced NFκB activation 
500 µM of N-acetyl cysteine was used. The role of RAGE in Rib-vH BSA induced NFκB 
activity was elucidated by 25 µg/mL of anti-RAGE and 1 µM of FPS-ZM1 which is a small 
molecule inhibitor of RAGE.         
Fluorescent labelling of Rib-vH BSA 
The cysteine residues of the rib-vH BSA were fluorescently labelled by a malemide 
derivative of a near infra-red cyanine dye called Cy5.5. It has an excitation wavelength of 675 
nm and an emission maximum at 695 nm. Cy5.5_malemide was dissolved in methanol aliquoted 
and dried by vacuum centrifugation and stored at -80 °C. Rib-vH BSA was diluted in PBS to a 
final concentration of 10 mg/mL and was then mixed with 2 molar excess of Cy5.5 and 
incubated for 30 minutes at RT by stirring. The free dye was removed by dialyzing the protein 
against 500 volumes of PBS. The presence of free dye was visualized by running the labelled 
protein on a SDS-PAGE gel. Absorbance was measured at 280 nm and 675 nm and the moles of 
dye bound to the mole of protein were determined. 
AGE uptake assay 
The kinetics of rib-vH BSA uptake was determined by measuring the fluorescence of 
Cy5.5 of the rib-vH BSA_Cy5.5 at different time points. Briefly, 50,000 cells per well were 
seeded in a cell culture 24 well plate and incubated at 37 °C overnight for the cells to adhere. 50 
ug/mL of the labelled rib-vH BSA was added to each well and incubated at 37 °C. The cells were 
lysed using TBS with 0.1% triton X-100 at different time points. For 0 hour time point the cells 
were lysed immediately as soon as the compound was added. Fluorescence of the cell lysate was 
measured in a 40 µL quartz cuvette with an excitation of 675 nm and an emission of 691 nm with 
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a slit settings of 5 nm on the Horiba Jvon spectrofluorimeter. The exact protein content taken up 
was determined by a calibration curve of the labelled rib-vH BSA.  
Western blot analysis for kinase activity 
Rib-vH BSA induced kinase activation was estimated by western blot analysis. Briefly, 
30 µg of total cell protein was loaded on a 12% SDS-PAGE gel and run at 150 V. The bands 
were transferred on to a nitrocellulose membrane at 250 mA for 1 hour. The blot was then 
blocked using 5% milk powder in TBS-T. SAPK/JNK (CST:  9358S), AKT (CST: 4685S), 
ERK1/2 (CST: 4695S), P38 (ab7952) and P53 (CST: 2527S) primary antibody dilution (1:1000 
dilution) was made in 2% milk powder in TBS-T. The blot was incubated with the respective 
primary antibody overnight at 4 °C. The blots were washed with TBS-T for 5 times (2 minutes 
each) and the HRP conjugated secondary antibody was added (Jackson: 711-035-152, 1:10000 
dilution). The blot was incubated for 2 hrs at RT then washed and developed on the X-ray film 
using the ECL substrate. The blot was then washed and stripped using 1.5% glycine, pH 2.2 with 
1% Tween 20 at 80 °C for 20 minutes. The blot was washed several times with TBS-T and 
blocked with 5% milk powder at RT for 2 hours. Then the phosphorylated SAPK/JNK (CST: 
4668S), phosphorylated AKT (CST: 4060S), phosphorylated p38 (ab45381), phosphorylated p53 
(CST: 9281P), phosphorylated ERK1/2 (CST: 9101S) antibodies were added respectively 
(1:1000 dilution) and incubated overnight at 4 °C. The HRP conjugated secondary antibody was 
added and incubated for 2 hrs at RT. After developing the blot was washed and stripped as 
described above and the blot was then incubated with actin antibody (sc-1616) at 4 °C overnight 
and was then incubated with HRP conjugated secondary antibody and  developed.   
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RNA extraction and cDNA synthesis 
The whole cell RNA was extracted from the PANC-1 and MIA PaCa-2 cells using the 
Ambion's Protein and RNA Isolation System, PARIS™ (Life Technologies). Briefly, 50000 cells 
were seeded in each well of a 6 well plate. The cells were allowed to adhere and reach a 
confluency of 60% by incubating at 37 °C for 24 hours. After the cells reached the required 
confluency, the cells were stimulated with 1 mg/mL of Rib-vH BSA. The cells were then 
incubated at 37 °C. Cells were harvested at 24 hrs after stimulation and the RNA was extracted.  
The concentration of the RNA was measured by UV absorbance at 260 nm and the ratio of the 
absorbance at 260 nm/280 nm was calculated to estimate the purity of RNA.  The RNA was 
immediately reverse transcribed using the Moloney Murine Leukemia Virus (M-MuLV) Reverse 
Transcriptase (NEB labs) using an oligo dT primer.  
Quantitative real time PCR (q RT-PCR) 
The expression of AGE-receptors (Table 2.1) in the PANC-1 and Mia PaCa-2 cells was 
determined by real time PCR using Eva green (Solis BioDyne) according to manufacturer’s 
protocol. 1 ng of cDNA was used in each PCR reaction (20 µL) and 250nM of forward and 
reverse primers were used and reaction was amplified for 40 cycles.  
Glycation of collagen 
To determine the effect of different glycation agents on the glycation of extracellular 
matrix (ECM) collagen was used as a model for ECM glycation. Sterile rat tail collagen was 
dissolved in 70% ethanol and 50 µg of collagen in 70% ethanol was added in each well of a 96 
well plate and were allowed to air dry under the sterile hood overnight for the ethanol to 
evaporate. The coated collagen was then washed with sterile glycation buffer twice and 600 µL 
the glycation agent was added in each well. The plate was sealed with tape and the incubated at 
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37 °C for 10 days to allow the collagen to glycate. After glycation, the glycation agent was 
aspirated and the collagen was washed 5 times with sterile PBS. Cells were seeded on the 
glycated collagen coated plates or the plates were sealed and stored at 4 °C.     
Effect of collagen glycation on cell adhesion 
The effect of collagen glycation on cellular adhesion was determined crystal violet 
staining. The sterile glycated collagen plates were seeded with 5000 cells per well and were then 
incubated at 37 °C for 12 hours. After 12 hours the media was aspirated and the un-adhered cells 
were removed by washing with sterile PBS twice. The adherent cells were then fixed with 
methanol: acetic acid (3:1) for 5 minutes at RT. The fixative was aspirated and the cells were 
washed with sterile PBS thrice. The cells were then stained with crystal violet solution for 15 
minutes at RT. The excessive stain was washed away with tap water. 50 µL of methanol added in 
each well to dissolve the crystal violet from the stained cells. Absorbance of the dissolved crystal 
violet was measured at 545 nm.          
Results and Discussions  
Rib-vH BSA uptake in pancreatic cancer cell lines  
The AGE compound uptake has not been studied and described in any cancer cells. It is 
not clear if the AGE compounds are taken up by the cancer cells or if they trigger signaling 
simply by binding to cell surface receptors. The Rib-vH BSA uptake was measured using the Cy 
5.5 labelled Rib-vH BSA in the PANC-1 and MIA PaCa-2 cell lines. The uptake of the Rib-vH 
BSA was followed by measuring the fluorescence from the cell lysate obtained after treatment at 
different periods of time. Rib-vH BSA uptake was observed in the PANC-1 cells and the uptake 
was time dependent. We observe a significant uptake of Rib-vH BSA after 3 hours of incubation 
and a continuous increase was observed till 24 hours. The exact amount of protein internalized 
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per well was determined using a standard curve. The uptake kinetics is shown in Figure 3.1. 
After 6 hours we observe an internalization of 4.15±0.02 µg per well and 7.4±0.01 µg per well 
after 10 hours. Internalization of 22.23±0.13 µg of the 25 µg added was observed after 24 hours 
of treatment. The internalization behavior of the PANC-1 cells was different from the RAW 
264.7 cells (Figure 4.1). The Rib-vH BSA uptake by the macrophages is described in chapter 
4.The uptake in macrophages was extremely rapid in the initial time points of the treatment, 5 
µg, 8 µg and 14 µg of the AGE compound was taken up within 30 minutes, 1 hour and 6 hours 
respectively after incubation. No internalization was observed in the MIA PaCa-2 cells even after 
24 hours of incubation. The role of multiple receptors in AGE compound uptake has been 
described (Chapter 2). However, the role a specific receptor primarily responsible for AGE 
compound uptake in pancreatic cancer cells has not been described. We suspect these differences 
could be due to the differences in the expression of AGE receptors. The macrophages express 
various scavenging receptors which could play a role in AGE uptake (Chapter 4).  Our qPCR 
results of the PANC-1 and MIA PaCa-2 cells suggest differential expression of the AGE 
receptors in these two cell lines more specifically higher expression (4.32±2.29 Ct units) of 
CD36 which is a class B scavenger receptor was observed in the PANC-1 cells when compared 
to the MIA PaCa-2 cells. The Ct values are shown in table 3.1 are normalized to actin expression 
in each cell line. Further investigation is required in this direction to identify the receptors 
responsible for AGE compounds.  
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Figure 3.1. Rib-vH BSA_Cy 5.5 uptake kinetics by PANC-1  
(Red) and MIA PaCa-2 (Orange) cells. (Representation of 2 independent experiments n=6 for 
each experiment). 
Table 3.1. Expression of AGE receptors in PANC-1 and MIA PaCa-2 cells at the RNA level. 
The Ct values were normalized to actin expression. (Lower the Ct value higher the expression).  
Gene 
(Gene ID) 
Primers 
(5’3’) 
ΔCt 
PANC-1 
ΔCt 
MIA PaCa-2 
CD36    
(NM_001001548) 
Forward: 
CTTTGGCTTAATGAGACTGGGAC 
Reverse: 
GCAACAAACATCACCACACCA 
8.09±0.18 12.4±2.47 
STAB1 
(NM_0151436) 
Forward: 
CCGGGAAATCCTTACCACAGC 
Reverse: 
ACCTTCGTGTTTGTTGGGTCC 
13.11±0.14 11.19±0.12 
STAB2 
(NM_017564) 
Forward: 
GTGCCCGGATGGTTACACC 
Reverse: 
CTTCCTACAAATATGGCGGCAT 
20.42±0.98 16.80±1.80 
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Table 3.1. Expression of AGE receptors in PANC-1 and MIA PaCa-2 cells at the RNA level 
(continued). 
Gene 
(Gene ID) 
Primers 
(5’3’) 
ΔCt 
PANC-1 
ΔCt 
MIA PaCa-2 
SCARB1 
(NM_001082959) 
Forward: 
ACTTCTGGCATTCCGATCAGT 
Reverse: 
ACGAAGCGATAGGTGGGGAT 
6.64±0.60 6.08±0.78 
SCARB2 
(NM_005506) 
Forward: 
AGATGGAGATTCTTTTCACCCAC 
Reverse: 
CAGGAACTTTATACCGAAAGGCA 
6.85±0.70 6.04±0.42 
MSR1   
(NM_002445) 
Forward: 
CCAGGTCCAATAGGTCCTCC 
Reverse: 
CTGGCCTTCCGGCATATCC 
21.08±0.52 16.79±3.71 
MARCO   
(NM_006770) 
Forward: 
CAGCGGGTAGACAACTTCACT 
Reverse: 
TTGCTCCATCTCGTCCCATAG 
22.11±0.05 15.87±4.13 
DDOST  
(NM_005216) 
Forward: 
GAGACTCATTCGCTTTTCTTCCG 
Reverse: 
CTCCAAAATCTTCTACCGAAGGG 
4.02±0.11 3.49±0.24 
PRKCSH  
(NM_002743) 
Forward: 
TCAGGTCAACGATGACTATTGC 
Reverse: 
CCCGGTTGGAGGGGATATACA 
No Ct No Ct 
OLR1 
(NM_002543) 
Forward: 
CAACGAGGAGCTGTTTATGC 
Reverse: 
GTGCCAATGATCACCTTGTT 
12.98±0.77 9.74±3.14 
RAGE 
(NM_001136.3) 
Forward: 
TTTCTGGGCTCTCATGTTTG 
Reverse: 
CACAAGATGACCCCAATGA 
11.79±0.16 9.20±2.18 
Gal-3 
(NM_002306) 
Forward: 
CCCGATGATTGTACTGCAAC 
Reverse: 
CTGGGGAAGGGAAGAAAGAC 
6.66±1.10 6.20±0.42 
 
 96 
The uptake of Rib-vH BSA was also determined by fluorescence microscopy. PANC-1 
cells were treated with Rib-vH BSA tagged with Cy5.5 and the images were taken after 3 hours 
of Rib-vH BSA treatment. We observe internalization of the Rib-vH BSA as indicated by our 
kinetic data.  This confirms the internalization of the Rib-vH BSA in the PANC-1 cells. The 
internalization of the Rib-vH BSA was also determined in the BxPC-3 cells which do not have 
the KRAS mutation. Internalization was also observe in the BxPC-3 cells as well (Figure 3.2).  
Figure 3.2. Internalization of Rib-vH BSA_Cy5.5 by fluorescence microscopy.   
Rib-vH BSA induced oxidative stress 
There is evidence that AGE compounds on their interaction with RAGE generate 
oxidative stress which subsequently elicits vascular inflammation in the context of diabetic 
complications 50, 256-259 . Inflammation and oxidative stress have been described as a contributing 
factor in the pathogenesis of pancreatic malignancy260, 261. However, the role of AGE compounds 
and AGE-RAGE axis in oxidative stress in pancreatic cancer etiology is unknown. Rib-vH BSA 
induced oxidative stress in PANC-1 cells was measured using the 2, 7-dichlorofluorescein 
diacetate. On treatment with 1mg/mL of Rib-vH BSA after 24 hours we observed a significant 
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increase in ROS production. Rib-vH BSA induced ROS production with respect to control 
untreated cells is shown in Figure 3.3. We observe a 1.48±0.09 fold increase in ROS production 
on Rib-vH BSA treatment after 24 hours. On the addition of 500 µM N-acetyl cysteine (NAC), 
which is a quencher of ROS, the Rib-vH BSA induced ROS produced was back to baseline 
levels. The role of RAGE in AGE induced ROS production was determined by treating the cells 
with 1µM of a small inhibitor of RAGE called FPS-ZM1 and 25 µg/mL of an anti-RAGE 
antibody 2A11.  When the cells were co-treated with Rib-vH BSA and FPS-ZM1 the ROS 
production was back to baseline levels (1.09±0.04 fold). Similar results were also obtained when 
the cells were co-treated with 2A11 antibody (0.99±0.03 fold). This clearly indicates that AGE 
induced ROS production is RAGE dependent.     
 
 
 
 
 
 
 
Figure 3.3. Rib-vH BSA induced ROS production in PANC-1 cells.  
The first column represents the non-treated control. (Representation of 2 independent 
experiments n=6 for each experiment. *** P<0.0005). 
Rib-vH BSA induced ROS production was also observed in the MIA PaCa-2 cell line 
(Figure 3.4). On Rib-vH BSA treatment a 1.96±0.11 fold increase in the ROS production was 
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observed after 24 hours of incubation. On the treatment with FPS-ZM1 a decrease in the ROS to 
1.45±0.05 fold was observed. Rib-vH BSA induced ROS production was also inhibited by the 
treatment with the anti-RAGE antibody 2A11 (0.988±0.07 fold).   
 
 
 
 
 
 
 
 
 
 
Figure 3.4. Rib-vH BSA induced ROS production in MIA PaCa-2 cells.  
The first column represents the non-treated control. RAGE inhibition inhibited Rib-vH BSA 
induced ROS production. (Representation of 2 independent experiments n=6 for each 
experiment. *** P<0.0005). 
Increased oxidative stress in pancreatic cancer has been implicated in the pathogenesis of 
pancreatic cancer 260. There is evidence to support the notion that ROS activates various 
signaling pathways mediated by NF-κB and kinases such as Janus kinase/signal transducer and 
activator of transcription (JAK/STAT) and p38 mitogen-activated protein kinases (MAPK) 262-
265, which in-turn leads to decreased cell apoptosis and cytokine release 235, 260.  
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Rib-vH BSA induced generation of super oxide  
Super oxide production has been described in various cancer cells (Reviewed in 266). 
Recent reports emphasize the role super oxide generation in pancreatic cancer cell growth 
specifically in the   K-ras mutated pancreatic cancer cells 267, 268. Recently a study reported the 
role of super oxide and nitric oxide in increased invasiveness in pancreatic ductal 
adenocarcinoma patients269. AGE induced super oxide generation has been described in various 
vascular complications of diabetes 270-272.   The role of AGE compounds in the induction of super 
oxide in cancer cells has not been described in the literature. This study was initiated to 
determine the role of Rib-vH BSA in super oxide generation in pancreatic cancer cells. 
The super oxide produced on Rib-vH BSA treatment was determined by using a 
fluorescent probe dihydroethidium. Super oxide oxidizes the dihydroethidium to form a red 
fluorescent compound called oxyethidium273. On treatment with Rib-vH BSA we observe a 
significant increase in the super oxide production in the PANC-1 cells. Figure 3.5 visualizes the 
increase in the superoxide production in the PANC-1 cells as a function of time. Rapid increase 
in the Rib-vH BSA induced super oxide production was observed as indicated by the 
oxyethidium fluorescence. Increase in fluorescence was observed after 30 minutes of Rib-vH 
BSA treatment and the Rib-vH BSA induced super oxide production was observed even 24 hours 
after the Rib-vH BSA treatment. Similar results were also observed in the MIA PaCa-2 cells. On 
Rib-vH BSA treatment significant super oxide production was observed (Figure 3.6). Super 
oxide production was observed after 30 minutes of treatment and continued till 24 hours of the 
treatment.   
Taken together, these results suggest that the AGE compounds increase super oxide 
production in pancreatic cancer cells and contribute to the oxidative stress in these cells.  
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Figure 3.5. Rib-vH BSA induced superoxide production in PANC-1 cells.  
Black: Control, Blue: BSA and Red: Rib-vH BSA (Representation of 2 independent experiments 
n=6 for each experiment). 
 
 
 
 
 
 
 
Figure 3.6. Rib-vH BSA induced superoxide production in MIA PaCa-2 cells.  
Black: Control, Blue: BSA and Red: Rib-vH BSA (Representation of 2 independent experiments 
n=6 for each experiment). 
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Rib-vH BSA induced nitric oxide generation 
AGE compounds have been described to induce nitric oxide production has been 
described in various vascular complications in diabetes 87, 274, 275. Rib-vH BSA induced nitric 
oxide release in macrophages has been also been described (See chapter 4). In pancreatic cancer 
the role of nitric oxide is contradictory not well understood. Both, a tumorigenic and anti-
tumorigenic activity of nitric oxide has been described 276, 277. The role of AGE compounds in the 
nitric oxide release in pancreatic tumors has not been described and this study was initiated to 
determine the role of AGE compounds in nitric oxide production in pancreatic cancer cells.  
Nitric oxide generation was measured using the Greiss reaction as described earlier. In 
the PANC-1 cells on treatment with Rib-vH BSA no detectable amounts of nitric oxide was 
observed even after 24 hours of treatment. Similar results were also observed in the MIA PaCa-2 
cells (Figure 3.7). These results suggest that Rib-vH BSA does not lead to nitric oxide 
production in the pancreatic cancer cells. 
 
 
 
 
 
 
 
Figure 3.7. Rib-vH BSA induced nitric oxide production in PANC-1(Red) MIA PaCa-2 (Orange) 
cells.  
(Representation of 2 independent experiments n=6 for each experiment. N.S.: No significant 
difference when compared to the control). 
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NF-κB activation  
Various aspects of the immune and inflammatory response genes are under the control of 
a dimeric transcription factor called NF-κB. It is hypothesized that the activation of NF-κB is 
responsible for tumor pathogenesis 26. It is believed that NF-κB provides a direct link between 
cancer development and progression and inflammation and immunity 278. As described earlier 
NF-κB can be activated by oxidative stress.  AGE-RAGE interaction has been described to 
trigger the NF-κB activity in diabetes associated with lacrimal gland and ocular surface 
dysfunctions by the activation of inflammatory signaling pathways 279, 280. Evidence in the 
literature also suggests the role of RAGE in triggering NF-κB activity by interacting with its 
ligands such as HMGB1 and S100 proteins in certain cancers 281, 282.  However, no direct 
evidence on the role of AGE compounds in the ROS mediated NF-κB activity in pancreatic 
cancer cells has been published till date. On Rib-vH BSA treatment, a 1.6±0.11 fold increase was 
observed in the NF-κB activity after 24 hours (Figure 3.9). To elucidate the role of ROS in the 
AGE induced NF-κB activity we treated the cells with 500 µM of N-acetyl cysteine (NAC) 
which is a potent quencher of ROS. On the treatment with NAC, we observe a decrease in the 
NF-κB activity to 1.49±0.06 fold when compared to the control. This suggests a role of the AGE 
induced ROS produced in NF-κB activation. In the MIA PaCa-2 cells no increase was observed 
in the NF-κB activity on Rib-vH BSA treatment (Figure 3.8). This suggests that in the MIA 
PaCa-2 cells the Rib-vH BSA does not activate NF-κB signaling.  
The role of AGE-RAGE interaction in NF-κB activity was determined using specific 
anti-RAGE antibody (2A11) and a small molecule inhibitor of RAGE (FPS-ZM1). On the 
treatment with 2A11 we observe a decrease in the basal NF-κB activity to 0.67±0.07 fold. This 
suggests the role of RAGE in basal NF-κB activity in the PANC-1 cells. We suspect this basal 
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NF-κB activity could also be the result of the presence of other RAGE ligands such as S100P 
and HMGB1. HMGB1 and S100P are released from the pancreatic cancer cells and have been 
reported to increase the NF-κB activity 235, 283. When the cells were co-treated with Rib-vH BSA 
and 2A11 no increase was observed in the NF-κB activity (0.067±0.07 fold). This further 
emphasizes the role of RAGE in the Rib-vH BSA mediated effects.  FPS-ZM1 treatment also 
reduces the basal NF-κB activity in the PANC-1 cells in a concentration dependent manner. 
When the cells were treated with 10 µM of FPS-ZM1 the NF-κB activity decreased to 0.12±0.01 
fold and no increase was observed when the cells were co-treated with FPS-ZM1 and Rib-vH 
BSA. Taken together we conclude that the Rib-vH BSA induced NF-κB activity in PANC-1 cells 
in a RAGE dependent manner and the ROS generated by AGE-RAGE interaction is also 
responsible for the activating the NF-κB.  
 
 
 
 
 
 
 
 
 
Figure 3.8. NFκB activity in MIA PaCa-2 cells.  
(Representation of 2 independent experiments n=6 for each experiment. N.S.: No significant 
difference when compared to the control). 
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Figure 3.9. Rib-vH BSA induced NFκB activity in PANC-1 cells.  
RAGE inhibition prevented the Rib-vH BSA induced NFκB activity. (Representation of 2 
independent experiments n=6 for each experiment. *** P<0.0005 when compared to the control, 
###P<0.0005 when compared to the RAGE induced sample). 
AGE compounds induced cell proliferation in PANC-1 cells 
Cancer progression is a complex process and it involves several different cellular 
processes such as cell proliferation, migration, angiogenesis, invasion and metastasis 284. In this 
study we determine the role of Rib-vH BSA in pancreatic cancer cell proliferation and migration. 
A mitogenic effect of AGE compounds has been described in the context of diabetic 
complications. AGE induced cell proliferation was first described in the murine kidney 
mesenglial cells 285 and murine macrophages 286. The role of AGE compounds in the migration 
of vascular smooth muscle cells contributing to diabetic vascular complications has been 
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described 287. The role of AGE-RAGE interaction has been implicated in the neo-intimal 
hyperplasia of balloon-injured arteries, thus playing a role in cardiovascular disease 288. The 
effect of AGE-RAGE has been reported to promote cancer cell proliferation in certain cancerous 
cell lines such as melanoma 241, myeloid leukemia 289 and breast cancer cell lines290.  The role of 
metformin, which is an inhibitor of glycation has also been described in the prevention of AGE 
induced cell growth in MCF7 cells (Breast cancer cell line) 290. Recently, the anti-inflammatory 
role of a DNA aptamer raised against AGE compounds has been described in melanoma291. 
However, the role of AGE compounds in cancer progression is not well understood and the 
research is still in its infancy. The role of AGE compounds in pancreatic cancer cell proliferation 
has been indicated 249. However, the molecular mechanisms of AGE induced cell proliferation is 
currently unknown. AGE biology is very complex owing to the heterogeneous nature of AGE 
compounds. As described in chapter 2, AGE compounds can be either toxic or benign to the 
body and it is not clear on what differentiates the toxic AGE compounds from the benign 
structurally.  
AGE dependent cellular proliferation was determined by treating the PANC-1 cells with 
the characterized panel of AGE compounds (Table 2.1). The cell proliferation was determined by 
measuring the alamar blue fluorescence. The AGE induced cell proliferation could be correlated 
to the multimeric content of the AGE compounds. Figure 3.10 indicates the effect AGE 
compounds on cancer cell proliferation and the multimeric content of the different AGE 
compounds is represented on the Y-axis.  The most significant effect was observed when the 
cells were treated with Rib-vH BSA which has a non-monomeric content of about 38.4 ± 1.5 %. 
On treatment with 1 mg/mL of Rib-vH BSA a 1.67±0.057 fold increase was observed when 
compared to the control cells (Figure 3.11). 
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Figure 3.10. AGE compound induced cellular proliferation correlated to the percentage of the 
non-monomeric content of the different AGE compounds.  
R=0.94 for the linear correlation (Representation of 2 independent experiments and n=6 in each 
experiment). 
 
 
 
 
    
 
 
Figure 3.11. Rib-vH BSA induced AGE compound induced cellular proliferation.  
(Representation of 2 independent experiments and n=6 in each experiment, ***P<0.0005). 
The role of RAGE in the AGE mediated mitogenic effects were determined by treating 
the cells with 25 ug/mL of anti-RAGE antibody (2A11) and also with 10µM of a RAGE 
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inhibiting peptide (RAP). On treatment with RAGE inhibitors we observe the inhibition of Rib-
vH BSA induced cellular proliferation (Figure 3.12). This emphasizes the role of RAGE in the 
AGE induced cellular proliferation.  However, there are certain limitations of the alamar blue 
assay. The alamar blue is a redox indicator and hence it is not a direct cell counting technique 
and it is highly likely that the fluorescence signal can be affected by both changes in cell number 
and cell metabolism.  To confirm the mitogenic effect of Rib-vH BSA we performed Ki-67 
staining. Ki-67 is a well-established marker of cellular proliferation. It is absent during resting 
phase (G(0)) and present during all active phases of the cell cycle (G(1), G (2) and mitosis)292.  
Ki-67 staining was performed in the non-treated and treated samples. After staining the overall 
fluorescence was quantified in each image. The analysis was performed with 10 independent 
images and in the Rib-vH BSA treated cells 8.22±2.37 fold increase in the Ki-67 fluorescence 
was observed (Figure 3.13). Figure 3.13 represents the Ki-67 staining of the control and the Rib-
vH BSA quantified using Imaris software and the Ki-67 fluorescence was normalized with the 
DAPI treated sample. This confirms that the Rib-vH BSA treatment induced a mitogenic effect 
in the PANC-1 cells as indicated by the alamar blue assay.  
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Figure 3.12. Rib-vH BSA induced cellular proliferation was prevented by using RAGE inhibitors 
RAP and 2A11 antibody.  
(Representation of 2 independent experiments and n=6 in each experiment, ***P<0.0005). 
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Figure 3.13. Rib-vH BSA induced cellular proliferation determined by Ki-67 staining.  
The Ki-67 fluorescence was normalized with the DAPI fluorescence in each image and then 
quantified. (Representation of 2 independent experiments and n=5 in each experiment, 
***P<0.0005). 
As described earlier the AGE compound induced cellular proliferation could be 
correlated to the non-monomeric content of the AGE compounds. Few reports in the literature 
suggest the role of ribosylation of serum albumin in the formation of protein oligomers which 
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leads to protein aggregation 223, 224.  As described in chapter 2, we observe significant 
oligomerization in the Rib-vH BSA sample but no aggregation was observed as lower 
concentrations of ribose were used.  This study was initiated to decipher the role of Rib-vH BSA 
induced oligomers in the mitogenic effect observed in PANC-1 cells. 
The Rib-vH BSA oligomers were separated by size exclusion chromatography as 
described earlier. Figure 2.14 shows the elution profile of the Rib-vH BSA. Different fractions 
were collected and then run on the SDS-PAGE and the fraction with the oligomeric content was 
used. The oligomers were concentrated and concentration was determined by the BCA assay and 
then sterile filtered. The PANC-1 cells were treated with the sterile Rib-vH BSA oligomers. As a 
negative control, BSA was cross linked using the EDC_NHS chemistry and then the oligomers 
were separated, collected, concentrated and sterile filtered (Figure 3.15). 
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Figure 3.14. Coomaisse blue stained Rib-vH BSA on SDS-PAGE gel (left). Separation of Rib-
vH BSA oligomers by size exclusion chromatography (Right).    
 
 
 
 
 
 
 
 
Figure 3.15. EDC-NHS crosslinking of BSA (Left); Separation of the BSA oligomers by size-
exclusion chromatography (Right).     
Lane 1: Ladder, Lane 2: BSA at 0 hours of cross linking, Lane 3: BSA after 3 hours of cross 
linking and Lane 4: BSA after 5 hours of cross linking.  
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The cells were treated with a final concentration of 65 µg/mL of the oligomers and equal 
concentration of the monomers and the unseparated Rib-vH BSA. On treatment with the purified 
oligomers we observe at significant increase (P<0.005) in the PANC-1 cellular proliferation 
(Figure 3.16). No increase in proliferation was observed when the cells were treated with equal 
amount of the Rib-vH BSA monomers. The treatment with 65µg/mL of unseparated Rib-vH 
BSA also did not induce any cellular proliferation. This suggests that the active AGE compounds 
necessary for cellular proliferation are present in the oligomeric content if the Rib-vH BSA and 
ribose induced cross linking plays a very important role in Rib-vH BSA mediated cellular 
effects.  The isolated BSA oligomers did not induce any effect on cellular proliferation (Figure 
3.16) 
 
 
 
 
 
 
 
 
 
 
Figure 3.16.  PANC-1cellular proliferation by Rib-vH BSA oligomers.  
(Representation of 2 independent experiments and n=6 in each experiment, **P<0.005). 
 113 
To further elucidate the role of Rib-vH BSA in pancreatic cancer progression, the role of 
Rib-vH BSA in reproductive viability of the PANC-1 cells was determined by clonal formation 
assay. On crystal violet staining we observe a significant increase in the clone formation in the 
Rib-vH BSA treated cells when compared to the control (Figure 3.17). However, no significant 
differences were observed in the size of the clones between treated and non-treated samples. This 
suggests that Rib-vH BSA increased the clonal formation ability of the PANC-1 cells and this 
would contribute to the tumor growth and progression.    
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.17. Rib-vH BSA induced colony formation in PANC-1 cells.  
(Representation of 2 independent experiments and n=6 in each experiment, ***P<0.0005). 
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AGE compounds induced cell proliferation in MIA Paca-2 and BxPC-3 cells 
Effect of further elucidate the role of mitogenic effect of AGE compounds in pancreatic 
cancer, we determine their role in other pancreatic cancer cell lines BxPC-3 and Mia PaCa-2.  In 
BxPC-3 cells, on treatment with the panel of AGE compounds we observe a relationship 
between the mitogenic effect and the oligomeric content of the AGE compounds as observed in 
the PANC-1 cells (Figure 3.18). The most significant effect was observed with the Rib-vH BSA 
sample where a 1.34±0.04 fold increase was observed (Figure 3.19). The role of RAGE in the 
Rib-vH BSA mediated cell proliferation was determined using the 2A11 and RAP. Both the 
2A11 and RAP inhibited the Rib-vH BSA induced cellular proliferation emphasizing the 
importance of RAGE interaction in Rib-vH BSA mediated effects (Figure 3.20). The treatment 
of BxPC-3 cells with isolated Rib-vH BSA oligomers also induced a significant increase in the 
cell proliferation, no increase in cellular proliferation was observed when the cells were treated 
with Rib-vH BSA monomers and unseparated Rib-vH BSA (Figure 3.21). This further 
emphasizes the importance of ribose induced cross linking in the Rib-vH BSA induced 
mitogenic effect of pancreatic cancer.   
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Figure 3.18. AGE compound induced cellular proliferation in BxPC-3 cells correlated to the 
percentage of the non-monomeric content of the different AGE compounds.  
R=0.92 for the linear correlation (Representation of 2 independent experiments and n=6 in each 
experiment). 
 
 
 
 
 
 
 
 
Figure 3.19. Rib-vH BSA induced AGE compound induced cellular proliferation.  
(Representation of 2 independent experiments and n=6 in each experiment, ***P<0.0005). 
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Figure 3.20. Rib-vH BSA induced cellular proliferation was prevented by using RAGE inhibitors 
RAP and 2A11 antibody.  
(Representation of 2 independent experiments and n=6 in each experiment, ***P<0.0005). 
 
 
 
 
 
 
 
 
Figure 3.21. BxPC-3cellular proliferation by Rib-vH BSA oligomers.  
(Representation of 2 independent experiments and n=6 in each experiment, **P<0.0005). 
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Similar results were observed in the MIA PaCa-2 cells. Figure 3.22 indicates the AGE 
induced cell proliferation and a linear correlation was observed with the oligomeric content of 
the AGE compounds. RAGE inhibition with the 2A11 anti-RAGE antibody also inhibited the 
Rib-vH BSA induced cell proliferation (Figure 3.24). Similar to the other cell lines the treatment 
with Rib-vH BSA oligomers also induced cell proliferation (Figure 3.25).  
 
 
 
 
 
 
 
 
 
Figure 3.22. AGE compound induced cellular proliferation in MIA PaCa-2 cells correlated to the 
percentage of the non-monomeric content of the different AGE compounds.  
R=0.74 for the linear correlation (Representation of 2 independent experiments and n=6 in each 
experiment). 
 
 
 
 
 118 
 
 
 
 
 
 
 
 
Figure 3.23. Rib-vH BSA induced AGE compound induced cellular proliferation.  
(Representation of 2 independent experiments and n=6 in each experiment, *P<0.001; 
**P<0.005). 
 
 
 
 
 
 
 
Figure 3.24. Rib-vH BSA induced cellular proliferation was prevented by using anti-RAGE 
2A11 antibody. 
(Representation of 2 independent experiments and n=6 in each experiment, **P<0.005). 
 119 
 
 
 
 
 
 
 
 
 
Figure 3.25. MIA PaCa-2cellular proliferation by Rib-vH BSA oligomers.  
(Representation of 2 independent experiments and n=6 in each experiment, ***P<0.0005). 
Similar to the PANC-1 cells, increase in clonal formation was also observed in the MIA 
Paca-2 cells. No increase was observed in the size of the colonies between the treated and non-
treated samples (Figure 3.26).   
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Figure 3.26. Rib-vH BSA induced colony formation in MIA PaCa-2 cells. 
(Representation of 2 independent experiments and n=6 in each experiment, ***P<0.0005). 
Taken together these results suggest the role of AGE compounds in pancreatic cancer cell 
proliferation. More specifically, the importance of the AGE compound oligomers in the cell 
proliferation has been shown. Our results also emphasize the role of RAGE inhibition in the 
prevention of the AGE mediated cellular effects.   
Rib-vH BSA induced cell migration  
Cancer cell migration is hallmark of cancer progression. More specifically; it is the initial 
stage of cancer metastasis.  Pancreatic cancer patients are characterized by very high metastatic 
rates and the mean survival rate of the patients with metastatic pancreatic tumor is about 3 to 6 
months 293. Certain AGE compounds have been demonstrated to induce cell migration and 
*** 
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invasion. For example, MG BSA AGE compounds have been described to increase cell 
proliferation, migration and invasion in breast cancer cell line MDA-MB-231 246, glyceraldehyde 
derived AGE compounds have been reported to interact with RAGE to induce migration in 
human oral cancer cells 248. AGE induced cell migration has not been described in pancreatic 
cancer. We used Rib-vH BSA to determine the AGE induced cell migration in the pancreatic 
cancer cells. The Boyden chamber assay was used to determine Rib-vH BSA induced cell 
migration. The most significant effect was observed in the PANC-1 cells. On Rib-vH BSA 
treatment for 24 hours 42.3±2.8% of the cells migrated through the chamber and only 
22.9±0.58% of cells migrated in the untreated control (Figure 3.27). 
 
 
 
 
 
 
 
Figure 3.27. Rib-vH BSA induced PANC-1 cell migration.  
(Representation of 2 independent experiments and n=6 in each experiment, ***P<0.0005). 
Increase in migration was also observed in the MIA PaCa-2 and BxPC-3 cells on Rib-vH 
BSA treatment. In the MIA PaCa-2 cells 20.11±0.99% of cells migrated on Rib-vH BSA 
treatment whereas only 11.7±0.5% (Figure 3.28) of cells migrated in the control samples and 
26.0±2.0% of the BxPC-3 cells migrated on Rib-vH BSA treatment when compared to the 
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16.0±2.4% (Figure 3.29) migrated cells in the untreated sample. These results demonstrate the 
role of Rib-vH BSA in increased cellular migration in pancreatic cancer cells.  
 
 
 
 
 
 
 
Figure 3.28. Rib-vH BSA induced MIA PaCa-2 cell migration.  
(Representation of 2 independent experiments and n=6 in each experiment, ***P<0.0005). 
 
 
 
 
 
 
 
Figure 3.29. Rib-vH BSA induced BxPC-3 cell migration.  
(Representation of 2 independent experiments and n=6 in each experiment, ***P<0.0005). 
Rib-vH BSA induced kinase signaling 
To obtain better insights into the AGE signaling pathways responsible of the AGE 
mediated cellular effects in pancreatic cancer, the role of Rib-vH BSA in the activation of kinase 
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signaling was determined in the PANC-1 cells. Rib-vH BSA induced phosphorylation of 
ERK1/2, p38, p53, AKT and SAPK/JNK was elucidated.    
ERK1/2 phosphorylation has been described to sustain pancreatic cancer progression 294 
and chemoresistance 295.  The role of RAGE induced phosphorylation has been of ERK1/2 has 
been elucidated in cancers such as breast cancer 296. The role of RAGE induced ERK1/2 
phosphorylation is not described in pancreatic cancer. On Rib-vH BSA treatment no increase 
was observed in the ERK1/2 phosphorylation (Figure 3.30). This suggests that Rib-vH BSA does 
not trigger ERK signaling pathways. We then evaluated the phosphorylation of AKT, p53, p38 
and JNK which have all been reported to enhance pancreatic tumor cell survival and disease 
progression 297-300. No increase was also observed in the phosphorylation of AKT, p38 and JNK 
(Figure 3.30). Total p53 could not be detected under our conditions. Hence, the role of Rib-vH 
BSA triggered kinase signaling could not be evaluated and requires further evaluation. 
 
 
 
 
 
 
Figure 3.30.  Western blots of the kinases.  
1: Control, 2: Rib-vH BSA treated after 24 hours. 
Role of extracellular matrix glycation in pancreatic cell adhesion 
The extracellular matrix plays a very important role in carcinogenesis. Cancer 
progression is affected by abnormal ECM as it promotes cellular migration and metastasis. 
 124 
Abnormal ECM facilitates angiogenesis and inflammation by deregulating the stromal cell 
behavior, which leads to the generation of a tumorigenic microenvironment 301.  Glycation of 
ECM leads to significant anomalies in the ECM structure302. Glycation induced cross-linking of 
ECM proteins such as collagen they stiffen the ECM98. The ECM proteins are characterized by 
very long half-life 303, 304, hence are susceptible to very significant levels of glycation. Glycation 
of collagen has been hypothesized to play an important role in various diabetic related vascular 
diseases 305-309. Glycation of collagen was reported to reduce cancer cell adhesion in lung 
carcinoma cells310. However, the role of ECM glycation has not been well understood in cancer. 
ECM glycation has not been described in pancreatic cancer. Collagen was glycated with five 
different glycation reagents to determine the effect of ECM glycation on cell adhesion in 
pancreatic cancer cells. On glycation, a decrease in the cell adhesion was observed in the PANC-
1 and BxPC-3 cells (Figure 3.31 and 3.32). We observe an approximately 33% decrease in 
cellular adhesion. These results are in agreement with literature reports in the lung carcinoma 
cells where a decrease was observed in the cellular adhesion 310. However, no change in the 
adhesion properties were observed with the MIA PaCa-2 cells on glycated collagen (Figure 
3.33), a decrease in the adhesion was observed in the non-glycated collagen when compared to 
the non-coated controls. This suggests that the MIA PaCa-2 cells do not adhere properly in the 
presence of collagen as strongly as other pancreatic cancer cells.  
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Figure 3.31. Effect of collagen glycation on PANC-1 cell adhesion.  
(Representation of 2 independent experiments and n=6 in each experiment, **P<0.005). 
 
 
 
 
 
 
 
 
 
 
Figure 3.32. Effect of collagen glycation on BxPC-3 cell adhesion.  
(Representation of 2 independent experiments and n=6 in each experiment, **P<0.005). 
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Figure 3.33. Effect of collagen glycation on MIA PaCa-2 cell adhesion.  
(Representation of 2 independent experiments and n=6 in each experiment, ***P<0.0005, N.S.: 
Non Significant when compared to non-treated collagen). 
Conclusions 
The goal of this study was to understand the AGE compounds and the role of AGE-
RAGE interaction in pancreatic cancer cell proliferation and migration leading to tumor growth 
and progression. It is not clear if the AGE compounds play a role in pancreatic cancer tumor 
growth. AGE compound research is highly complex due to the heterogeneous nature of the AGE 
compounds as described in chapter 2 the reason for the toxicity of AGE compounds is still 
unclear. Ribose modified BSA was used as the model AGE compound to study the AGE induced 
cellular effects in pancreatic cancer cell lines. Two pancreatic cancer cell lines with high RAGE 
expression; PANC-1 and MIA PaCa-2 were selected to understand the role of AGE compounds. 
Interestingly, we observe different cellular effects and diverse AGE induced cellular signaling in 
these two cell lines (summarized in Figures 3.34 and 3.35).  
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Figure 3.34. AGE-RAGE signaling in PANC-1 cells.  
AGE-RAGE interaction triggers ROS formation which can in-turn trigger NF-κB activation. NF-
κB  is translocated into the nucleus where it binds to specific DNA sequence to trigger various 
cellular events such as cell proliferation and migration. AGE compounds are cleared by the AGE 
clearance receptors such as the scavenging receptors. AGE compounds are internalized and 
degraded by the endosomes and lysosomes respectively.       
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Figure 3.35. AGE-RAGE signaling in MIA PaCa-2 cells.  
AGE-RAGE interaction triggers ROS formation. No activation of NF-κB was observed on AGE 
treatment. Increased cell proliferation and migration was observed via NF-κB independent 
signaling.  No AGE compound internalization was observed in these cells.       
Rapid Rib-vH BSA uptake was observed in PANC-1 cells and no uptake was observed in 
the MIA PaCa-2. Rib-vH BSA uptake lead to the increase in oxidative stress and super oxide 
production in PANC-1 cells which was RAGE dependent. RAGE dependent Rib-vH BSA 
induced oxidative stress and super oxide production was also observed in the MIA PaCa-2 cells. 
The ROS triggered NFκB activity in PANC-1 cells which was also inhibited by RAGE 
inhibitors.  On the contrary, no increase in NFκB activity was observed in the MIA PaCa-2 cells 
on treatment.   
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The entire panel of AGE compounds (described in chapter 2) was used to describe the 
mitogenic role of AGE compounds. Both in the PANC-1 and the MIA PaCa-2 cells we observe a 
correlation in the mitogenic effect of the AGE compounds and to their oligomeric content with 
the Rib-vH BSA having the most significant effect. Higher mitogenic effect of the Rib-vH BSA 
was observed in the PANC-1 cells when compared to the MIA PaCa-2 cells. Rib-vH BSA 
triggered cellular proliferation was identified to be RAGE dependent in both cell lines. To obtain 
a better understanding of the role of glycation induced oligomers in pancreatic cell proliferation, 
the isolated Rib-vH BSA oligomers were used to treat the PANC-1 and MIA PaCa-2 cells. An 
increase in cell proliferation was observed in both the cell lines when the cells were treated with 
the oligomers. This emphasizes the importance of glycation induced protein cross linking of the 
Rib-vH BSA for its mitogenic effects in pancreatic cancer cells. Rib-vH BSA treatment also 
induced increased colony formation in both the cell lines. The effect of Rib-vH BSA on cellular 
migration was also determined. On Rib-vH BSA treatment the migratory ability of PANC-1 and 
MIA PaCa-2 cells also increased. This indicates that the Rib-vH BSA not only influences 
cellular proliferation but also migration which could initiate metastasis. However, the signaling 
mechanisms involved in the Rib-vH BSA induced cellular effects could not be elucidated and 
require further studies. Our results suggest that Rib-vH BSA triggers diverse signaling pathways 
in the PANC-1 and MIA PaCa-2 cells even though they are RAGE dependent. We suspect other 
kinases such as p65 and JAK which has been reported to play a role in the RAGE induced 
autophagy 311 might play a role in the Rib-vH BSA triggered signaling. In the MIA PaCa-2 cells 
we suspect other transcription factors such as STAT-3 could play an important role. RAGE 
induced STAT-3 activation has been described in the Pan2.03 cells 235, 311.   
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The proliferative and migratory effect of Rib-vH BSA was also determined in the low 
RAGE expressing BxPC-3 cells. We observe that the AGE compounds induced cellular 
proliferation and the increase in cell proliferation could be correlated to their oligomeric content. 
The Rib-vH BSA induced cell proliferation was RAGE dependent as observed in the PANC-1 
and MIA PaCa-2 cells. The isolated Rib-vH BSA oligomers also had a proliferative effect on the 
BxPC-3 cells. Rib-vH BSA also induced BxPC-3 migration as described in the other two cell 
lines.   
Taken together our results suggest a novel role of AGE compounds in the pancreatic 
cancer cell proliferation and migration. Our results also emphasize the importance of glycation 
induced protein cross-linking in the toxicity of the AGE compounds. The role of RAGE in the 
AGE mediated effects can also be highlighted. Building on these results in future the intra 
cellular signaling of Rib-vH BSA can be evaluated. The receptors involved in AGE uptake also 
have to be determined.  
The effect of extracellular matrix (ECM) glycation on cell adhesion was also determined. 
We observe decreased cell adhesion in the PANC-1 and the BxPC-3 cells. No change the cellular 
adhesion as observed in the MIA PaCa-2 cells on the glycated ECM. These results form the basis 
for future evaluations into the mechanisms of ECM glycation in pancreatic cancer as the ECM 
glycation has not been described and studied in pancreatic cancer.  
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CHAPTER 4: THE ROLE OF RIBOSE DERIVED ADVANCED GLYCATION END 
PRODUCTS (AGES) IN MACROPHAGE ACTIVATION AND PRO-INFLAMMATORY 
CYTOKINE RELEASE 
Introduction 
Advanced glycation end products (AGEs) and diabetes   
Diabetes mellitus is characterized by long standing hyper glycemic conditions which 
promote the formation of AGEs by non-enzymatic glycation. AGE compound formation and 
deposition has been described in several microvascular and macrovascular complications of 
diabetes 312.  The cellular interaction of AGEs is believed to induce several biological responses, 
which are responsible for the development of diabetic vascular complications 313. The AGE 
compounds interact with cell surface receptors such as RAGE 127, “AGE-receptor complex” and 
consists of three proteins AGE-R1 (OST-48), AGE-R2 (80-K-H) and AGE-R3. AGE-R3 is also 
known as galectin-3 (LGALS3) and is responsible for AGE binding 130, type I (SR-AI) and type 
II (SCARA2) macrophage scavenger receptors 122, CD-36 123, FEEL-1 and FEEL -2 124, 
scavenger receptor proteins SR-BI and SR-BII 125 and the lectin-like oxidized low-density 
lipoprotein receptor 1 (Lox-1) 126 and mediate their cellular effects. In-Vitro studies provide 
evidence that on AGE stimulation the renal tubular cells secrete MCP-1 or express ICAM-1314, 
315 which can in-turn trigger the recruitment of macrophages.  The interaction of AGE 
compounds and scavenger receptors expressed on macrophages (RAW 264.7 cells) has been 
reported to induce the production of several cytokines such as plasmogen activator 316. The AGE 
compounds can also trigger pro-inflammatory cytokine release, the methyl glyoxal modified 
human serum albumin has been reported to upregulate TNF-α and IL-1β mRNA levels 317. AGE 
compounds such as heavily modified glycolaldehyde-derived AGE-LDL induced macrophage 
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foam cell formation contributing to the pathogenesis of atherosclerosis 318.  Taken together, all 
these reports indicate a definitive role of AGE compounds in macrophage activation and 
cytokine release. However, there are gaps in our understanding of the role of AGE compounds 
mediated cellular effects in macrophages. The uptake and intra-cellular internalization of AGE 
compounds is not fully understood. This study was initiated to fill these gaps in our 
understanding of AGE mediated macrophage uptake. Previously, we have characterized a panel 
of AGE compounds using chemically different glycation reagents 220, 318, 319. The Ribose 
modified BSA (Rib-vH BSA) had the most significant cellular effect hence, we select Rib-vH 
BSA as the model AGE compound and its uptake, effect on the mRNA levels of inflammatory 
mediators was determined in a murine macrophage cell line; RAW 264.7. This cell line was 
selected as the role of AGE uptake and some of its cellular consequences have been studied 
previously in this cell line 313, 316, 320-323 and moreover, this cell line also closely mimics human 
bone marrow-derived macrophages in terms of cell surface receptors and response to microbial 
ligands 324. The role of Rib-vH BSA to increase macrophage proliferation was also determined.  
Inflammation and diabetic complications 
Diabetes mellitus is a chronic disease characterized by long standing hyperglycemic 
conditions.  The effect of diabetes on human vascular tree is the major source of morbidity and 
mortality in both type I and type II diabetes 325 and diabetes has grown into pandemic 
proportions worldwide. The diabetic vascular complications can be divided into microvascular 
complications such as diabetic retinopathy, nephropathy and macrovascular complications such 
as peripheral arterial disease, coronary arterial disease and cardiomyopathy.   In recent years, our 
knowledge regarding the pathophysiology of diabetic vascular complications has improved 
considerably at the molecular level. These studies provided clear evidence that the traditional 
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factors such as metabolic and hemodynamic altercations are only a partial aspect of a more 
complex picture 326. More importantly, the importance of immune system mediated 
inflammatory processes in the pathophysiology of diabetic complications has come into light. 
327,328  
Accumulating evidence suggests that inflammatory signals play a very important role in 
the progression and development of many of the diabetic complications such as diabetic 
nephropathy which was traditionally considered to be a non-immune disease 329,330.  The role of 
proinflammatory cytokines, chemokines and other inflammatory molecules contributing to 
persistent low grade inflammation, leading to retinal vascular damage and neovascularization, 
has been supported by a large body of literature 87, 331-333.   Highly complex and diverse immune 
signaling are involved in the pathogenesis of diabetic complications. The role of several pro-
inflammatory molecules such as chemokines (monocyte chemoattractant protein-1), 334, 
335enzymes like cyclooxygenase-2 and nitric oxide synthase 336-339, adhesion molecules 
(intercellular adhesion molecule-1 (ICAM-1) 315, 340, nuclear factors like NfkB 341, 342, growth 
factors such as vascular endothelial growth factor, insulin like growth factor (IGF) and tumor 
growth factor beta (TGF-β) 343-346 has been implicated in diabetic complications.  The role of 
inflammatory cytokines in diabetic complications has considerable attention in the recent past. 
Pro-inflammatory cytokines such as IL-1, IL-6, IL-18, TNF-α have been implicated in the 
pathogenesis of diabetic complications. These cytokines can also active a wide range of immune 
cells including macrophages, leukocytes and monocytes 347-349.   
Macrophages and diabetic complications 
Macrophage literally means “big eaters” and is a leukocyte that identifies and engulfs 
several pathogenic particles, cell debris and also cancer cells by phagocytosis and plays a very 
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important role in antigen presentation, in innate and adaptive immune responses.  All tissues 
contain resident macrophages. Depending on stimulation with external stimuli the macrophages 
are activated into distinct cells 350, 351. Inflammatory stimuli such as lipopolysaccharide (LPS), 
IFN-γ and TNF-α lead to classical activation which generates M1 macrophages with high 
antigen-presenting capacity which leads to the production of pro-inflammatory cytokines such as 
IL-1β, TNF-α, IL-6 and subsequent induction of Th1 response. On the other hand, cytokines 
such as IL-4 and IL-13 which are Th2 cytokines and lead to alternative activation of 
macrophages to M2 macrophages. The M2 macrophages play a role in tissue remodeling and 
immunoregulation. There are three main groups of M2 macrophages: M2a activated by IL-4 and 
IL-13, M2b induced by immune complexes or TLRs, and M2c activated by IL-10 352. 
Furthermore, the macrophages express general markers, such as F4/80, CD68, CD11b, and Ly6c, 
in a heterogeneous fashion, dependent on tissue of origin, maturation, and activation degree 353-
355.  
Several recent findings report a substantial increase in tissue macrophages as a common 
feature in diabetic complications including nephropathy, atherosclerosis, neuropathy and 
retinopathy 356-359. Recent findings have helped to provide an understanding of the potential 
importance of macrophages in promoting these complications 360. Macrophage accumulation has 
been described in human and experimental Type 2 diabetic nephropathy and its role has been 
reported to promote renal injury349, 357.  Studies performed in genetically modified db/db mice, 
have demonstrated that macrophage-mediated injury plays a central role in the development of 
Type 2 diabetic nephropathy314, 315. 
In peripheral neuropathy, macrophage accumulation has been reported in perivascular 
lesions and their presence has been associated with nerve demyelination, suggesting that they 
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may be involved in the nerve damage359, 361, 362.  The presence of macrophages has been reported 
in the epiretinal membrane356 and macrophage-derived cytokines are frequently detected in 
vitreous samples,358, 363 among patients suffering from proliferative retinopathy which is another 
microvascular complication of Type 2 diabetes and it has been suggested that macrophages play 
a role in cell apoptosis, neovascularization and fibrosis. Macrophage accumulation has also been 
described in atherosclerotic lesions among patients suffering from acute myocardial infraction 42.  
Animal studies have also demonstrated that macrophage depletion provides resistance to 
atherosclerosis 364, 365 emphasizing the role of macrophages in pathogenesis of atherosclerosis. It 
has also been reported that the development of Type 2 diabetes induces macrophage recruitment 
by upregulating the tissue expression of molecules including several macrophage-attracting 
chemokines, such as monocyte chemoattractant protein-1 (MCP-1), osteopontin, macrophage 
migration inhibitory factor (MIF) and macrophage colony stimulating factor and intercellular 
adhesion molecule-1 (ICAM-1)315, 349, 366.  The infiltrated macrophages have been suggested to 
contribute to diabetic tissue injury through the production of reactive oxygen species (ROS) and 
metalloproteinases367, 368.    
We hypothesized that the AGE-RAGE interaction triggers cellular signaling leading to 
macrophage activation and pro-inflammatory cytokine release. 
Materials and Methods 
Reagents were of molecular biology or ACS purity grade and purchased through Fischer 
Scientific or VWR. Bovine serum albumin (BSA), fraction V, was purchased from Amresco. 
Antibodies and SiRNA were purchased from R&D Systems and SantaCruz Biotechnology. 
Molecular biology reagents and enzymes were purchased from New England Biolabs, Life 
Technologies, OriGene and Fermentas. Chromatography media for protein purification were 
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purchased from GE Healthcare. Reagents and media for cell culture were from ATCC. The 
RAW blue cells were purchased from Invivogen. 
AGE compound preparation 
Described in chapter 2. 
Cell culture conditions 
RAW 264.7 cell line, a mouse macrophage cell line was purchased from ATCC and were 
cultured in DMEM media (ATCC) with 10% FBS (ATCC) as described by ATCC. RAW blue 
cells were purchased from Invivogen (San Diego, CA).  The RAW blue cells were cultured in the 
presence of Zeocin (200ug/mL) and Normocin (100ug/mL) as described by the manufacturer. 
The cells were maintained in a sterile incubator at 37 °C with 5% CO2.   
RNA extraction and cDNA synthesis 
The whole cell RNA was extracted from the RAW 264.7 cells using the Ambion's Protein 
and RNA Isolation System, PARIS™ (Life Technologies). Briefly, 50000 cells were seeded in 
each well of a 6 well plate. The cells were allowed to adhere and reach a confluency of 60% by 
incubating at 37 °C for 24 hours. After the cells reached the required confluency, the cells were 
stimulated with 1 mg/mL of Rib-vH BSA. The cells were then incubated at 37 °C. Cells were 
harvested at 30 min, 3 hrs, 6 hrs, 12 hrs and 24 hrs after stimulation and the RNA was extracted.  
The concentration of the RNA was measured by UV absorbance at 260 nm and the ratio of the 
absorbance at 260 nm/280 nm was calculated to estimate the purity of RNA.  The RNA was 
immediately reverse transcribed using the Moloney Murine Leukemia Virus (M-MuLV) Reverse 
Transcriptase (NEB labs) using an oligo dT primer.  
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Quantitative real time PCR (q RT-PCR) 
AGE induced upregulation of several pro-inflammatory genes were analyzed by real time 
PCR using Eva green (Solis BioDyne).  We differentiated genes based on their function as 
oxidative stress genes, genes responsible for inflammation and we also determined the AGE 
mediated upregulation of AGE-receptors at the RNA level.  In order to determine the accurate 
housekeeping gene we carried out a house keeping gene analysis using the Normfinder, 
Bestkeeper and GeNorm algorithms on a set of 14 housekeeping genes (Table 4.1).  Normfinder 
program calculates the geometric mean of all the reference genes and takes into account 
systematic differences between sample subgroups to find the most appropriate housekeeping 
gene 369. Bestkeeper program uses pair wise correlations to determine the most appropriate 
housekeeping gene 370.  Genorm calculates a gene expression normalization factor for each 
sample based on the geometric mean of the reference genes 371. Rib-vH BSA induced changes in 
the house keeping gene expression was measured at 30 min, 3 hrs, 6 hrs, 12 hrs and 24 hrs.  
Based on the Ct values of the house keeping genes in the different treatment groups, RPL4 was 
determined to be the most stable housekeeping gene by all the three programs. No improvement 
was observed in theRPL4 gene stability in the presence of a second housekeeping gene. Hence 
we decided to use RPL4 alone as the house keeping gene.    The fold change with respect to 
untreated control was calculated using the following equations   
Δct= ct value of gene-ct value of housekeeping gene    (4.1) 
ΔΔct= Δct value of the gene before treatment- Δct value of gene after treatment (4.2) 
Fold Increase= 2ΔΔct         (4.3) 
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Table 4.1. Housekeeping genes used in the study to determine the most stable housing keeping 
gene. 
Gene 
(Gene ID) 
Function 
Primers 
(5’3’) 
GAPDH 
(NM_008085) 
Glyceraldehyde 
Dehydrogenase 
Forward: CAAGGCTGTAGGCAAAGTCA 
Reverse: GAGACCACCTGGTCCTCTGT 
PPIB 
(NM_011149) 
 
Peptidyl-prolyl cis-
trans isomerase B 
Forward: TCGTCTTTGGACTCTTTGGA 
Reverse: TCTTTCCTCCTGTGCCATCT 
TBP 
(NM_013684) 
TATA box binding 
protein 
Forward: CAGTGCCCAGCATCACTATT 
Reverse: AGCATAAGGTGGAAGGCTGT 
ACTBG 
(NM_009609) 
Actin beta and gamma 
Forward: 
CATTGCTGACAGGATGCAGAAGG 
Reverse: TGCTGGAAGGTGGACAGTGAGG 
ACTB 
(NM_007393) 
Actin beta 
Forward: AGTGTGACGTTGACATCCGT 
Reverse: TGCTAGGAGCCAGAGCAGTA 
Casc3 
(NM_138660) 
Cancer susceptibility 
candidate 3 
Forward: AGGAGATGCTGTTCTTTCCG 
Reverse: GCAGCATCGTTAGCTTCTGA 
YWHAZ 
(NM_011740) 
Tyrosine 3-
monooxygenase/tryptop
han 5-monooxygenase 
activation protein 
Forward: GTCTGTCACCGTCTCCCTTT 
Reverse: GTAGGGTGTGAGCTTTGGGT 
HMBS 
(NM_013551) 
Hydroxymethylbilane 
synthase 
Forward: ATCTTGGACCTAGTGAGTGTGT 
Reverse: GTACAGTTGCCCATCTTTCATCA 
RPL37A 
(NM_009084) 
Ribosomal protein 
L37A 
Forward: GCTAAACGCACCAAGAAGGTC 
Reverse: GCCACTGTTTTCATGCAGGAA 
EIF2B2 
(NM_145445) 
Eukaryotic translation 
initiation factor 2B, 
subunit 2 beta 
Forward: TAGGACAGTTGAGGCCTTCC 
Reverse: GTGCCAATGATCACCTTGTT 
RPL4 
(NM_024212) 
Ribosomal protein L4 
Forward: CGCAACATCCCTGGTATTACT 
Reverse: AAAGCACTCTCCGTCCAGAT 
SDHA 
(NM_023281) 
Succinate 
dehydrogenase 
complex, subunit A 
Forward: CTACAAGGGACAGGTGCTGA 
Reverse: GAGAGAATTTGCTCCAAGCC 
HPRT1 
(NM_013556) 
Hypoxanthine 
phosphoribosyltransfera
se 1 
Forward: AGGACCTCTCGAAGTGTTGG 
Reverse: CGTGATTCAAATCCCTGAAG 
RPL13A 
(NM_009438) 
Ribosomal protein 
L13A 
Forward: AGCAGATCTTGAGGTTACGGA 
Reverse: TTATTGGGTTCACACCAGGA 
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Fluorescent labelling of Rib-vH BSA 
The cysteine residues of the Rib-vH BSA were fluorescently labelled by a malemide 
derivative of a near infra-red cyanine dye called cyanine5.5 (Cy5.5® malemide, Lumiprobe). It 
has an excitation wavelength of 675 nm and an emission maximum at 695 nm. Cy5.5 ® 
malemide was dissolved in methanol aliquoted and dried by vacuum centrifugation and stored at 
-80 °C. Rib-vH BSA was diluted in PBS to a final concentration of 10 mg/mL and was then 
mixed with 2 molar excess of Cy5.5 and incubated for 30 min at RT by stirring. The free dye 
was removed by dialyzing the protein against 500 volumes of PBS. The presence of free dye was 
visualized by running the labelled protein on a SDS-PAGE gel and then visualizing the bands on 
infra-red fluorescence (NIRF) imaging using a Kodak FX Pro Imager (Carestream Health 
Incorporation, Rochester, NY) . Absorbance was measured at 280 nm and 675 nm and the moles 
of dye bound to the mole of protein was determined to be 0.3.  
Rib-vH BSA uptake assay 
The kinetics of Rib-vH BSA uptake was determined by measuring the fluorescence of 
Cy5.5 of the Rib-vH BSA_Cy5.5 at different time points. Briefly, 50,000 cells per well were 
seeded in a cell culture 24 well plate and incubated at 37 °C overnight for the cells to adhere. 50 
µg/mL (25 µg per well) of the labelled Rib-vH BSA was added to each well and incubated at 37 
°C. The media was aspirated and the cells were washed twice with PBS. The cells were lysed 
using TBS with 0.1% triton X-100 at different time points. For 0 hrs time point the cells were 
lysed immediately as soon as the compound was added. Fluorescence of the cell lysate was 
measured in a 40 µL quartz cuvette with an excitation of 675 nm and an emission of 691 nm with 
a slit setting of 5 nm on the Horiba Jobin Yvon Spectramax-4 fluorimeter. The exact protein 
content taken up was determined by a calibration curve of the labelled Rib-vH BSA.  
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Internalization of Rib-vH BSA by live cell confocal imaging 
Rib-vH BSA tagged with Cy5.5 was used to determine the uptake in RAW 264.7 cells. 
The lysosomes of the RAW 264.7 cells were labelled using the CellLight® Lysosomes-GFP, 
BacMam 2.0 (Life Technologies).  This system uses Bacmam 2.0 technology to transfect a 
construct expressing GFP fused to lamp1 (lysosomal associated membrane protein 1).  50,000 
cells were seeded in an Ibidi µ-dish designed for live cell imaging and the cells were allowed to 
adhere overnight. 25µL of the CellLight® Lysosomes-GFP construct was added to the dish and 
incubated at 37 °C for 24 hrs.  The dish was then placed in the environmental control chamber 
for time-lapse cell culture related experiments. The temperature of the chamber was set to 37 °C, 
with 5 % CO2 and 95% humidity. 20 µL of the Rib-vH BSA_Cy5.5 (Final concentration of 1 
mg/mL) was added and the cells were imaged at different time points. The imaging was carried 
out using the Zeiss AxioObserver Z1, fully motorized inverted scope with LSM700 laser 
scanning head attachment. Images were taken at different time points using Zeiss Zen Black 
software and analyzed using the Zeiss AxioVision Rev. 4.8.1.    
Estimation of endotoxin content and endotoxin removal  
The endotoxin content of the AGE samples was quantified using the Pierce™ Limulus 
Amebocyte Lysate (LAL) Chromogenic Endotoxin Quantitation Kit (Life Technologies) 
according to manufacturer’s protocol.  Briefly, 500 ng (50 µL) of AGE protein was pipetted in 
each well of a 96 well plate and incubated at 37 °C for 5 min.  50 µL of LAL was added and 
incubated at 37 °C for 10 min. After the incubation 100 µL of the substrate was added into each 
well and incubated at 37 °C for 6 min. The absorbance was then measured at 405 nm using the 
SpectraMax M5 plate reader.  
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Endotoxin was removed using the removed by phase separation using nonionic 
polyoxyethylene surfactant Triton X-114. Briefly, the Rib-vH BSA was diluted to a 
concentration of 5 mg/mL using phosphate buffered saline, pH 7.5. 1% v/v of Triton X-114372 
was added and this solution was vigorously stirred for 10 min. The solution was then heated to 
55 °C for 15 min and immediately placed on ice for 10 min.  The samples were then centrifuged 
at 10,000 rpm for 5 min. The supernatant was collected and the process was repeated 3 times. 
After the final purification the endotoxin content was determined as described above. 
Estimation of reactive oxygen species (ROS)  
AGE induced ROS formation was determined by a cell-permeable non-fluorescent ROS 
probe 2, 7-dichlorofluorescein diacetate. This compound is de-esterified intracellularly and on 
oxidation by ROS turns in to 2, 7- dichlorofluorescein which is highly fluorescent. 25,000 cells 
per well were seeded in a 96 well plate and incubated at 37 °C overnight. The media was 
aspirated and the cells were washed twice with PBS and were loaded with 5 µM per well of 2, 7- 
dichlorofluorescein diacetate and incubated at 37 °C for 30 min. The cells were then treated with 
the AGE compound (1 mg/mL) and incubated at 37 °C. Fluorescence emission was measured at 
535 nm with an excitation wavelength of 500 nm using the SpectraMax M5 plate reader.          
Estimation of nitric oxide formation  
The effect of AGE compounds on nitric oxide production was evaluated by Griess 
reaction. Griess reaction measures the formation of the nitric oxide by measuring the nitrite ion 
which is a stable breakdown product of nitric oxide. 25,000 cells per well were seeded in a 96 
well plate and were incubated at 37 °C overnight for the cells to adhere. The media was then 
aspirated and replenished with serum free media. The cells were then treated with 1 mg/mL Rib-
vH BSA and incubated at 37 °C for 24 hrs. from each well 50 µL of the cell supernatant was 
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collected and transferred to a fresh 96 well plate, 50 µL of sulfanilamide solution (solution 1) 
was added in each well and incubated at RT in dark for 10 minutes and finally 50 µl of N-1-
napthylethylenediamine dihydrochloride (NED) solution was added and incubated I dark for 10 
minutes at RT. The absorbance of the azo compound formed was measured at 570 nm. Serial 
dilutions of sodium nitrite were made and the nitrite content was determined and a calibration 
curve was obtained. The exact nitrate content of the cells was measured using this standard 
curve. 
Estimation of NF-κB activity 
The Nf-κB activity was determined by a commercially engineered cell line called RAW-
blue ™ (Invivogen). RAW blue cells contain secreted embryonic alkaline phosphatase (SEAP) 
reporter construct inducible by NF-κB and AP-1.  100,000 cells were seeded in each well of 96 
well plate as per supplier’s protocol and the cells were immediately treated with the required 
concentration of AGE compounds and then incubated for 24 hrs at 37 °C. After the incubation 50 
uL of the cell supernatant was collected and added to 150 µL of the supplied QUANTI-blue ™ 
media and then incubated at 37 °C for 1 hr. The absorbance was measured at 630nm using the 
SpectraMax® M5 plate reader. 
RNA silencing 
Small Interfering RNA (siRNA) were used to knockdown galectin-3, scavenging 
receptor; SR-A and MyD88 which is an adaptor protein of the toll like receptors (TLRs). The 
siRNAs were purchased from Santa Cruz Biotechnology (galectin-3: sc-35443, MyD88: sc-
35987 and SR-A: sc-40188). The cells were transfected with the siRNA using lipofectamine® 
2000 (Life Technologies). Briefly, the cells were seeded and allowed to adhere and reach about 
50% confluency. The media was replaced with serum free media and the siRNA-lipofectamine® 
 143 
2000 complex was added. The cells were then incubated at 37 °C for 24 hrs. After the incubation 
the cells were washed and the media was then replaced by normal serum containing media. The 
efficiency of knockdown was estimated by western blotting or by q RT-PCR.  
Western Blot analysis 
The siRNA knockdown was estimated using the western blotting. Briefly, 25 µg of the 
total cell protein was loaded on a 12% SDS-PAGE gel and run at 150 V. The bands were 
transferred on to a nitrocellulose membrane at 250 mA for 1 hr. The blot was then blocked using 
5% milk powder in TBS-T. Primary antibody dilutions (1:1000) were made in 2% milk powder 
in TBS-T. The primary antibodies were purchased from Santa Cruz biotechnology (MyD88: sc-
11356, galectin-3: sc-20157, SR-A:  sc-20660). The blot was incubated with the primary 
antibody overnight at 4 °C. The blots were washed with TBS-T for 5 times (2 minutes each) and 
the HRP conjugated secondary antibody was added (Jackson: 711-035-152, 1:10000 dilution). 
The blots were incubated for 2 hrs at RT then washed and developed on the X-ray film using the 
ECL substrate. 
Cell proliferation 
To determine the mitogenic effect of Rib-vH BSA we measured cell proliferation by a 
fluorogenic oxidation-reduction indicator “Resazurin”. The non-fluorescent resazurin under goes 
reduction in the reducing environment of the cells to form resorufin which exhibits 
absorption/emission maxima at around 575 nm and 585 nm respectively. Briefly, 5000 cells were 
seeded in a cell culture 96 well plate and allowed to adhere overnight at 37 °C. The media was 
then replaced with fresh DMEM media with reduced serum of 2%. The cells were then treated 
with Rib-vH BSA (1mg/ml) for 24 hrs at 37 °C. After the required time period, 10% of the total 
well volume was added with resazurin (0.1 mg/ml in D.I water and sterile filtered) and the plate 
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was incubated at 37 °C the emission maxima was measured at 585 nm using the SpectraMax M5 
plate reader. For RAGE inhibition 25 µg/mL anti-RAGE antibody (2A11) or 1 µM small 
molecule inhibitor of RAGE (FPS-ZM1) were added with the Rib-vH BSA.  
Results and discussion 
AGE BSA uptake by the macrophages 
Historically, AGE uptake (glucose modified AGEs) has been studied using radioactive 
isotopes 320, 321. This method is highly sensitive but radioactive isotopes are hazardous to work 
and can have long lasting health issues. We develop a fluorescence based assay to study the 
uptake ribose modified BSA and this method can detect nano-gram quantities of the protein.  
Rib-vH BSA was labelled with a near infrared dye cyanine dye called Cy5.5 to determine the 
kinetics of AGE uptake by the macrophages.  The cells were lysed and the fluorescence of the 
lysate was determined at different time points to quantify the AGE compound uptake. The total 
protein content was determined using the BCA assay and fluorescence was normalized based on 
the total protein content in the cells. A very rapid increase in the AGE compound fluorescence 
was observed. This is in agreement with previous reports of glucose modified AGE uptake 320, 
321.  Our data indicates an 18 fold increase in the fluorescence emission after 10 min of 
incubation with AGE BSA. We observe 30 fold, 55 fold, and 81 fold increase in the fluorescence 
after 1, 3 and 6 hrs of incubation at 37 °C respectively. After 24 hrs we observe a 137 fold 
increase in the Rib-vH BSA fluorescence.  This data demonstrate a rapid and continuous uptake 
of the Rib-vH BSA by the macrophages.   
The amount of AGE compound accumulated in the macrophages was then determined 
using these fluorescence values. A standard curve was obtained by measuring the fluorescence of 
known amount of AGE compound under the exact same conditions.  The results are presented as 
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the amount of AGE compound internalized in the macrophages adhered in a well of a 24 well 
plate.  After 24 hours of incubation about 25 µg of the AGE compound was internalized (Figure 
4.1). Hence, the macrophages internalized the entire AGE compound added in the well over a 
period of 24 hrs. On the contrary, the uptake of non-glycated BSA has been reported to be very 
slow and very little amount of non-glycated BSA was taken up by the macrophages 320, 321, 373. 
The RAW cells are cultured in the presence of 10% FBS and the FBS contains very high 
amounts of non-glycated serum albumin. Taken together these results suggest rapid uptake of the 
glycated serum albumin.       
The kinetics of AGE uptake in macrophages is not very well understood, it is not clear 
whether the macrophages internalize the AGE compounds continuously or not. Glucose modified 
BSA has been used to study the uptake over a relatively short duration of time 320, 321, 373. This 
study provides useful insights of the AGE compound uptake by macrophages. Macrophages are 
believed to play very important roles in AGE compound uptake and degradation. The role of 
tissue macrophages in AGE compound degradation has been proposed 374. As described earlier 
the AGE compounds are believed to activate the macrophages and trigger the release of pro-
inflammatory cytokines. However, it is not clear if the AGE compounds need to be internalized 
for them to activate the macrophage or if they initiate signaling by their interaction through 
pattern recognition receptors on the macrophages. To get a better understanding on AGE 
compound inter cellular compartmentalization we performed live cell imaging and is described 
later in this chapter.   
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Figure 4.1. Internalization of Rib-vH BSA tagged with Cy5.5 into RAW 264.7 cells.  
Rapid uptake of the Rib-vH BSA was observed. (Representation of two independent experiments 
n=6 for each experiment). 
To assess the specificity of the AGE BSA uptake of the cells a competition assay was 
performed using Cy5.5 labeled Rib-vH BSA and various concentrations of unlabeled Rib-vH 
BSA.  The macrophages were treated with 50ug/mL of Cy5.5 labeled Rib-vH BSA and different 
concentrations of unlabeled Rib-vH BSA, the cells were incubated at 37 °C for 2 hours and then 
the cells were lysed and the fluorescence of the lysate was measured as described earlier.  The 
unlabeled AGE compound efficiently competed with labeled AGE compound and reduced the 
uptake to < 5% of the control value (7µg) (Figure 4.2). 
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Figure 4.2. Competition assay was performed with increasing concentrations of unlabeled Rib-
vH BSA.  
The RAW 264.7 cells were incubated at 37 °C for 2 hours. (Representation of two independent 
experiments n=6 for each experiment). 
AGE internalization in the macrophages 
There is little information about the intracellular fate of endocytosed AGEs and their 
influence on proteolytic systems.  A recent report suggested that in RAW 264.7 cells the AGE 
compounds increase the number of lysosomes and the increased the lysosomal activity, mRNA 
and protein expression of cathepsins D and L 322. We performed live cell confocal fluorescence 
imaging to understand the internalization of Rib-vH BSA.  The Cy5.5 labeled Rib-vH BSA was 
used to study the AGE internalization and the lysosomes were labeled using the CellLight® 
Lysosomes-GFP ®as described earlier.  In agreement with the uptake assay, rapid internalization 
of the Rib-vH BSA_Cy 5.5 was observed in RAW 264.7 cells. Figure 4.3 shows the uptake of 
Rib-vH BSA at different time points; the green fluorescence represents lysosomes and Rib-vH 
BSA is represented by red fluorescence. Due to photo-bleaching images from same cell could 
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not be presented. Figure 3.3A represents time 0; Rib-vH BSA did not enter the macrophage. The 
arrows represent the lysosomes inside the macrophages. Figure 4.3B and 4.3C shows the uptake 
at 1 hour and 2 hours respectively. We observe that Rib-vH BSA internalized into the lysosomes 
after 1 hour. Interestingly, we observe continuous internalization of Rib-vH BSA into the 
lysosome was observed even after 2 hours. The arrow in Figure 3.3C shows a new Rib-vH BSA 
particle being taken up the lysosome. These images confirm the lysosomal uptake of Rib-vH 
BSA. Hence, we conclude that the Rib-vH BSA is taken up by the lysosomes and there is 
continuous uptake and internalization of the Rib-vH BSA by the macrophages.   
Macrophages can internalize particles by three major strategies, i.e. by pinocytosis, 
receptor-mediated endocytosis and phagocytosis375. Phagocytosis is an actin-dependent 
mechanism and clathrin independent mechanism which is responsible for the uptake of large 
particles (>0.5 µm). The Rib-vH BSA particles are the in the order of few nano meters hence it is 
unlikely that the Rib-vH BSA is internalized by phagocytosis. Pinocytosis and receptor mediated 
endocytosis are closely related they share a clathrin-mediated mechanism and do not involve 
actin polymerization. However, pinocytosis is a process by which fluid and solutes are taken up 
by the cell and cannot be involved in Rib-vH BSA uptake. Hence, most likely the Rib-vH BSA is 
internalized by receptor mediated endocytosis.     
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Figure 4.3. Rib-vH BSA uptake in the macrophages by live cell imaging. 
Green: Lysosomes, Red: Rib-vH BSA. A), B), C) Time 0, 1hr and 2hrs after the addition of Rib-
vH BSA respectively. (The experiment was performed 2 times independently). 
Role of receptors in AGE uptake 
Several AGE receptors have been identified and can be classified as clearance receptors 
which are responsible the clearance of AGEs or inflammatory receptors that are responsible for 
AGE induced signaling.  Clearance of AGE proteins involves scavenger receptors CD36 123, 376, 
FEEL-1 (STAB1), FEEL-2 (STAB2), SR-BI (SCARB1), SR-BII (SCARB2)121, 124, 376-379, and 
the macrophage scavenger receptors type I (SR-AI, MSR1) and type II (SCARA2, MARCO)122, 
380. Receptors that are not primarily involved in clearance, but have signaling functions are the 
AGE-receptor complex and the receptor for advanced glycation end products. The AGE-receptor 
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complex consists of three proteins AGE-R1 (OST-48, DDOST), AGE-R2 (80 K-H, PRKCSH), 
and AGE-R3 (galectin-3, LGALS3) 130, 381-383. The receptor for advanced glycation endproducts 
RAGE (AGER) belongs to the immunoglobulin-like protein family and mediates many of the 
physiological effects AGE products 28, 194, 384, 385. Recently, in the macrophages the nucleolin 
receptor was reported to recognize the glycolaldehyde and glyceraldehyde AGEs 386.  
In order to elucidate the role of AGE receptors expressed on the surface of macrophages 
in AGE uptake we perform real time quantitative PCR. We select 18 potential AGE binding cell 
surface receptors (Table 4.2) which include RAGE, galectin-3, scavenging receptors and pattern 
recognition receptors such as toll like receptors. Based on our housekeeping gene analysis the 
ribosomal protein L4 was selected as the house keeping gene and the ΔΔct values with respect to 
untreated control are reported in (Figure 4.4). On 24 hour Rib-vH BSA treatment we observe a 
significant upregulation in the genes of the AGE-receptor complex more specifically in the gal-3 
(7.2±2.6 ct units) and the PRKCSH (5.3±3.1 ct units) genes. However, we do not see any 
upregulation of RAGE. We also observe an upregulation of the toll like receptors 2, 4, 6 and 9. 
TLR2 was upregulated by 5.8±0.45 ct units. The role of TLRs in AGE uptake and signaling has 
not been described and their upregulation suggests a possible role of pattern recognition 
receptors such as TLRs in Ribose modified AGE signaling. Further investigation is necessary in 
this direction to determine the role of TLRs in AGE uptake and signaling.  
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Table 4.2. Receptors genes studied using q RT PCR to determine their AGE induced expression.  
Gene 
(Gene ID) 
Function Primers 
5’3’ 
RAGE 
(NM_007425) 
Receptor for advanced 
glycation end products 
Forward: AGAAGCTTGGAAGGTCCTGA 
Reverse: TTGGACTTGGTCTCCTTTCC 
DDOST 
(NM_005216) 
Advanced glycation 
endproduct receptor 1 
Forward: TGCACATGAAGGAGAAGGAG 
Reverse: GAGGTAAGGCTGTGCCATTT 
PRKCSH 
(NM_002743) 
Advanced glycation 
endproduct receptor 2 
Forward: GGAACTTGACGACAACATGG 
Reverse: CGGTCATAGAAGGAGGTGGT 
LGAL3 
(NM_005567) 
 
Galectin-3; Advanced 
glycation endproduct 
receptor 3 
Forward: AGACAGCTTTTCGCTTAACGA 
Reverse: GGGTAGGCACTAGGAGGAGC 
TLR2 
(NM_011905) 
Toll like receptor 2 
Forward: TTCTGATGGTGAAGGTTGGA 
Reverse: TTGACGCTTTGTCTGAGGTT 
TLR4 
(NM_021397) 
Toll like receptor 4 
Forward: ACACCAGGAAGCTTGAATCC 
Reverse: GAGGTGGTGTAAGCCATGC 
TLR6 
(AF314636) 
Toll like receptor 6 
Forward: TTGCTGGAACCCATTCTACA 
Reverse: CCTTCTCAGTAGGCCATTCC 
TLR9 
( NM_031178) 
Toll like receptor 9 
Forward: ATCTCCCAACATGGTTCTCC 
Reverse: CAGACTTCAGGAACAGCCAA 
SCARB1 
(CT010222) 
Scavenging receptor 
Forward: CCCGTCCCTTTCTACTTGTC 
Reverse: GGTGTCGTTGTCATTGAAGG 
SCARB2 
(NM_007644) 
Scavenging receptor 
Forward: TTCATCCGCTGATAAGCAAG 
Reverse: GGGTATACAGAAGCCAGCGT 
STAB1 
(NM_0151436) 
Scavenging receptor 
Forward: TTCTGCTCTGTGTCCTGGTC 
Reverse: AGGGACATAGTTGCCTCCTG 
STAB2 
(NM_017564) 
Scavenging receptor 
Forward: CGGAAGAGACTGTGTGGAGA 
Reverse: CAATTCCGTTTCCTCGAAAT 
CD 36 
(BC010262) 
Scavenging receptor 
Forward: GCCTTCACTGTCTGTTGGAA 
Reverse: GGAACCAAACTGAGGAATGG 
MSR1 
(BC003814) 
Macrophage 
scavenger receptors 
Class A 
Forward: GGATGCAATCTCCAAGTCCT 
Reverse: TGCGCTTGTTCTTCTTTCAC 
MARCO 
(NM_010766) 
Macrophage 
scavenging receptor 
type II 
Forward: ACAGAGCCGATTTTGACCAAG 
Reverse: CAGCAGTGCAGTACCTGCC  
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Table 4.2. Receptors genes studied using q RT PCR to determine their AGE induced expression 
(Continued).  
Gene 
(Gene ID) 
Function Primers 
5’3’ 
OLR1 
(NM_138648) 
Oxidized low-density 
lipoprotein receptor 1 
Forward: CAGATGTTAGCCCAGCAGAA 
Reverse: GAGTTTGCAGCTCTTTGCAG 
Ncl 
(BC005460) 
Nucleolin 
Forward: TCGAGAAGTCAACCATCCAA 
Reverse: GAACCAGTTTCCCGATCAGT 
 
 
 
 
 
 
 
 
 
 
Figure 4.4. Rib-vH BSA induced receptor mRNA upregulation after 24 hours of treatment. 
Ribosomal protein L4 (RPL4) was used as the house keeping gene and the ΔΔct values are 
calculated with respect to the gene expression at time 0. (Representation of two independent 
experiments). 
Macrophages also express several scavenging receptors 387-389. These receptors play a 
very important role in the in the removal of many foreign substances and waste materials in the 
living body and hence contribute to the scavenging (cleaning) activity of the macrophages. We 
investigated the upregulation of known AGE binding scavenging receptors on Rib-vH BSA 
treatment. We observe a significant upregulation in the SCARB1 (6.38±4.03 ct units), SCARB2 
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(3.8±1.4 ct units) and CD 36 (3.46±0.01 ct units).  No upregulation was observed in the STAB1 
and STAB2 expression. A significant upregulation was observed in the MSR1 gene. This gene 
encodes the class A macrophage scavenger receptors, which include three different types (1, 2, 
3) generated by alternative splicing of this gene. These results suggest a role for the class A 
macrophages scavenger receptors in the Rib-vH BSA uptake. The class A scavenger receptors 
are involved in the endocytosis of modified low density lipoproteins (LDLs) 390.  We also 
determined the upregulation of low density lipoprotein receptor (OLR1). The role of OLR1 has 
also been described to bind to sugar modified AGEs 391. AGEs have been described to induce 
foam cell formation as well 392. On Rib-vH BSA treatment the OLR1 was upregulated by around 
3.4±1.15 ct units.  
In order to elucidate the role of specific AGE receptors in Rib-vH BSA uptake we 
performed siRNA knock down of the receptors and also used receptor specific inhibitors. RAGE 
is the most well characterized receptor for AGEs; however our q RT-PCR data suggested very 
low expression of RAGE (31.25±1.73 ct units) in the RAW 264.7 cell line and no upregulation 
was observed in RAGE expression on Rib-vH BSA treatment (Figure 4.4). Hence we do not 
suspect the role of RAGE in Rib-vH BSA mediated uptake. Our q RT-PCR data suggest that 
galectin-3 was upregulated significantly, therefore the role of gal-3 in Rib-vH BSA uptake was 
determined. 500uM of N-acetyllactosamine, a potent inhibitor of gal-3 393 was used to the role of 
gal-3 Rib-vH BSA uptake in RAW 264.7 cells. In the presence of N-acetyllactosamine we do not 
observe any difference in the Rib-vH BSA uptake kinetics (Figure 4.6). The rapid uptake of the 
Rib-vH BSA also suggests a scavenging receptor mechanism. SR-A, which is a type I 
macrophage scavenging receptor was upregulated on Rib-vH BSA treatment, hence we elucidate 
the role of SR-A in the Rib-vH BSA recognition and uptake.  SR-A knocked down using siRNA.  
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The knock down was estimated by western blotting. A knockdown of 52.8±1.3% was observed 
(Figure 4.5). However, SR-A knockdown also did not influence the AGE uptake (Figure 4.6).  
These results do not conclusively point at any receptor involved in Rib-vH BSA uptake and 
needs further investigation.  AGE biology is very complex and several different receptors have 
been reported in the uptake of AGE as described above. We observe a simultaneous upregulation 
of multiple receptors on AGE treatment hence a possibility of multi receptor complexes in AGE 
uptake cannot be ruled out. The role of phagocytosis in Rib-vH BSA is unlikely as reports 
suggest that AGE compounds reduce the phagocytic potential in macrophages 394.   
 
 
 
 
 
 
 
 
 
Figure 4.5. SR-A knockdown in RAW 264.7 cells by SR-A siRNA.  
(Representation of two independent experiments). 
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Figure 4.6. Rib-vH BSA uptake.  
Red; Control cells, Blue; N-acetyllactosamine (galectin-3 inhibitor) and Green (SR-A) 
knockdown (Representation of two independent experiments, n=6 for each experiment). 
Rib-vH BSA induced oxidative and nitrogen stress in RAW 264.7 cells 
On stimulation with DAMPS macrophages are potent producer of reactive oxygen 
species (ROS) such as super oxide anion, singlet oxygen, hydroxyl radicle and hydrogen 
peroxide 395, 396. The production of reactive nitrogen species such as nitric oxide has been 
described to play a key role in the pathological process observe in diabetes and has also been 
associated with the diabetic complications 397, 398. Under diabetic conditions, there are several 
sources of ROS described, among them AGEs are one of the most potent sources399. A large 
volume of literature implicates the role of AGEs in oxidative stress formation and contribution to 
the chronic stress in diabetes 399-401.  Certain reports suggest the role of AGE induced oxidative 
stress in the macrophages402. However, the role of AGE induced oxidative stress in macrophages 
is not well understood. The role of AGE compounds in the upregulation of genes associated with 
oxidative stress has not been described. 
We select a panel of a 10 genes which have been reported to be responsible for nitrogen 
and oxidative stress in macrophages (Table 4.3). The highest upregulation was observed in the 
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inducible isoform of nitric oxide synthase (iNOS) gene; 12.4±0.25 ct units. The upregulation for 
iNOS was followed at different time points and a rapid upregulation was observed (Figure 4.7), a 
significant upregulation was observed after 30 min of AGE treatment and the upregulation 
increased over a 24 hrs.  The iNOS upregulation and nitric oxide synthesis has been described 
extensively in the literature as an inflammatory response in macrophages 403. The upregulation of 
iNOS suggests a pro-inflammatory role of the Rib-vH BSA. Rib-vH BSA induced nitric oxide 
production was quantified by the Griess assay. We quantify the nitric oxide produced after 24 
hours of treatment with Rib-vH BSA and 1281.5±55.9 pmol of nitric oxide was produced (Figure 
4.8).  
 
 
 
 
 
 
 
 
Figure 4.7. Time course of the iNOS mRNA upregulation on Rib-vH BSA treatment.  
Ribosomal protein L4 (RPL4) was used as the house keeping gene and the ΔΔct values are 
calculated with respect to the iNOS expression at time 0. (Representation of two independent 
experiments). 
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Figure 4.8. Nitric oxide produced after 24 hours on Rib-vH BSA treatment.  
1ug/mL of LPS and 1mg/mL BSA was used as the positive and negative control respectively. 
(Representation of two independent experiments). 
Significant upregulation was also observed in the genes associated with oxidative stress 
such as COX-2 and NOX-2 (Figure 4.9). COX-2 is an inflammatory mediator that catalyzes the 
formation of prostaglandins from arachidonic acid and can in-turn cause the production of 
oxidative stress 404. COX-2 is upregulated in several pathological processes involving 
inflammation, such as infectious diseases, cancer, arthritis and atherosclerosis 405-408. The role of 
DAMPS such as LPS in the upregulation of COX-2 has been well elucidated 409. However, the 
role of AGEs in COX-2 upregulation has not been described in the literature. The upregulation of 
COX-2 by Rib-vH BSA suggests the pro-inflammatory role of AGEs in activating the 
macrophages. The NOX2 was upregulated NOX or NADPH oxidase family transfer electrons 
across biological membranes and contributes significantly to the production of reactive oxygen 
species 410. NOX-2 isoform is the most well characterized and abundantly reviewed in the recent 
past and its role in macrophage oxidative stress is very described and understood 411-413.  On Rib-
vH BSA treatment upregulation of NOX-2 was observed (Figure 4.8) emphasizing the role of 
 158 
AGEs in ROS generation in macrophages.  We also observe upregulation of NOX-1 and NOX-4.  
The Rib-vH BSA mediated upregulation of COX-2 and NOX2 was determined at different time 
points (Figure 4.10 and 4.11). The expression levels of both the genes peaked at the 6 hour time 
point and then the expression flattened out till 24 hours of the treatment.   
Table 4.3. Genes associated with oxidative stress studied using q RT PCR to determine their 
AGE induced expression.  
Gene 
(Gene ID) 
Function Primer 
5’3’ 
iNOS 
(NM_010927) 
Inducible nitric oxide 
synthase 
Forward: GTTCTCAGCCCAACAATACAAGA 
Reverse: GTGGACGGGTCGATGTCAC 
COX-2 
(NM_011198) 
Cyclooxygenase-2 
Forward: TTCAACACACTCTATCACTGGC 
Reverse: AGAAGCGTTTGCGGTACTCAT 
NOX1 
(NM_172203) 
NADPH oxidase 1 
Forward: GTTTCTGGTTTCCTGGTTGG 
Reverse: AGCAGATTTCGACACACAGG 
NOX2 
(NM_007807) 
NADPH oxidase 2 
Forward: GTGAGAGGTTGGTTCGGTTT 
Reverse: GGAGCAGAGGTCAGTGTGAA 
NOX4 
(AF276957) 
NADPH oxidase 4 
Forward: GTTGGGCCTAGGATTGTGTT 
Reverse: CTCCTGCTAGGGACCTTCTG 
HIF1a 
(AF003695) 
Hypoxia-inducible 
factor 1-alpha 
Forward: CGACACCATCATCTCTCTGG 
Reverse: AAAGGAGACATTGCCAGGTT 
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Figure 4.9. Upregulation of genes associated with oxidative stress after 24 hrs of Rib-vH BSA 
treatment.  
Ribosomal protein L4 (RPL4) was used as the house keeping gene and the ΔΔct values are 
calculated with respect to the gene expression at time 0. (Representation of two independent 
experiments). 
 
 
 
 
 
 
 
 
 
Figure 4.10. Time course of the COX-2 mRNA upregulation on Rib-vH BSA treatment.  
Ribosomal protein L4 (RPL4) was used as the house keeping gene and the ΔΔct values are 
calculated with respect to the COX-2 expression at time 0. (Representation of two independent 
experiments). 
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Figure 4.11. Time course of the NOX-2 mRNA upregulation on Rib-vH BSA treatment.  
Ribosomal protein L4 (RPL4) was used as the house keeping gene and the ΔΔct values are 
calculated with respect to the NOX-2 expression at time 0. (Representation of two independent 
experiments). 
Building up on these studies we determined the AGE induced ROS production by 
determining the fluorescence of 2, 7- dichlorofluorescein (DCF).  DCF is de-esterified 
intracellularly and undergoes oxidation by ROS to form the highly fluorescent 2, 7- 
dichlorofluorescein.  DCF measures hydrogen peroxide, hydroxyl radicles, peroxyl radicles, 
peroxynitrite anion and super oxide anions. A basal fluorescence in control cells was measured 
to be 1008.7±58 counts on Rib-vH BSA treatment for 24 hours the fluorescence emission 
increased about 2.5 times to 2529.1±165.5 counts indicating  significant increase in the ROS 
production. The Rib-vH BSA induced ROS production was followed at different time points and 
we observe a linear correlation of the ROS production and time. When we used an ROS inhibitor 
500 µM N-acetyl cysteine (NAC), the Rib-vH BSA induced ROS attenuated (Figure 4.13).  AGE 
induced ROS production was also determined for the other AGE compounds (Figure 4.12). The 
highly modified AGE compounds were used and a detailed characterization of all the AGE 
 161 
compounds is described in chapter 1. The MG-H BSA treatment also induced significant ROS 
production (Figure 4.12). The MG-H BSA induced ROS levels were similar to the Rib-vH BSA 
induced ROS levels. The role of methyl glyoxal derived AGE compounds in macrophage 
activation and ROS production has been described previously described414 and our data validates 
the same. Increased ROS levels were also observed with the But-H BSA and Gly-H BSA and all 
other AGE compounds including the glucose derived AGE compounds did not show any ROS 
production. These differences among different AGE compounds could be a result from the 
heterogeneity of these AGE compounds and this emphasizes the fact that each AGE compound is 
unique and has certain structural features which are responsible for their recognition and uptake. 
For this work we concentrate only on the Rib-vH BSA however, this data suggest that other 
AGE compounds can also trigger ROS production in macrophages.         
ROS production upregulates several ROS responsive genes one such gene is the Hypoxia 
inducing factor (HIF-α).  HIF-α is undetectable or present at very low levels under normal 
oxygen supply however, in the inflammatory response under normoxic conditions HIF-α is 
upregulated by reactive oxygen and reactive nitrogen species (ROS and RNS)415-418. Rib-vH 
BSA also induced a significant upregulation of the Hypoxia inducing factor-alpha (HIF-α) and 
the upregulation increased in a time dependent manner. Upregulation of HIF-α is crucial for 
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differentiation, survival and functionality of immune cells, and HIF-1α seems to be a potent 
cellular survival factor 419 and Rib-vH BSA plays an important role in survival of macrophages.   
 
 
 
 
 
 
 
 
 
Figure 4.12. ROS production in RAW 264.7 cells after 24 hrs of AGE compound treatment.  
(Representation of two independent experiments, n=6, ***P<0.0005, *P<0.01, N.S.: not 
significant). 
 
 
 
 
 
 
 
Figure 4.13. 500uM N-acetyl cysteine (NAC) quenched the Rib-vH BSA induced oxidative 
stress.  
(Representation of two independent experiments, n=6). 
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AGE induced NF-κB activation 
Following the ROS production, the NF-κB signaling is one of the most important 
pathways described to be activated. NF-κB is a nuclear transcription factor and its activation in 
the macrophages mainly leads to the expression of several genes involved in inflammation420. 
Several reports emphasize the role of AGE-RAGE interaction and NF-κB activation in-vitro 
which is mediated via the oxidative stress generated in cell types such as endothelial cells, 
vascular cells and pulmonary smooth muscle cells 32, 271, 421. The role of AGE compounds and 
NF-κB activation has been described in different disease states such diabetes 280 and also in age 
related macular degeneration 279. AGE induced ROS production and NF-κB activation has been 
suggested in the macrophages however, the role of AGE induced ROS production in NF-κB 
activation in macrophages has not been described.  We study the AGE induced NF-κB activation 
in the commercially engineered cell line called RAW-blue ™ (InvivoGen).  RAW blue cells are 
engineered RAW cells with chromosomal integration of secreted alkaline phosphatase (SEAP) 
reporter construct which is inducible by NF-κB. The cells were treated with 1mg/mL AGE 
compound for 24 hours. A significant increase (P<0.0005) was observed the NF-kB activity 
when the cells were treated with the Rib-vH BSA, MG-H BSA, Glc-vH BSA, But-H BSA and 
Gly-H BSA. Increase in the NF-κB activity was also observed with the Ace-H BSA and Gal-H 
BSA (P<0.001).  No increase was observed when the cells were treated with H-CML BSA 
(Figure 4.14).  The Rib-vH BSA showed the most pronounced activity. In order to confirm the 
role of ROS in NF-κB activity we used N-acetyl cysteine to quench the Rib-vH BSA induced 
ROS. On the addition of N-acetyl cysteine the Rib-vH BSA induced NF-κB activity disappeared 
(Figure 4.15).  This confirms the role of Rib-vH BSA induced ROS in the NF-κB activation in 
macrophages.        
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Figure 4.14. AGE induced NFκB activation after 24 hrs of treatment.  
(Representation of two independent experiments, n=6 in each experiment, 
***P<0.0005,*P<0.001, N.S.: Not significant). 
 
 
 
 
 
 
 
 
Figure 4.15. 500uM N-acetyl cysteine (NAC) inhibited the Rib-vH BSA induced NFκB 
activation.  
(Representation of two independent experiments, n=6 for each experiment, ***P<0.0005). 
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Inflammatory cytokines 
The activation of NF-κB leads to the activation of several pro-inflammatory cytokines 
such as IL-1β, IL-6 and TNF-α 420. A huge body of literature also suggests that activated 
macrophages can also secrete several other cytokines and inflammatory factors such as MCP-1, 
MIP-2, GMCSF-1. We select a panel of cytokines and inflammatory mediators (Table 4.4) and 
their Rib-vH BSA induced expression was followed at different time points by real time 
quantitative PCR. 
Table 4.4. Inflammatory cytokine and mediator genes used in the study to determine the effect of 
Rib-vH BSA treatment.   
Gene Function Primers 
5’3’ 
Basal 
expression 
levels 
(Ct) 
IL-1β 
(NM_000576) 
Interleukin-1β 
Forward: 
GAAATGCCACCTTTTGACAGTG 
Reverse: 
TGGATGCTCTCATCAGGACAG 
28.38±0.82 
IL-6 
(NM_031168) 
Interleukin-6 
Forward: 
AGTCCGGAGAGGAGACTTCA 
Reverse: 
TTGCCATTGCACAACTCTTT 
32.02±1.51 
TNF-α 
(NM_013693) 
Tumor necrosis 
factor-alpha 
Forward: 
CAGACCCTCACACTCAGATCA 
Reverse: 
TTGTCTTTGAGATCCATGCC 
24.62±1.48 
MCP-1 
(BC145869) 
Monocyte 
chemoattractant 
protein-1 
Forward: 
GCTCTCTCTTCCTCCACCAC 
Reverse: 
CAGCCTACTCATTGGGATCA 
29.74±0.28 
MIP-2 
(BC119511) 
Macrophage 
inflammatory 
protein-2 
Forward: 
CTGTCCCTCAACGGAAGAAC 
Reverse: 
TAACAACATCTGGGCAATGG 
26.06±0.26 
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Table 4.4. Inflammatory cytokine and mediator genes used in the study to determine the effect of 
Rib-vH BSA treatment (continued).   
Gene Function Primers 
5’3’ 
Basal 
expression 
levels 
(Ct) 
GM-CSF 
(X03019) 
Granulocyte 
macrophage 
colony-
stimulating 
factor 
Forward: 
GAAGCATGTAGAGGCCATCA 
Reverse:  
TTGAGTTTGGTGAAATTGCC 
28.66±1.41 
CSF-2α 
(NM_009970) 
GM-CSF 
receptor-alpha 
Forward: 
CTGCTCTTCTCCACGCTACTG 
Reverse: 
GAGACTCGCCGGTGTATCC 
33.04±0.23 
MKI-67 
(BC053453) 
Ki-67; Marker 
of proliferation 
Forward: 
TTCCAAACATCAGGCCATAA 
Reverse: 
CGTGAACTTTCCTCAGACCA 
24.87±1.48 
Rib-vH BSA induced pro-inflammatory gene upregulation is shown in Figure 4.16. Our 
PCR data suggests a significant increase in the expression of pro-inflammatory genes such as IL-
1β, IL-6 and TNF-α. IL-1β is a pro-inflammatory cytokine which is a part of the IL-1 family of 
cytokines. IL-1β expression has been reported to be induced by NFκB in macrophages after their 
exposure with DAMPS 422.  We observe an upregulation of IL-1β of 6.32±0.7 ct units when 
compared to the control. The upregulation of IL-1β increased over time and peaked at 6 hrs, the 
upregulation was constant at 12 hrs and then a slight decrease in the upregulation was observed 
at 24hrs (Figure 4.17). The secreted IL-1β has been described to be involved in a wide range of 
immune responses, the ability of IL-1β in the upregulation of COX-2 and iNOS which account 
for increased prostaglandin-E2 and nitric oxide (NO) production has been described 423. The 
ability of IL-1β to increase the expression of cell adhesion molecules on mesenchymal cells and 
endothelial cells has also been described 424. These properties lead to the infiltration of 
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inflammatory and immunocompetent cells from the circulation into the extravascular space and 
then into tissues where tissue remodeling is the end result of chronic IL-1-induced 
inflammation425. The production of IL-1β has also been implicated to upregulate the production 
of certain other cytokines such as IL-6 426. The qRT-PCR data indicates a huge upregulation of 
IL-6 (8.61±0.11 ct units).  The IL-6 upregulation was also observed to be time dependent (Figure 
4.18) and the upregulation peaked around 6 hours and the expression was constant till about 24 
hrs. IL-6 has been reported to have important role in both innate and adaptive immunity427. It 
also plays a very important role in attracting monocytes, IL-6 trans-signaling has been shown to 
promote macrophage differentiation from monocytes by upregulating GM-CSF receptor 
expression428.  On Rib-vH BSA treatment the upregulation of TNF-α was also observed. The 
expression levels of TNF-α gene was upregulated after 30 min of treatment and the expression 
levels remained same till 24 hours (Figure 4.19). TNF-α plays vital roles in macrophage 
activation and leads to NFκB activation through autocrine signaling 429. TNF-α is also termed as 
the master cytokine regulator and plays a very important role in orchestrating the production of 
pro-inflammatory cytokine cascade430. The role of TNF-α in macrophage survival and 
proliferation has also been described 431. These results emphasize the role of AGE compounds in 
pro-inflammatory cytokine release.  The expression of pro-inflammatory cytokines such as IL-
1β, IL-6 and TNF-α induces the upregulation of chemokines such as macrophage inflammatory 
proteins (MIP) and macrophage chemoattractant protein (MCP) 432. We determine the 
upregulation of MIP- 2α and MCP-1. Rib-vH BSA also induced a significant upregulation of the 
MIP-2α and MCP-1(Figure 4.16). MIP-2α, MCP-1 and other chemokines play an important role 
in guiding immune cell traffic such as neutrophils and hematopoietic stem cells to site of 
inflammation 433, 434.  
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The granulocyte monocyte-colony stimulating factor (GM-CSF) is a haemopoietic 
growth factor which is identified to production and differentiation of haemopoietic cells from 
precursors435. In macrophages it is responsible for macrophage polarization into “M1-like” 
inflammatory macrophages in combination with other inflammatory stimuli 436. GM-CSF binds 
to the GM-CSF receptor (CSF2R) which is a heterodimer, composed of a specific ligand-binding 
α-chain (CSF2Rα), which binds GM-CSF with low affinity and a signal-transducing β-chain 
(CSF2Rβ) 437, 438. The binding of GM-CSF to CSF2Rα triggers pro-inflammatory signaling in 
macrophages.  AGE induced upregulation of the GM-CSF and CSF2Rα was determined using 
the q RT-PCR. Rib-vH BSA treatment induced upregulation of GM-CSF by 2.59±0.5 ct units 
and CSF2Rα by 8.46±0.5 ct units. Finally, we determine the AGE upregulation of marker of 
proliferation Ki-67 (MKI67).  Rib-vH BSA treatment induced an upregulation of MKI67 
4.47±0.1 ct units. This suggests the mitogenic ability of the Rib-vH BSA.   Taken together our q 
RT-PCR data suggests the Rib-vH BSA activates pro-inflammatory signaling. 
 
 
 
 
 
 
 
 
 
Figure 4.16. Pro-inflammatory gene upregulation on 24 hrs of Rib-vH BSA treatment.   
Ribosomal protein L4 (RPL4) was used as the house keeping gene and the ΔΔct values are 
calculated with respect to the gene expression at time 0. (Representation of two independent 
experiments). 
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Figure 4.17. Time course of Rib-vH BSA induced IL-1β upregulation.  
Ribosomal protein L4 (RPL4) was used as the house keeping gene and the ΔΔct values are 
calculated with respect to the gene expression at time 0. (Representation of two independent 
experiments). 
 
 
 
 
 
 
 
 
 
Figure 4.18. Time course of Rib-vH BSA induced IL-6 upregulation. 
Ribosomal protein L4 (RPL4) was used as the house keeping gene and the ΔΔct values are 
calculated with respect to the gene expression at time 0. (Representation of two independent 
experiments). 
 170 
 
 
 
 
 
 
 
 
 
Figure 4.19. Time course of Rib-vH BSA induced TNF-α upregulation. 
Ribosomal protein L4 (RPL4) was used as the house keeping gene and the ΔΔct values are 
calculated with respect to the gene expression at time 0. (Representation of two independent 
experiments). 
Rib-vH BSA induced macrophage proliferation  
Classically, the concept that monocyte recruitment dictates macrophage buildup is well 
accepted. However, recent studies also reveal that macrophage accumulation does not depend on 
monocyte recruitment in some inflammatory contexts and involves the proliferation of 
macrophages. The proliferation of macrophages has been described in disease states such as 
atherosclerosis 439-441 and in certain inflammatory conditions involving the TH2 cells 
442. The 
mitogenic effect of Rib-vH BSA on macrophages was determined using the redox active dye, 
Resazurin. On Rib-vH BSA after 24 hours we observe a 1.46±0.06 fold increase in the rate of 
proliferation (Figure 4.20). Figure 4.21 shows the dose response curve of the Rib-vH BSA 
induced proliferation. To emphasize the role of RAGE signaling, we use 25ug/mL of anti-RAGE 
antibody (2A11) or 1 µM of a small molecule inhibitor of RAGE (FPS-ZM1) to inhibit the AGE-
RAGE interaction and no difference was observed in the Rib-vH BSA induced macrophage 
proliferation. This suggests a RAGE independent pathway of the Rib-vH BSA in macrophages.  
 171 
 
 
 
 
 
 
 
 
 
Figure 4.20. Rib-vH BSA induced macrophage proliferation is RAGE independent.  
(Representation of two independent experiments, n=6 for each experiment). 
 
 
 
 
 
 
 
 
 
 
Figure 4.21. Dose response curve of Rib-vH BSA induced macrophage proliferation.  
(Representation of two independent experiments, n=6 for each experiment). 
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Role of TLR signaling in Rib-vH BSA mediated cellular effects  
The Rib-vH BSA induced activation of macrophages and proinflammatory-cytokine 
release observed is typical to TLR signaling in macrophages when activated by DAMPS. A clear 
role of RAGE, galectin-3 or the scavenger receptor SR-A could not be established. The 
macrophages express several pattern recognition receptors such as the toll like receptors (TLRs) 
and we hypothesize that the TLRs play an important role in AGE induced macrophage activation 
and cytokine release.  The upregulation of TLR2, 4, 6 and 9 genes was determined after 24 hours 
of Rib-vH BSA treatment. We observe the most significant upregulation in the expression of 
TLR4, 5.8±0.45 ct units (Figure 4.23). The upregulation of TLR2, TLR6 and TLR9 was also 
observed.  The role of TLR signaling on the AGE induced inflammation in macrophages was 
further elucidated by siRNA knockdown of myeloid differentiation primary response 88 
(MyD88).  MyD88 is an adaptor protein which is necessary for the activation of TLR 
signaling443. Evidence from the literature suggests of a MyD88 dependent signaling which is 
common to all TLRs a MyD88-independent pathway that is peculiar to the TLR3- and TLR4 
signaling pathways444. MyD88 was knocked down using the MyD88 siRNA and the knockdown 
was confirmed by western blotting  using the MyD88 antibody (sc-11356 ) and a knockdown of 
82.24±2.9% was achieved (Figure 4.22). After 24 hours of knockdown the cells were treated 
Rib-vH BSA and the q-RT PCR was performed after 24 hours of the treatment. Firstly, our RT-
PCR data also confirms the knockdown of MyD88 we observe a 27.8±1.74 fold (4.8±0.8 ct 
units) knockdown of MyD88. Interestingly; we also observe the knockdown of TIRAP which is 
another important adaptor molecule which plays an important role in TLR-mediated MyD88-
dependent signaling.  The expression of 12 pro-inflammatory genes which were upregulated 
previously on Rib-vH BSA treatment was determined. As shown in the Figure 4.23, we observe 
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partial down regulation of the upregulated pro-inflammatory cytokines such as IL-1β and a 
complete down regulation of TNF-α were observed. The down regulation of IL-6 and COX-2 
was not significant. Down regulation was also observed in the expression of iNOS and CSF-2a 
genes. These observations are very interesting and are different from the MyD88 knockdown 
studies by Björkbacka et al., 445 where the authors use LPS for stimulation. On LPS stimulation 
in MyD88 knockdown mice bone marrow macrophages the expression of IL- β, IL-6 and COX-2 
completely disappeared and the expression of TNF-α did not completely subside 445. These 
results suggest a role for the TLRs in the observed Rib-vH BSA induced inflammation. 
However, we do not observe any significant down regulation of MIP-2 and MCP-1 genes on 
MyD88 knock down. This suggests a MyD88 independent pathway for the upregulation of MIP-
2 and MCP-1 genes. The MyD88 independent upregulation of MIP-2 and MCP-1 has been 
reported in the literature using LPS stimulation in bone marrow macrophages 445.  Taken 
together, these results suggest the role of TLRs in Rib-vH BSA induced inflammation; however, 
this needs further investigation. We suspect TLRs in conjunction with other AGE receptors could 
play a major role in AGE compound induced macrophage activation and inflammation. Figure 
4.24 summarizes TLR dependent AGE signaling. 
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Figure 4.22. siRNA mediated knockdown of MyD88 in RAW 264.7 cells.  
(Representation of two independent experiments). 
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Figure 4.23. Effect of MyD88 knockdown on pro-inflammatory genes upregulation.  
Ribosomal protein L4 (RPL4) was used as the house keeping gene and the ΔΔct values are 
calculated with respect to the gene expression at time 0. (Representation of two independent 
experiments, *P<0.01, N.S.: Not significant). 
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Figure 4.24. TLR dependent AGE signaling in RAW 264.7 cells.  
AGE dependent TLR signaling was determined by MyD88 knockdown. On knockdown the 
expression of TNF-α and CSF2a completely decreased (red).  A decrease was also observed in 
the expression of COX-2, iNOS and IL-1b. No decrease was observed in the expression of MIP2, 
MCP1 and IL-6 suggesting a TLR independent pathway.   
Endotoxin contamination of AGE compounds 
Endotoxins interfere with the signaling as they are recognized by pattern recognition 
receptors and can trigger inflammation. The level of endotoxins in the AGE compounds was 
determined using the Pierce LAL Chromogenic Endotoxin Quantitation Kit (Life Technologies 
®). We observe a significant contamination of the AGE compounds with endotoxins. The Rib-
vH BSA has an endotoxin content of around 709.08±16.3 EU/mg and the endotoxin content of 
unmodified BSA was 719±52.4 EU/mg (Figure 4.25). This means that the endotoxin 
contamination of the Rib-vH BSA comes from the BSA used for glycation.     
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Figure 4.25. Endotoxin content in the unmodified BSA and Rib-vH BSA.  
(Representation of two independent experiments). 
The endotoxin was removed by phase separation using nonionic polyoxyethylene 
surfactant Triton X-114. On treatment with Triton X-114 Rib-vH BSA was >98% endotoxin free 
after two steps of purification.  However, when the RAW 264.7 cells were treated with 1mg/mL 
of detoxified Rib-vH BSA the mitogenic affects disappeared (Figure 4.27, represented as Rib-vH 
BSA E.F). This result is in agreement with a previously reported paper, where the detoxification 
of glycolaldehyde modified β-lactoglobulin with Triton X-114 led to the loss of activity in 
human lung epithelial cell line, Beas2b446. The authors concluded that the glycolaldehyde 
modified β-lactoglobulin is benign and the cellular effects are due to the LPS.  We wanted to get 
a better insight into the loss of activity of the Rib-vH BSA detoxified with Triton X-114 and 
confirm if the possible endotoxin contamination is what  which leads to the cellular activity or if 
the Triton X-114 modified the protein structure which led to the loss of activity. Dynamic light 
scattering experiments were performed to determine the particle size distribution of the Rib-vH 
BSA.  The hydrodynamic radius of Rib-vH BSA is 8.72±0.10 with a polydispersity index of 
0.31±0.008 and on treatment with Triton X-114 the hydrodynamic radius increased two fold to 
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17.6±0.52 with a polydispersity index of 0.27±0.003. The size versus percentage intensity plots 
reveal that Rib-vH BSA has two peaks and whereas on treatment with the Triton X-114 only one 
peak was observed (Figure 4.26).  This suggests that Triton X-114 treatment induced a 
biophysical change in the protein. We suspect this could be the reason for the loss of activity. In 
order to obtain further insights, Rib-vH BSA was detoxified by chromatographic methods. We 
use the Detoxi-Gel endotoxin removing columns ™ (Thermo- Scientific) which uses Polymixin 
B ligand immobilized on beaded affinity resin to bind and extract endotoxins from antibody or 
protein samples as this is milder method when compared to the Triton X-114 extraction.  When 
the Rib-vH BSA was passed through the column the entire colored i.e. glycated fraction of the 
AGE compound bound to the column and we could not elute this fraction even under extremely 
basic conditions. This also led to a considerable loss of the protein. We could not determine the 
reason why the AGE compound could not be eluted out of the column.    
 
 
 
 
 
 
 
 
Figure 4.26. Effect of Triton X-114 on the particle size of Rib-vH BSA.  
Blue: Rib-vH BSA and Red: Rib-vH BSA treated with Triton X-114 (Representation of 10 
independent experiments). 
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In order to further address the role of possible endotoxin contamination in AGE-induced 
cellular effects. We performed the proliferation assay by treating the cells with equal amounts of 
LPS (72 ng) and no effect was observed with LPS alone. We also pre-mixed 1mg/mL detoxified 
Rib-vH BSA (Rib-vH BSA E.F.) with LPS (72 ng) and the cell were treated with this material 
for 24 hours. No increase in cellular proliferation was observed.  And finally, we treated the Rib-
vH BSA for 5 minutes at 100 °C before adding to RAW 264.7 cells as described earlier447. As 
shown in Figure 4.23, heated Rib-vH BSA also failed to induce any proliferation suggesting that 
the endotoxin contamination does not play a role in the mitogenic effect of Rib-vH BSA.  And 
all the experiments were performed with BSA as the control to rule out any possible effect from 
the endotoxin. The MyD88 knockdown also suggests that pro-inflammatory effect of Rib-vH 
BSA is independent of the endotoxin contamination.  
 
 
 
 
 
 
 
 
 
Figure 4.27. Rib-vH BSA induced macrophage cell proliferation is LPS independent.  
(Representation of two independent experiments, n=6 for each experiment). 
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Conclusions 
The goal of this study was understand the uptake and internalization of AGE compounds 
and their role in pro-inflammatory cytokine release and macrophage proliferation. Based on our 
previous studies we used Rib-vH BSA as a model for diabetic AGE compounds to study the 
effects of AGE compounds in a murine macrophage cell line RAW 264.7.  
A rapid uptake of the Rib-vH BSA was observed by the fluorescence based uptake assay 
and the Rib-vH BSA internalized into the lysosomes after an hour of incubation.  We tested the 
role of AGE receptors RAGE, galectin-3 and SR-A in AGE uptake however, the receptor 
responsible for Rib-vH BSA uptake could not be established by knockdown studies such as the 
SR-A knockdown or by using specific receptor inhibitors to inhibit the binding of AGE to RAGE 
and galectin-3 and requires further investigation. The internalization of Rib-vH BSA led to an 
upregulation of genes associated with increased oxidative stress such as the NADPH oxidase 2 
and hypoxia inducing factor-α and also led to the increased ROS production. The oxidative stress 
triggered NFκB activity in the RAW 264.7 cells.  The Rib-vH BSA treatment also triggered the 
upregulation of pro-inflammatory cytokines such as IL-1β, IL-6 and TNF-α mRNA. The 
upregulation of inflammatory genes such as MIP-2, MCP-1, COX-2, CSF2R and iNOS was also 
observed indicating that the Rib-vH BSA internalization led to the activation of the macrophages 
and polarized them into “M1-like” inflammatory macrophages.  
The Rib-vH BSA also had a mitogenic effect on the macrophages, a 1.46±0.06 fold 
increase in the macrophage proliferation was observed on Rib-vH BSA treatment after 24 hours. 
Upregulation of the proliferation marker KI67 was also observed.  
The upregulation of several cell surface receptors such as AGE receptor complex, class A 
scavenging receptors and TLRs was observed on Rib-vH BSA treatment. The role of RAGE 
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could not be established in the Rib-vH BSA induced cellular effects in macrophages.  Our q RT-
PCR data suggest a role of the TLRs in Rib-vH BSA induced effects. Figure 4.28 summarizes 
the AGE compound signaling in RAW 264.7 cells. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.28. AGE dependent signaling in RAW 264.7 cells.  
AGE compounds interact with AGE signaling receptors such as RAGE and AGE-receptor 
complex to trigger ROS formation which can in-turn trigger NF-κB activation. NF-κB is 
translocated into the nucleus where it binds to specific DNA sequence to trigger the upregulation 
of various pro-inflammatory cytokines. The upregulation of NOX2 has also been observed on 
AGE activation (dashed arrow) which can trigger ROS formation in the intra cellular space. 
RAGE activation also upregulates the iNOS expression leading the generation of nitric oxide.  
AGE compounds are cleared by the AGE clearance receptors such as the scavenging receptors. 
AGE compounds are internalized and degraded by the endosomes and lysosomes respectively.       
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Endotoxin contamination of the AGE compounds was observed and the endotoxin 
removal by Triton X-114 modified the biophysical properties of the protein which led to the loss 
of activity and the endotoxin could not by purified using the polymyxin-B column. Several 
control experiments were performed with LPS which suggest that the Rib-vH BSA induced 
effects observed are independent of the endotoxin contamination. 
In summary, these results provide us a better understanding on the AGE compound 
uptake and macrophage activation. Our findings should accelerate our understanding of the 
biological role of AGE compounds in the pathogenesis of diabetic complications. 
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CHAPTER 5: THE ROLE OF TRYPTOPHAN RESIDUES OF RAGE FOR V-DOMAIN 
STABILITY AND S100B BINDING 
Introduction 
RAGE, RAGE-ligand interaction and disease 
The receptor for advanced glycation end products (RAGE) is an immunoglobulin type 
cell surface receptor sensing damage associated molecular patterns (DAMPs) in stressed and 
damaged tissues 21, 22. As described earlier, the ligands of RAGE are structurally diverse and 
include advanced glycation end products (AGE), for which the receptor is named, members of 
the S100 protein family, high mobility group box protein (HMGB1), nucleic acids, 
phospholipids, negatively charged polysaccharides, as well as amyloid peptides 1-3, 15, 16 17-20. A 
significant body of cell biological and preclinical animal studies have identified RAGE 
activation as an important contributing factor to diabetic vascular complications 52, 53, 
neurodegeneration 50, 51, chronic inflammatory diseases 46, 47 and certain cancers 54. Animal 
studies provide strong support for the hypothesis that RAGE inhibition could be beneficial to the 
treatment of these diseases (Described in detail in Chapter 1).  
Despite the recognition of RAGE as a disease relevant receptor protein and as a potential 
pharmacological target, fundamental mechanistic questions regarding ligand recognition and 
induction of ligand specific signaling by RAGE remain unanswered. In particular, it remains 
unknown how RAGE can on the one side recognize structurally unrelated ligands, such as S100 
proteins, AGE compounds and amyloid beta peptide, and on the other side demonstrate exquisite 
ligand specificity. RAGE cannot only distinguish between individual members of the S100 
protein family 448, but also activate distinct cellular signaling pathways as a function of ligand 
concentration. 
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The extracellular portion of RAGE consists of three Ig-like domains, a single pass 
transmembrane helix and a C-terminal intracellular tail 1-3 . The majority of RAGE ligands have 
been shown to interact with the V-domain, but some appear to also be able to bind to the C1 and 
C2 domains. The mechanism(s) by which ligand binding leads to intracellular signaling via 
RAGE are generally believed to involve the multimerization of the receptor, followed by 
rearrangement of the C-terminal tail and subsequent exchange or recruitment of intracellular 
signaling proteins 449.  
The observation that most RAGE ligands bind to the V-domain raises the question if 
structural adaptation by either the RAGE V-domain or the bound ligand facilitates RAGE: ligand 
complex formation.  
S100 proteins and RAGE 
The S100 protein type RAGE ligands are small, single domain, calcium-binding proteins 
that form conformationally rigid homo- and hetero-dimers 198.  The calcium concentration in the 
extracellular milieu is sufficiently high to saturate the calcium-binding sites of S100B, thus 
locking the protein into a stable conformation.  Higher order oligomers (tetramers 450, hexamers 
451 and octamers 452 can also be formed by the calcium-loaded forms of S100 proteins. Binding 
of zinc, copper and manganese to additional metal binding site in some S100 proteins may allow 
additional conformations 198, 453, 454.  
In contrast to the stable folding of the S100 proteins, the V-domain of RAGE is less 
stable and displays more structural flexibility. This is reflected in multiple NMR and X-ray 
structures of the V-domain, that show significant differences on local secondary structure, 
domain organization and loop arrangements 197, 455, 456. 
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It has also been pointed out that many RAGE ligands, including the S100 protein ligands, 
are negatively charged, while the VC1-domain of RAGE contains a positively charged surface 
449. Thus, electrostatic interactions have been suggested as a major driving force for RAGE-
ligand interactions449. However, simple charge complementarity may be not sufficient to explain 
the low micromolar binding affinity of different S100 proteins to the RAGE V-domain and 
suggests that structural changes within the V-domain facilitate multi-modal S100 protein binding 
to RAGE. 
 These observations suggest that structural changes in the V-domain are enabling the 
multi-ligand binding properties of RAGE. Understanding those structural changes in the RAGE 
V-domain should be useful for understanding mechanistic aspects of RAGE biology, as well for 
the development of ligand specific RAGE inhibitors.  
Tryptophan residues and RAGE 
Tryptophan (Trp) is the largest of the naturally occurring amino acids, which has an 
indole ring that accounts for its hydrophobicity. The high electron density of the aromatic ring 
results in the energetically favorable cation-[pi] interactions 457, 458. It can also form hydrogen 
bonds due to the dipole moment of the nitrogen atom in the indole ring 459. Trp is fluorescent 
with high a quantum yield and more importantly its fluorescence properties like emission, 
quantum yield and quenching depends on its position in the protein and its surrounding 
environment, which makes it a good probe of the protein conformation 460, 461. The 
environmental sensitivity of Trp fluorescence intensity is due to non-radioactive processes like 
inter system crossing, solvent quenching, excited-state proton transfer and excited-state electron 
transfer, which compete with emission for deactivation of excited state 460 . Lastly, it has also 
been reported that the Trp residues are enriched in the binding hotspots of protein interfaces than 
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any other amino acid indicating that Trp plays an important role in the stability of protein 
complexes 462. Trp is the least abundant amino acid in proteins 463. However, the V-domain 
contains three Trp residues and these residues occur within a stretch of 21 amino acids (Trp51, 
Trp61 and Trp72). These residues could function as hydrophobic anchor residues for the binding 
of S100B and other S100 proteins.  
We hypothesized that the Trp residues in the V domain of RAGE are necessary of 
domain stability and S100B binding. 
To investigate these possibilities, we have generated three single, three double and one 
triple TrpAla mutant of the RAGE V-domain and characterized folding and stability of the 
recombinant domains. Our spectroscopic studies identify the relative location of each Trp 
residues within the V-domain and V-domain: S100B complex and its contribution to V-domain 
folding and stability. To gain further insights at the atomic level in the RAGE:S100B interaction, 
we solved the crystal structures of S100B in complex with peptide Trp61464 and in complex with 
Trp72, which were derived from the RAGE V-domain and contain Trp61 and Trp72 respectively 
as a central residue.  
Materials and Methods 
The crystallization of the S100B and the Trp containing RAGE peptides and their 
structure solutions were performed by Jaime Jensen and Dr. Christopher Colbert. 
Protein mutagenesis, expression and purification 
 The V-domain of RAGE (residues 23 – 132) was cloned into the pET15b expression 
vector using the NcoI and XhoI restriction sites. Site-specific mutation of tryptophan to alanine 
was achieved using the quick change site specific mutagenesis kit (Stratagene, La Jolla). The 
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plasmids’ regions encoding the RAGE domain genes were sequenced to confirm correct 
mutagenesis and sequence integrity. 
Proteins were expressed in the disulfide isomerase (DsbC) expressing E.coli strain 
Shuffle T7 Express (New England Biolabs) in LB medium. The plasmid (1 µL) was inserted into 
electro-competent Shuffle T7 Express cells (100 µL) by electroporation at 1600 V. The cells 
were expanded in Luria-Bertani (L.B.) media containing the selection antibiotic ampicillin. 
The cells were grown in 400 mL media in 2 L culture flasks at 37 °C with continuous shaking at 
220 rpm. The cells were induced with 100mM IPTG after they have reached an OD600 of 0.6. 
After induction the temperature was reduced to 30 °C, the cells were grown for 4 hours and 
harvested by centrifugation at 4000rpm. The cells from 4 liter culture were suspended in a buffer 
containing 50mM Tris, 20mM Imidazole, 300mM NaCl, pH-8.0 and frozen at -20 °C.       
For purification, the cells expressing V domain were thawed on ice and sonicated with a 
power of 15 (Misonix XL-2000). The cell debris was separated by centrifugation at 16000 RCF 
at 4 °C and the supernatant was collected. The protein was purified from the supernatant by a 
two-step process. First, using a pre-packed 1mL HisTrap HP column (GE  Lifesciences) the His-
tagged RAGE VC1 was purified. The bound RAGE-VC1 was eluted using 50mM Tris, 200mM 
Imidazole, 300mM NaCl, pH-8.0. Protein elution was detected by 280 nm UV absorbance at 1 
second intervals. The eluted protein was collected and diluted (1:1) using 10mM Na-acetate 
buffer, pH 5.5. We then used the pre packed HiTrap SP FF column (GE Lifesciences) which 
contains the cation sulfopropyl to separate out the DNA bound to the protein.  The bound protein 
was eluted from the column using a linear gradient of NaCl from 0 M to 1 M in the 10 mM Na-
acatate buffer, pH 5.5. The eluted protein was collected, concentrated by ultra-filtration using 
regenerated cellulose 3 KDa MWCO membrane (Millipore), aliquoted and stored at -80 °C. The 
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purity of the protein was estimated by sodium dodecyl sulfate polyacrylamide gel electrophoresis 
(SDS-PAGE).  
Recombinant human S100B was expressed in the plasmid pGEMEX and was purified as 
described by Smith et al. 465.  Briefly, S100B was expressed in the BL-21 E. Coli cells and were 
grown at 37 °C overnight.  The cells were harvested as described above and resuspended in 50 
mM Tris, 5 mM MgCl2, pH 8.0 and frozen. The cells were sonicated on ice and centrifuged at 
10,000 g to remove the cell debris. Ammonium sulfate was added to a final saturation of 90% 
and the pH was adjusted to 8 and was stirred on ice for 30 min. The sample was then centrifuged 
at 10,000 g. The supernatant was collected and the pH was reduced to 4 with 10% H3PO4. The 
sample was then centrifuged at 10000 g and the pellet was collected and dissolved in 50mM Tris 
1 mM EDTA and again centrifuged at 10,000 g to remove any insoluble materials.  The sample 
was then dialyzed against 25 mM Tris, 1 mM EDTA and 5 mM BME. pH 7.6. The sample was 
then loaded on a Q-Sepharose column and eluted with a linear gradient of buffer B containing 
1M NaCl. The fraction which contain protein was pooled and then loaded on the phenyl 
Sepharose column. S100B was eluted with a step gradient of buffer B containing 50 mM Tris 2 
mM EDTA, pH 7.7.      
Peptide synthesis 
(Peptides were synthesized by Kevin P. Cunningham and titration experiments were 
performed by Timothy Logue at Florida Atlantic University University) 
 Peptides (Table 5.1) were synthesized using standard solid phase peptide synthesis with 
Fmoc-protection and HBTU/HOBt activation chemistry. The dansyl fluorophore was coupled to 
a C-terminal gamma-amino butyric acid (Abu) spacer by reaction with dansyl-chloride in 
dichloromethane / methanol and triethylamine as base. Peptide were cleaved off the resin and 
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side chains deprotected with 95% trifluoroacetic acid, 2.5% triisopropyl silane and 2.5% water. 
The crude peptides were further purified by preparative HPLC to single peak purity on an 
analytical HPLC column. MALDI-TOF mass spectrometry was used to confirm the expected 
molecular of the peptides.  
Table 5.1. RAGE peptides in the study. 
Peptide Sequence 
51 Trp KPPQRLEWKLNTGRT 
61 Trp NTGRTEAWKVLSPQG 
72 Trp SPQGGGPWDSVARVL 
51 Ala KPPQRLEAKLNTGRT 
61 Ala NTGRTEAAKVLSPQG 
72 Ala SPQGGGPADSVARVL 
Steady state fluorescence measurements 
Steady state excitation and emission spectra were recorded on a FluoroMax® (Horiba 
Jvon Yvon) spectrofluorometer using quartz cuvettes of either 5 mm or 10 mm path length. 
Tryptophan was excited at 295 nm to eliminate the tyrosine excitation. Three scans were 
recorded and averaged.  
Fluorescence life-time measurements 
 Time resolved tryptophan fluorescence lifetime measurements of the V domain of 
RAGE and its mutants were determined using the photon counting fluorohub® (Horiba Jobin 
Yvon) connected to Fluoromax®. The samples were excited at 280nm with a nano LED. The 
emission was recorded at 350 nm and 375 nm to reduce the tyrosine influence.  Peak saturation 
was set to 1000 counts and 4 nm slit width was used for the measurements. For fluorescence 
decay experiments 1µM of the protein was used in a quartz cuvette with reduced path length of 5 
nm to record the tryptophan lifetime.  The effect of S100B binding on fluorescence lifetimes of 
the mutants was also studied. S100B was mixed with V domains in the presence of 2 mM 
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calcium and the lifetimes were measured after an equilibration period of 2 min. To study the 
affect the Guanidinium chloride (GudCl) unfolding on the decay times, the protein samples were 
unfolded with 5 M GudCl overnight and the lifetimes of the samples were measured. The 
lifetimes of the samples were analyzed by the DAS6 software (Horiba Jvon Yvon).  A two 
exponential model was used to determine the lifetimes of the WT, single mutants and double 
mutants. 
Fluorescence quenching 
Acrylamide quenching of tryptophan fluorescence measurements were performed with a 
protein concentration of 1 µM and increasing acrylamide concentrations up to 0.25 M. A quartz 
cuvette with 5mm path length was used.  A correction factor of ε295=0.25 M-1cm-1 was applied to 
account for the inner filter effect of acrylamide 466. The samples were excited at 295nm and the 
emission spectra were recorded.   
Fluorescence based S100B: V-domain binding measurements 
S100B was labelled with fluorescein isothiocyanate (FITC) and the binding affinity 
between S100B and the wild type and all the mutants of the RAGE V-domain was determined by 
measuring the change in fluorescence polarization as a function of V-domain concentration. The 
V-domain was titrated into a solution of fluorescein-labeled S100B (1 mM) in 30mM Tris pH 
7.1, 300 mM NaCl, 2 mM CaCl2 and fluorescence polarization was calculated with an excitation 
wavelength of 494nm and an emission wavelength of 518 nm. Titrations were repeated  in 
triplicates and the best fit for the titration curves was obtained using a 1:1 RAGE:S100B 
stoichiometry model as described by Andersen et al. 172 and Vetter et al. 467.  
The binding of RAGE V-domain derived peptides to S100B was measured by 
fluorescence titration using a dansyl labeled peptide, similar to as described above.  
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Secondary structure analysis by circular dichroism (CD) spectroscopy 
The role of tryptophan residues in the structural stability of the V domain was evaluated 
by CD spectroscopy. The spectra were recorded on a Jasco J815 spectropolarimeter equipped 
with a PFD-425S Peltier cell holder in a 1 mm path length cuvette. 25 µM of protein was used to 
record the spectra. The samples were scanned from 180  nm to 260 nm with a scanning rate of 10 
nm per minute and an integration time of 8 sec. CD-spectra were deconvoluted using spectral 
data ranging from 180 to 260 nm using the CONTIN algorithm in the DichroWeb software170.  
Crystallization of S100B with the W61 and W72 peptides  
(Experiment performed by Jaime Jensen) 
S100B in 25 mM Tris HCl pH 7.8, 150 mM NaCl, 4mM CaCl2 was concentrated by 
centrifugation to 50 mg/mL. For co-crystallization of S100B and W61, 2 mM S100B was 
combined with 2 mM W61 peptide and stored on ice for 30 min prior to crystallization-tray 
setup. Crystallization trials were performed via the sitting-drop vapor-diffusion method by 
mixing 0.75 µl drops of S100B–W61 peptide with 0.75 µl reservoir solution consisting of 0.1 M 
sodium cacodylate pH 6.8, 25%(w/v) PEG 3350, 9 mM CaCl2 and incubating at 20C against 500 
ml reservoir solution. Crystals were observed within one week, and were harvested and flash 
cooled in liquid nitrogen using reservoir solution plus 20 %( v/v) glycerol as a cryoprotectant 
prior to diffraction experiments. 
For S100B-W72 Lyophilized peptide W72 was resuspended in water to 8 mM, 
respectively. For co-crystallization of S100B and W72, 2 mM S100B was combined with 3 mM 
peptide and stored on ice for ~ 30 min prior to crystallization tray set-up. Crystallization trials 
were performed by the sitting drop diffusion method by mixing 0.75 μL drops of protein-peptide 
with 0.75 μL of the 500 μL reservoir. Diffracting crystals were obtained with 0.1 M cacodylate 
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pH 6.8, 22% w/v PEG 3350, 5 mM CaCl2 for W72 (3 mM) and 0.1 M cacodylate pH 6.8, 25% 
w/v PEG 3350, 9 mM CaCl2 for W61 (2 mM). Crystals were observed within 1 week at 20°C, 
and were immersed in cryo-protectant solution and flash-frozen in liquid nitrogen prior to data 
collection. The cryo-protectant solution contained reservoir solution of the respective crystals 
plus 20% v/v glycerol.  
Crystal structure determination of S100B-W61 RAGE peptide and S100B-W72 RAGE 
peptide complexes 
(Structures were solved by Jaime Jensen and Dr. Christopher Colbert)  
Diffraction data were collected under cryogenic conditions (100 K). The high-resolution 
diffraction data used for refinement were collected at a wavelength of 0.9792 Å on NE-CAT 
beamline 24-ID-C of the Advanced Photon Source (APS), Argonne, Illinois, USA. The S100B 
structures were determined using the molecular replacement method and the peptides were built 
into the electron density  
Atomic models and structure factors have been deposited in the Protein Data Bank as 
PDB entry 4XYN for S100B-W61 RAGE peptide complex and PDB entry 5D7F for S100B-
W72 RAGE peptide complex. 
Sensitivity of V-domain mutants to trypsin digestion 
The V-domains were prepared to a final concentration of 500 µg/mL in 100 mM Tris 
buffer pH-7.5. Sequencing grade, modified trypsin (Promega) was dissolved in 20 L of 
resuspension buffer provided at a concentration of 1 mg/ml and further diluted in 100 mM Tris 
buffer pH-7.5. The V-domain and the trypsin solutions were mixed 1:1 to reach a final V-
domain: trypsin ration of 50,000:1. The reaction was incubated at 37 °C and 20 L samples were 
collected at time points 0, 10, 20, 30, 45, 60, 120 and 240 minutes. Samples were immediately 
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mixed with SDS-PAGE sample buffer with β-mercaptoethanol, dipped into boiling water for 3-5 
min and then stored on ice. Samples from a single digestion experiments were separated on a 
single 18% SDS-PAGE gel and stained with Coomassie blue. The final developed gels were 
scanned and the band intensity of the non-digested material was quantified with the ImageJ 
software package 468.  
Thermofluor assay to determine protein stability 
The thermal stability of the V domain Trp mutants was determined using a fluorescent 
dye called SYPRO orange which binds to the hydrophobic regions of the protein. Briefly, the 
5000X stock solution of SYPRO orange (Sigma Aldrich #S5692) was diluted in water to obtain a 
final concentration of 100X. This 100X solution was further diluted down to 10X in phosphate 
buffered saline. 5 µM stock solutions of the V domain mutants in 1M ammonium sulfate were 
prepared. 25 µL of the V domain stock was mixed with 25 µL of the Sypro orange stock. The 
assay was carried out in the Stratagene Mx3000P ™ qPCR machine. The molecular beacon 
melting curve program was used and FRROX filter setting were selected. The first segment of 
the program was set to 25 °C for 3 minutes and in the second segment; starting at 25 °C the 
sample was heated in 1 °C increments for 30 seconds for 74 cycles. Hence, the protein sample 
was heated from 25 °C to 99 °C with a rate of 2 °C/min and the fluorescence was measured after 
30 sec.  The assay was performed as two independent experiments and a new stock of protein 
was used for each experiment. In each experiment, the sample was run 5 times.  
1M ammonium sulfate buffer was selected based on our initial screening. We used the 
HR2-110 crystal screen (Hampton Research) to screen different buffer conditions to determine 
the stability of the wild type V domain. We observed that the V domain was not stable in low salt 
containing buffers. Our data indicate two buffer conditions in which the V domain was the most 
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stable. The V domain was highly stable in 1 M ammonium sulfate and in 0.1M HEPES, pH 7.5 
containing 1.4 M sodium citrate tribasic dehydrate. We select 2M ammonium sulfate to perform 
the assay.  
Results 
 Trp residues are not required for folding of the RAGE V-domain 
The mutation of Trp to Ala replaces the large hydrophobic indole ring system of Trp with 
a single hydrogen in Ala. Depending of the position of the replaced side chain within the folded 
protein, this can create voids in the packing of protein side chains and may prevent folding of the 
polypeptide 461, 469-471. We found that all seven V-domain mutants not only expressed well in 
E.coli, but also folded spontaneously and were recovered from the soluble fraction from NEB T7 
SHuffle express cells. This engineered E.coli strain constitutively expresses the disulfide 
isomerase DsbC and supports the correct formation of a single disulfide bridge within the V-
domain between residues Cys38 and Cys99. 
Detailed characterization of the secondary structure composition of the purified V-
domain and its mutants was done by circular dichroism spectrometry (Table 1). Our analysis of 
CD-spectra of wild type V-domain showed that approximately one third (32%) of all residues are 
in beta-sheet conformation, one third (36%) of residues are unordered, 22% are in turn 
conformation and 10% in a helical conformation. These values are comparable to a previous 
report of the CD secondary structure analysis of the V-domain, in which a beta-sheet content of 
33 % and coil content of 35.2% was reported 472. The secondary structure analysis of the 
published NMR structure of the V-domain (pdb: E2E5) using the program Stride 473 resulted in 
similar values as well (37% beta-sheet, 27% turn, 28% coil, and 8% helical). Substitution of any 
one of the three Trp residues had no major effect on the secondary structure composition. We 
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found a slight increase in beta-sheet content, accompanied by a reduction of amino acids in 
helical, unordered or turn conformations. Statistical comparison between the wild-type V-domain 
and the single substitution mutants showed that these changes were statistically significant 
(p<0.05) only for alpha-helical and beta-sheet content for the Trp51Ala substitution. Similar 
trends were seen for the double mutants, which all had statistically significantly (p<0.05) 
decreased helical content, but only the W51A W61A double mutant also showed a significant 
increase in beta-sheet secondary structure (Table 5.2). The triple mutant, containing no Trp 
residues , showed the highest beta-sheet (40%) and lowest helical content (4%). 
These data show that the Trp residues are not required for folding of the V-domain to 
occur and that the absence or presence of Trp residues has only a limited effect of the overall 
secondary structure of the V-domain. 
In general, the dominant secondary structure elements of the V-domain and its TrpAla 
mutants, are beta-sheets and turns, with a minor alpha helical content and a significant number of 
residues in an unordered conformation. This is in agreement with the overall IgG fold and the 
known structure of the V-domain. The finding that the Trp residues are not required by the 
domain to adopt its fold, indicate that they are not critically involved on the folding process of 
the domain itself, nor are they required to maintain the overall fold. On the other side, about one 
third of all residues are in an unordered conformation, indicating a high degree of plasticity in 
the structure. 
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Table 5.2. Secondary structure analysis of the V domain mutants by circular dichroism.  
V-domain 
Mutant 
Helix % -Sheet % Turn % Unordered % 
WT 10.1 + 0.4 32.2 + 1.2 22.1 + 0.3 35.6 + 0.6 
W51A 6.6 + 0.4 39.8 + 0.6 21.4 + 1.7 32.2 + 1.8 
W61A 9.6 + 0.8 37.5 + 1.3 21.3 + 0.8 31.6 + 1.2 
W72A 9.3 + 0.4 38.1 + 0.3 20.1 + 0.5 32.5 + 0.4 
W51A W61A 5.0 + 0.3 39.3 + 1.3 21.6 + 0.8 34.1 + 0.7 
W51A W72A 5.4 + 0.5 38.4 + 1.6 22.3 + 0.2 33.9 + 0.8 
W61A W72A 5.5 + 0.6 37.0 + 1.9 23.5 + 0.9 34.0 + 2.2 
W51A W61A 
W72A 
4.0 + 0.4 40.8 + 1.0 21.3 + 0.9 33.9 + 0.3 
Trp Ala mutations enhance the stability of the V-domain to proteolytic degradation 
We next compared the susceptibility of the mutants to proteolytic degradation by trypsin. 
Limited proteolytic digestion can be used to assess the folding rigidity and plasticity of proteins 
and protein complexes 474, 475.   A protein with a tightly packed protein fold and therefore little 
plasticity exposes fewer potential trypsin cleavage sites on its surface and thus shows slower 
proteolytic degradation compared to a protein with a loosely folded structure and a high degree 
of structural plasticity. Because the RAGE V-domain is folded in as a single domain, proteolytic 
susceptibility will correlate with structural plasticity. 
The RAGE V-domain has 15 potential trypsin cleavage sites and we monitored the time-
dependent degradation of the V-domains by trypsin by quantifying the disappearance of the full-
length protein band by SDS-PAGE. The kinetics of the proteolytic degradation process is 
complex because of the sequential cleavage at multiple sites within the protein sequence and 
because cleavage of short peptide sequences close to the N-or C-terminus may not be detected by 
SDS-PAGE. Our experiment therefore monitored the cleavage of the V-domain in one or 
multiple position(s) that generated fragments, which could be clearly distinguished from the full-
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length V-domain by SDS-PAGE. The representation of the trypsin digestion of the wild type, 
W72A and W51AW61AW72A is shown in Figure 5.1  
 
 
 
 
 
 
 
 
 
 
Figure 5.1. Representation of trypsin digestion of the V domain mutants. 
1) Ladder 2) 0 min 3) 10 min 4) 20 min 5) 30 min 6) 45 min 7) 60 min 8) 120 min 9) 240 min of 
trypsin digestion.  
The trypsin digestion of the V-domain mutants showed distinct kinetics (Figure 5.2). The 
wild type V-domain and the mutant domains with two or all three Trp residues substitute by Ala 
showed degradation kinetics that could be approximated with a first order reaction kinetics.  
The wild type V-domain is readily degraded by trypsin with an estimated (t1/2 ~ 14.3 
min).  Interestingly, substitution of one or two Trp residues for Ala decreased the susceptibility 
to typsin proteolysis of the mutant V-domains.  Mutant domain with two TrpAla substitution 
showed similar domain stability with t1/2 ranging from about t1/2 ~18 to t1/2 ~20 min (Table 5.3). 
The triple Trp mutant in contrast showed the least resistance to trypsin degradation (t1/2 ~8 min), 
suggesting that the removal of all three Trp residues greatly destabilized the domain.   
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The single Trp mutants showed more complex multi-phasic degradation kinetics. All 
three mutants appear to be more stable than the wild-type. Enhanced stability was particular 
evident for the Trp72Ala mutant compared to the wild type domain (t1/2 ~31 vs. t1/2 ~14 min). 
The Trp51Ala mutant showed pronounced biphasic proteolysis kinetics, possibly indicating the 
presence two alternate conformations with distinct proteolytic resistance.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2. The trypsin digestion kinetics of the V domain mutants.  
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Table 5.3. Trypsin digestion kinetics of the V domain mutants. 
Sample Rate 
Constant 
T ½  
(min) 
WT 0.048537 14.3 
W51A 0.03303 21.0 
W61A 0.030517 22.7 
W72A 0.022260 31.1 
W51A W61A 0.038225 18.1 
W51A W72A 0.038008 18.2 
W61A W72A 0.034400 20.2 
W51A W61A 
W72A 
0.088396 7.8 
The V-domain stability (measured as t1/2) could be correlated with the content of helical 
secondary structure.  We found that the individual mutants clustered into defined groups (Figure 
5.3). The least stable mutant was found to be the mutant with all three Trp residues replaced by 
alanine. This mutant was also the mutant with the least helical content (4%). The three mutants, 
in which two Trp had been replaced showed very similar domain stability among each other and 
at the same time a significant reduction in helicity by about 50 % compared to the wild-type V-
domain (5.0 to 5.5%  compared to 10%, p <0.03).  
The data suggest that residues Trp 61 and Trp 72 contribute relatively little to the folding 
of the V-domain, while at the same time increasing the plasticity of the domain. In contrast 
Trp51, clearly stabilizes the helical component of the folded domain and its mutation to alanine 
causes shift to a domain fold with increased beta-sheet content.   
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Figure 5.3. Correlation of V domain mutant stability to the α-helical content. 
 
To further rationalize these differences is was important to determine the relative 
positions of the three Trp residues within the folded V-domain. We used a classical 
spectroscopic approach exploiting the environmental sensitivity of Trp fluorescence.  
Steady state fluorescence data 
The fluorescence properties of the tryptophan indole side chain, such as quantum yield, 
emission spectrum and lifetime are sensitive to its environment 460. Trp emission maxima can 
vary from 308 nm to 353 nm in proteins and reflect the interaction of the local environment with 
the excited state of the indole ring system. In general, hydrophobic environments lead to 
emission maxima at shorter wavelength, whereas tryptophan residues in a more polar 
environment have emission maxima at longer wavelengths 476 477.  The observed florescence 
spectra are the sum of the combined contributions of each of the three Trp residue fluorescence 
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emission and fluorescence quenching. Substitution of individual Trp residues reduces the total 
number of Trp residues, thus eliminating the contribution of these residues to the observed 
overall fluorescence spectra. Comparative analysis of the wild-type V-domain and its single and 
double TrpAla substitution mutants allows identifying the relative position of each Trp residue 
within the folded V-domain.  
The steady state fluorescence emission spectra of wild-type V-domain at four different 
excitation wavelengths (280 nm, 285 nm, 290 nm, 295 nm) show a single peak and no shoulders 
or other features. The emission scans of the V domain mutants when excited at 295 nm are 
shown in Figure 5.4 and 5.5. The emission maxima (343 to 344 nm) did not shift with changing 
excitation wavelengths, showing that the contribution of two Phe and two Tyr residues to the 
overall fluorescence of the protein is negligible. The WT V-domain has an emission maximum 
of 344 nm with a half-peak width of 58 nm (Figure 5.4), which is about 8 nm blue shifted 
compared to free tryptophan in water. This indicates that the Trp residues are partially exposed to 
water molecules with long dipole relaxation times, typical for water molecules within the 
hydration shell of the protein.  
Similarly, the fluorescence spectra of all TrpAla mutants are very similar in terms of 
emission maxima (342-345 nm) and overall peak shape (Table 5.4). The wavelength of the 
emission maxima suggest that the three Trp residues of the RAGE V-domain are all in a 
polarizable environment, but it does not preclude the possibility that the tryptophan rings are 
partially or completely in the interior of the protein.  
Changes in fluorescence intensity under different salt conditions can be associated with 
changes in fluorescence quenching, either by solvent molecules or by internal Trp fluorescence 
quenching within the folded protein domain. Comparing the steady state fluorescence properties 
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under low salt (50 mM NaCl) and high salt (300 mM NaCl) did not reveal significant changes in 
spectral properties, but did show a reduction in reduced fluorescence intensities.  The single 
TrpAla mutants clearly show that Trp51 is distinct from Trp 61 and Trp72 (Figure 5.4 and 
5.5). Substitution of Trp51 by Ala leads to a much more pronounced decrease in fluorescence 
intensity than substitution of residues Trp61 or Trp72 and suggests that Trp51 is the least 
quenched Trp residue of the V-domain. This would agree with the hypothesis that Trp51 is 
located in the interior of the folded domain and shielded from solvent molecules 
The single Trp61Ala mutation has only a minor effect on the overall fluorescence 
intensity of the V-domain and this can be interpreted as either, demonstrating that Trp61 
fluorescence is largely quenched in the wild-type V-domain, or that the Trp61Ala mutation leads 
to an “unquenching” of the Trp 51 and/or Trp 72 fluorescence and thus compensates for the loss 
of fluorescence emission by Trp61. 
The double TrpAla mutants show lower than expected fluorescence intensities, which 
can be explained by increased fluorescence quenching, compared to the wild-type and the single-
Trp mutants. Increased quenching is probably the results of increased solvent exposure of the 
Trp residues, which in turn indicates increased plasticity of these domain mutants. Data for the 
double mutants suggest that Trp61 and Trp72 are both equally solvent exposed, whereas Trp51 is 
in a more solvent shielded, interior, position. 
Important additional information can be gained from changes in quantum yield upon 
mutation of individual residues. Quantum yields of Trp in proteins can vary between 0.4 to close 
to 0 and several mechanisms can contribute to the quenching of the excited state and lead to low 
quantum yields. Prominent mechanisms of Trp fluorescence quenching in proteins include 
radiation less energy transfer to other Trp or His residues, proton transfer from nearby protonated 
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acidic groups or electron transfer to disulfides, amides or the protein backbone. The exact 
contribution of each of these mechanisms to Trp fluorescence quenching is difficult to assess, but 
changes in quantum yield are clear indications of changes in the environment of the fluorophore. 
Figure 5.4 shows the fluorescence emission spectra for the WT V-domain and the 
mutants in which a single Trp residue has been replaced. The areas under the spectral curve are 
directly proportional to the fluorescence intensity and therefore representative of the quantum 
yields of the individual mutants.  
The Trp61Ala mutant has nearly the same fluorescence intensity as the wild type protein, 
despite the fact that the mutant has only two instead of three Trp residues. Thus, residue Trp61 
does not appear to contribute to the overall fluorescence of the WT V-domain.  In contrast, 
mutants Trp51Ala and Trp72Ala show a clearly reduced fluorescence intensity compared to the 
wild type. Removal of Trp51 does in fact reduce the fluorescence intensity by more than 50% 
compared to the WT V-domain, which indicates that Trp51 contributes disproportionately to the 
fluorescence of the WT V-domain. The double mutants, in which only one of three Trp residues 
is retained, lead to the same conclusion, showing about twice the fluorescence intensity for the 
mutant containing Trp51 compared to the two mutants lacking Trp51.  
As mentioned above, Trp fluorescence can be quenched by multiple mechanisms, one of 
which is radiation less resonance energy transfer to nearby Trp residues. The RAGE V-domain is 
small (100 residues) and contains three Trp residues in close proximity.  The Forster distances 
for Trp-Trp resonance energy transfer are between 4 to 16 nm and our analysis of the available 
NMR and X-ray structures of the RAGE V-domain showed that the three Trp residues are within 
a distances suitable for quenching. We interpret the observed changes in fluorescence intensities 
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for the V-domain mutants in two different ways: i) either Trp51 and Trp 72 quench each other 
effectively, or ii) they are only weakly fluorescent due to other quenching mechanisms. 
The Trp double mutants contain only a single Trp residue and allow us to further dissect 
the contribution of the individual residues to the overall fluorescence. As can be seen in Figure 
5.5, the mutant that contains only Trp 51 (mutants W61A W72A) shows strong fluorescence 
exceeding 50% of the intensity of the wild type domain with three Trp residues. In contrast, the 
mutants with either only Trp 61 (mutant W51A W72A) or Trp 72 (W51A, W61A) have nearly 
identical fluorescence intensities, but these are about 50% weaker than the fluorescence 
associated with Trp51. These results suggest the Trp 61 and Trp 72 are weak fluorophores for 
reasons other than Trp-Trp resonance energy transfer. 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.4. Fluorescence emission scans of the V-domain single mutants and the wild type. 
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Figure 5.5. Fluorescence emission scans of the V-domain double and triple mutants. 
 
Table 5.4. Fluorescence properties of the V-domain mutants and the V-domain S100B 
complexes. 
V-domain 
mutant 
max 
(Vdom) 
max 
(Vdom:S100B) 

(nm) 
Ratio FL Intensity  
(Vdom)/(Vdom:S100B) 
WT 344 336 8 1.45 
W51A 346 337 9 1.54 
W61A 345 334 11 1.11 
W72A 345 336 9 1.1 
W51A 
W61A 
346 337 9 0.99 
W51A 
W72A 
342 336 6 1.30 
W61A 
W72A 
346 332 14 2.14 
Fluorescence quenching 
To directly investigate the solvent exposure of the individual Trp residues we used 
collision quenching. In this technique, the excited state of the fluorophore is quenched without 
 206 
radiation by direct collision with a quencher. We used acrylamide, as a commonly used 
quencher. Acrylamide does not readily penetrate into compact folded proteins and consequently 
Trp residues on the protein surface are more susceptible to quenching then Trp residues in the 
protein interior 478 479.   
Stern-Volmer plots of the quench experiment are shown in Figure 5.6 and we used a modified 
Stern-Volmer equation to calculate fractional quenching for the individual mutants Figure 5.7. 
Fractional quenching identifies the fraction of fluorescence that is not quenched and thus can 
identify residues that are better shielded from quenching within a protein with two or more Trp 
residues. The interpretation of increased shielding from quenching suggests that these Trp 
residues are protected from the quencher and thus embedded in the protein’s interior. As can be 
seen from Figure 5.8 only a minor fraction (20-25%) of the total fluorescence is protected from 
quenching. In the single Trp mutants, the fluorescence originating in residue Trp61is more 
accessible to the quencher then residues Trp51 and Trp72. This is also seen in the double 
mutants. The quenchability of fluorescence associated with residues Trp51 and Trp72 appears to 
be similar in the single mutants, whereas in the double mutant residue Trp51 appears more 
sensitive to quenching than Trp72. However, it is important to consider that the absolute 
fluorescence intensity originating from Trp51 is higher than from the other two Trp residues, 
thus increased sensitivity to the quencher is not unexpected.  
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Figure 5.6. Acrylamide quenching of the V-domain mutants. 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.7. Percentage of quenched fluorescence in the V-domain mutants.  
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Figure 5.8. Percentage of unquenched fluorescence in the V-domain mutants.  
Fluorescence lifetime 
The lifetime of tryptophan fluorescence is two exponential in water at pH 7.0, it has 
lifetimes of 0.5 ns and 3.1ns 480. The reason for the short and long lifetime components is due to 
structural heterogeneity in the ground state of tryptophan which exposes the indole ring to 
different environments. However, the fluorescence decay of tryptophan in  proteins is multi 
exponential and the lifetimes vary widely from 0.014 ns to 9.8 ns  even though only one 
tryptophan is present 480.  
The tryptophan lifetime depends on several factors like the environment surrounding the 
tryptophan residues, its neighboring residues and also the multiple microstates of the protein can 
add to the heterogeneity of the Trp lifetimes 481. Thus by studying the Trp lifetimes of the 
different mutants we aim to understand the microenvironment surrounding these Trp and also 
their effect on overall structure of the protein.   
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 We measured Trp fluorescence life times for all mutants generated and the wild type 
under folded conditions and after complete denaturation in 6M guanidinium chloride. The 
deconvolution and interpretation of Trp fluorescence lifetimes with multiple Trp residues is 
complex. The time dependent emission intensity traces were analyzed by double-exponential 
fitting, which yielded the best fitting results among several fitting models evaluated. The double-
exponential models yielded a short lifetime component of 2.3 ns and a long life-time component 
of 6.4 ns in the wild type V-domain. The corresponding amplitudes were 0.33 and 0.67, 
respectively.  These numbers should be interpreted as fitting parameters that reflect the overall 
combined fluorescence properties of the fluorescent systems. To further simplify the 
interpretation of the fluorescence lifetime data we used the mean lifetime m for each system. 
The mean lifetime is the weighted average of the two life times and amplitudes obtained by 
double exponential fitting 481. Figure 5.9 shows the mean life times at 350 nm emission 
wavelength for the wild type V-domain and the six Trp mutants. It is clear that the double 
mutants, with only a single Trp residue, have short m values of around 3.5 ns. In contrast, the 
wild type domains with all three tryptophans have a significantly longer m of about 5 ns. For the 
single Trp mutants, which still have two Trp residues a dependence of m on site of Trp mutation 
is observed. The Trp51Ala mutant has a significantly shorter m, suggesting that Trp51 
contributed a long lived fluorescence component to the system in the wild type domain.  The 
Trp72Ala mutant had an increased m compared to the wild type, suggesting that Trp 72 
contributes predominately a short lived component to the wild type system. The lifetime of an 
excited state depends on many factors and changes in lifetimes reflect changes in the physico-
chemical environment of the fluorophore. However, it is often not possible to predict what 
specific changes in the environment of a fluorophore have caused changes in lifetime. This 
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complicates the interpretation of changes in lifetimes as the results of induced structural changes 
in a protein as results of mutations or protein-ligand interactions.  
We also measured the lifetimes of the domains after denaturation in 6M guanidinium 
chloride. This was done as a control to show by fluorescence life-time that the Trp residues in the 
individual domains are indeed in a particular folded state. Under denaturing conditions, the V-
domains assume a random coil conformation and the Trp residues are thus all exposed to an 
identical random environment. Correspondingly, fluorescence m values are nearly identical for 
all mutants and they were clearly shorter than the m observed in folded domains. Lifetimes of 1 
nsand 2 ~ 4 to 5 ns were obtained by double exponential fitting of the decay data. These 
values are very typical for GudCl denatured Trp containing proteins 481. 
 
 
 
 
 
 
 
 
 
 
Figure 5.9. Average Trp lifetime of the of the V-domain mutants. 
Red: Average m of V-domain mutants, Blue: Average m of the V-domain mutants in the 
presence of guanidinium chloride.  
Figure 5.10 and Table 5.5 also contains lifetimes for the V-domains in the presence of 
S100B. The binding of S100B will be discussed in more detail below. S100B does not contain a 
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Trp residue and the observed changes in Trp life-time are exclusively the results of the 
interaction between the V-domains and S100B. The interpretation of the observed changes in 
lifetime is not unambiguous. However, the measured lifetimes upon addition of S100B reflect 
changes in the physico-chemical environment of the Trp fluorophores. A decrease in lifetime 
does not necessarily mean that a residue becomes more solvent exposed, it can also be the result 
of repositioning of amino acid that can quench the excited state. Quenching of Trp fluorescence 
can occur by proton transfer from nearby acid groups, through electron acceptors such as 
protonated acidic groups, electron transfer to disulfides, amides or the protein backbone, or 
quenching by other side chains such as Trp (indole side chain), Phe (phenyl side chain), or His 
(imidazole side chain).  
 
 
 
 
 
 
 
 
 
 
Figure 5.10. Average Trp lifetime of the of the V-domain mutants on S100B binding. 
Red: Average m of V-domain mutants, Blue: Average m of the V-domain mutants in the 
presence of S100B.  
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Table 5.5. Average Trp lifetime of the V-domain mutants.  
Sample Kd (µM) 
WT 2.7±0.3 
W51A 0.5±0.06 
W61A 1.3±0.2 
W72A 0.6±0.03 
W51A W61A 0.5±0.07 
W51A W72A 0.5±0.04 
W61A W72A 0.4±0.01 
W51AW61A W72A 0.07±0.005 
S100B-peptide binding 
To further explore the possibility of multiple binding modes between RAGE and S100B, 
we have measured the binding between S100B and three short V-domain peptides that could be 
directly involved in the protein: protein interaction. These three peptides containTrp51, Trp61 
and Trp72 as central residues and we speculated that the Trp residues could function as 
hydrophobic anchor residues to S100B. The calcium loaded form of S100B exposes a 
hydrophobic surface area, which has previously shown to be involved in the binding of S100B 
binding peptides 492. 
We performed binding titrations between dansylated-V domain peptides and S100B. 
Table 5.6 summarizes calculated binding affinities. From these studies it became apparent that 
all three peptides did bind to S100B with comparable binding affinities and that the replacement 
of the Trp residues within the peptides by Ala did not abolish binding affinity. The binding 
interaction was also sensitive to the ionic strength of the solvent, suggesting a significant 
contribution of ionic and H-bond interactions to the binding.  
 
 
 213 
 
Table 5.6. Binding affinities of Trp containing RAGE peptides to S100B. 
Peptide Low Ionic 
Condition 
(20mM NaCl) 
High Ionic 
Condition 
(150mM NaCl) 
Ca-dependent  
Dns-51Trp 0.6 M 8 M Yes 
Dns-51Ala 1 M 5 M Yes 
Dns-61Trp 3 M 14 M Yes 
Dns-61Ala 4 M 25 M Yes 
Dns-72Trp 20 M 80 M Yes 
Dns-72Ala 20 M 65 M Yes 
Interaction of W61 and W72 RAGE peptides with S100B 
(The structures were solved by Jaime Jensen and Dr. Christopher Colbert. Only a brief 
summary is provided here) 
To investigate  the atomic  details of S100B ability to accommodate different modes of 
interaction with the RAGE V-domain we  determined the structure of the two RAGE derived 
peptides (W61 and W72) in complex with S100B and  compared the binding of these peptides  to 
the TRTK-12:S100B model (PDB: 3IQQ) 492. Figure 5.17 shows the structure of S100B in 
complex with all the three peptides. Interestingly, the W72 peptide binds in the same S100B 
surface groove as the TRTK-12 peptide, but runs in the opposite direction, which results in the 
Trp being buried in a completely different pocket on the surface of S100B.  Additionally, our 
S100B structures clearly extend beyond the edge of the binding groove where the TRTK12 
structure tucks its C-terminus into the binding groove of S100B 464   
Structures of S100B: peptide complexes determined by nuclear magnetic resonance- 
S100B:p53 C-terminal regulatory domain (1DT7; 486) and S100B: NDR kinase N-terminal 
regulatory domain (1PSB; 493 )- indicate selective binding of the partially-helical peptide to 
binding site 1 of the “three persistent binding sites” of the S100B dimer 487. Thus far, no data are 
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available for proteins, peptides, or small molecules that join all three binding sites, although 
development of inhibitors to target all sites is of particular interest 487.  
Structures of S100B:peptide complexes determined by nuclear magnetic resonance- 
S100B:p53 C-terminal regulatory domain (1DT7; 494) and S100B:NDR kinase N-terminal 
regulatory domain (1PSB;493)- indicate selective binding of the partially-helical peptide to 
binding site 1 of the “three persistent binding sites” of the S100B dimer 487. Small molecule 
inhibitors typically bind either sites 1, 2, or 3 of the S100B 487, 488 489-491. Thus far, no data are 
available for proteins, peptides, or small molecules that join all three binding sites, although 
development of inhibitors to target all sites is of particular interest. 
Unlike the S100B:W61 and S100B:TRTK12 complexes, the S100B:W72 structure 
exhibits a significant 4 residue extension beyond binding site 2. Notably, the orientation of the 
N- and C-termini varies between the S100B:W72 structure, and the S100B:W61 and 
S100B:TRTK12 structures. In the S100B:W72 model, the C-terminus extends beyond the hinge 
region, with the N-terminus positioned for extension beyond helix 3. Both the S100B:W61 and 
S100B:TRTK12 structures orient the C-termini near helix 3, with the N-termini extending near 
the hinge region.  
Although available S100B: peptide complexes solved by X-ray crystallography all 
incorporate a tryptophan-containing peptide, the S100B: peptide complexes display variability in 
the positioning of the tryptophan within the S100B hydrophobic groove, and in binding site 1, in 
particular. Each tryptophan indole occupies a different cavity within binding site 1. For the 
S100B:TRTK12 complex, the site occupied by Trp7 for TRTK12 is populated by Ala60 of W61 
464. Similarly, the hydrophobic pocket that positions Trp72 of the W72 peptide is equivalently 
occupied by Ile10 in the TRTK12 peptide, and Val63 in the W61 peptide. Compared to the 
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S100B:W61 and S100B:TRTK12 structures, the S100B:W72 Trp exhibits the greatest buried 
surface area at 164.4 Å2, compared to 65.9 Å2 and 141.2 Å2 for the Trp residues in the 
S100B:W61 and S100B:TRTK12 structures, respectively. The total ligand surface area is also 
the greatest for the W72 peptide, and the W72 peptide reveals the most interface polar contacts, 
with 5 hydrogen bonds and one bidentate salt bridge. Neither the W61 peptide nor the TRTK12 
peptide are stabilized by a salt bridge. Differences in peptide conformations are summarized in 
Table 5.7. 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.11. Surface representation of S100B with W61, W71 and TRTK-12 peptides. 
Pink: W61 RAGE peptide; Cyan: W72 RAGE peptide; Green: TRTK-12 peptide.  
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Table 5.7. Differences in peptide conformations of the W61, W71 and the TRTK-12 binding to 
S100B. 
Peptide Total ligand 
surface area 
(Å2) 
Ligand 
interface 
area (Å2) 
Ligand 
interface 
area (%) 
Interface 
polar 
contacts 
Buried 
surface 
area of Trp 
(Å2) 
W72 1565.3 537.8 34.4 5 H-bonds, 1 
salt bridge 
164.4 
W61 1334.3 485.6 36.4 3 H-bonds 65.9 
TRTK12 1219.3 586.7 48.1 6 H-bonds 141.2 
Conclusions 
This study was initiated to understand the role of tryptophan residues in stability and 
ligand binding of V-domain of RAGE. RAGE-ligand interactions are not well understood. The 
exact binding region on the V domain of RAGE has not been identified. Role of tryptophan 
residues in the stability of proteins has been well elucidated 461, 495, 496. Tryptophan residues have 
also been described to be enriched in binding hotspots for their stabilization of protein-protein 
interactions. However, the role of tryptophan residues has not been extensively studied in the 
context of V-domain even though it has three tryptophan residues in its 94 amino acid long 
sequence which is unique as tryptophan is one of the least abundant amino acids in proteins 462.  
We have utilized the fluorescence properties of tryptophan to probe the environment 
surrounding the tryptophan residues. The results from our fluorescence experiments indicate that 
the positions of the three tryptophan residues in the V-domain  are in agreement with known 
structures of tryptophan (PDB ID: 2L7U, 3CJJ, 3S58, 3S59, 3O3U, 2E5E, 2M1K, 4LP4, 4LP5, 
4OI7, 4OI8, 2MJW, 4OF5, 4OFV, 4P2Y, 2MOV) 455 197, 456, 497-500. The position of Trp51 is on 
the interior of the protein and Trp61is on the exterior, but the position of Trp72 is ambiguous 
indicating that this residue can shuttle between the interior and the exterior regions of the protein. 
We expect RAGE to have a certain degree of flexibility that enables it to bind to several different 
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ligands. The flexibility of Trp72 adds to the plasticity of the V-domain. Our CD data show that 
the Trp residues are not required for folding of the V-domain and that the absence or presence of 
Trp residues has only a limited effect on the overall secondary structure of the V-domain. This 
finding , indicate that the Trp residues are not critically involved in the folding process of the 
domain itself, nor are they required to maintain the overall fold. On the other hand, about one 
third of the V-domain residues are in an unordered conformation, indicating a high degree of 
plasticity in the structure. 
Our fluorescence emission scans suggest that the Trp51 is the strongest fluorophor 
followed by Trp72 and Trp61. From the fluorescence lifetime results of the single mutants we 
could conclude that the Trp61 contributed a long lived fluorescence component to the system in 
the wild type domain.  The Trp72Ala mutant had an increased m compared to the wild type, 
suggesting that Trp 72 contributes predominately a short lived component to the wild type 
system. The measured lifetimes upon addition of S100B reflect changes in the physico-chemical 
environment of the Trp fluorophores.  
Thermofluor data provide insights in the function of individual Trp residues for domain 
stability and show that Trp51 stabilizes the RAGE V-domain, whereas Trp61 has a limited 
contribution to domain stability and Trp72 appears to destabilize the domain. Our fluorescence 
polarization results indicate tighter binding of the S100B to the Trp mutants. This suggests that 
RAGE V-domain mutants are able to refold to effect S100B binding and RAGE being a 
multiligand receptor capable of binding many different protein ligands and structural changes in 
the V-domain are probably necessary to bind different ligands. Our S100B-Trp containing 
RAGE peptide structures indicate that S100B can accommodate different modes of interaction of 
the RAGE V-domain.  
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The results described in this study improve our understanding about the V domain of 
RAGE and its domain stability. Understanding the structural basis behind RAGE: S100B 
interaction would assist in the discovery of new and efficient RAGE inhibitors.  
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CHAPTER 6. SUMMARY AND FUTURE DIRECTIONS 
This thesis provides novel insights into the understanding of the RAGE-ligand 
interactions; more specifically the interaction RAGE with AGEs and S100B has been elucidated.  
AGEs are highly heterogeneous in nature and multiple glycation reagents lead to the 
formation of diverse and distinct AGEs. AGE modifications are not equally significant from a 
patho-physiological stand point. Only certain glycation reactions yield AGE compounds which 
are toxic (glycotoxins) while the others are benign 118, 220, 501, 502. AGEs derived under a wide 
variety of conditions have been used by various researchers which have not been characterized 
(reviewed in 118, 220 ) hence; it is very difficult to compare results as the nature of modification 
responsible for their toxicity has not been elucidated. To obtain further insights into the process 
of glycation and to co-relate the glycation induced changes to activity we prepared a panel of 
AGEs by using different glycation reagents under near physiological conditions by using serum 
albumin as the model protein. Our biochemical and biophysical characterization of the AGEs 
reveal that each of the glycation reagents modified the protein differently.  The chemical 
reactivity and concentration of the glycation reagent determined the extent of side chain 
modification. For example, ribose and the aldehydic intermediates such as glycolaldehyde or 
methylglyoxal were more potent glycation reagent when compared to glucose. Fluorescence 
spectroscopic analysis also shows the formation of unique AGE compounds with distinct 
fluorescence properties. These results suggest the possibility of using spectroscopic analysis for 
the characterization of the AGE compounds. Spectroscopic analysis has been previously used to 
estimate the levels of glycated albumin 162, 503. Differences were also observed in the thermal 
stability and secondary structure of the glycated albumin and were dependent on the glycation 
reagent used. However, we observe that even high levels of glycation did not unfold the protein 
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completely but lead to heterogeneous population of molten globulin like conformations.  
Glycation also induced protein multimerization with ribose having the most significant effect and 
no aggregation was observed. The fact that BSA remains soluble even in a highly glycated state 
may not be a general feature of glycation. Few reports in the literature suggest that high levels of 
glycation induced protein aggregation 223, 224. This suggests that the highly glycated AGE 
compounds can exist in a soluble form and bind to AGE signaling receptors such as RAGE and 
galectin-3 to trigger signaling. In vitro binding studies between AGE-BSA and RAGE or 
galectin-3 revealed that binding of most compounds to the AGE-receptors is weaker than our 
detection limit (Kd  ~ 50 µM). However, ribose glycated protein bound tightly to RAGE (2.0 
µM), as well as to galectin-3 (2.0 µM). Interestingly, the binding affinity (Kd) increased with the 
extent of glycation, which suggests a qualitative difference between the samples. It may be 
possible that higher glycation generates more potential binding sites for RAGE or galectin-3 in 
the protein surface, or that oligomerization clusters more binding epitopes. In both scenarios, 
avidity effectively increases the apparent macroscopic binding affinity.  
The biological effect of the AGE compounds was elucidated by determining the 
mitogenic effect of AGEs on cancer cell proliferation.  A melanoma cell line (WM115) over 
expressing RAGE was used to determine the mitogenic effect of the AGE compounds. The 
observed increase in cell proliferation could be correlated with the extent of lysine residue 
modification, β-sheet content and oligomerization state of the glycated protein. However, other 
factors, most probably the chemical structure of the formed AGE modifications on the protein 
surface are important too. It is conceivable that RAGE or galectin-3 receptors form larger 
clusters on the cell surface, thus effectively increasing binding affinity by avidity. In fact, RAGE 
has been shown to form dimers in the plasma membrane 225. Alternatively, RAGE or galectin-3 
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may associate with additional co-receptors on the cell surface, which could increase binding 
affinity for glycated proteins. 
Building on these results we then determined the role of AGE-RAGE interaction in 
pancreatic cancer cell proliferation and migration. Recent studies have shown that there is an 
upregulation of RAGE significantly during PDAC progression and could be a potential 
therapeutic target 237. It has been reported that on interaction with its ligands such as S100 
proteins and HMGB1, RAGE can trigger cell survival and proliferation 235, 236, 239, 240, 311. 
However, the role of AGE compounds has not been described in pancreatic cancer. We 
hypothesized that AGE-RAGE interaction can trigger pro-inflammatory cellular signaling which 
leads to cancer cell proliferation. Two pancreatic cancer cell lines with high RAGE expression; 
PANC-1 and MIA PaCa-2 were selected to understand the role of AGE compounds. Our results 
show the AGE-RAGE interaction triggered inflammation in the pancreatic cancer cells by 
inducing ROS production and eventually leading to cellular proliferation. To obtain a better 
understanding of the role of glycation induced oligomers in pancreatic cell proliferation, the 
isolated Rib-vH BSA oligomers were used to treat the PANC-1 and MIA PaCa-2 cells. An 
increase in cell proliferation was observed in both the cell lines when the cells were treated with 
the oligomers. This emphasizes the importance of glycation induced protein cross linking of the 
Rib-vH BSA for its mitogenic effects in pancreatic cancer cells. Treatment with anti-RAGE 
antibody inhibited the AGE induced cellular proliferation emphasizing the role for anti-RAGE 
treatment strategies in combinational anti-pancreatic cancer therapies. Interestingly, we observe 
diverse intracellular signaling in both the cell lines. The upregulation of NF-κB was observed 
only in the PANC-1 cells and not in the MIA PaCa-2 cells. However, the intracellular signaling 
pathways including the activation of kinases could not be elucidated and is a matter of future 
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investigation by the lab. Building on the in-vitro data, the in-vivo efficacy of anti-RAGE 
antibodies in tumor xenograft mice models can be determined in the near future. I also propose 
the identification of the chemical nature of the AGE induced cross-linkages which lead to the 
cellular effects and finally to identify these AGE-cross linkages in human pancreatic cancer 
tissue arrays by immunofluorescence in the future.     
To further elucidate the pro-inflammatory role of the AGEs, the role of AGEs in 
macrophage activation and pro-inflammatory cytokine release was determined in the 
macrophage cell line; RAW 264.7 cells. The cellular interaction of AGEs is believed to induce 
several biological responses, which are responsible for the development of various pro-
inflammatory diabetic vascular complications 313. Several recent findings report a substantial 
increase in tissue macrophages as a common feature in diabetic complications including 
nephropathy, atherosclerosis, neuropathy and retinopathy 356-359. Recent findings have helped to 
provide an understanding of the potential importance of macrophages in promoting these 
complications 360. The AGE compounds can also trigger pro-inflammatory cytokine release, the 
methyl glyoxal modified human serum albumin has been reported to upregulate TNF-α and IL-
1β mRNA levels 317. AGE compounds such as heavily modified glycolaldehyde-derived AGE-
LDL induced macrophage foam cell formation contributing to the pathogenesis of 
atherosclerosis 318.  Taken together, all these reports indicate a definitive role of AGE 
compounds in macrophage activation and cytokine release. However, there are gaps in our 
understanding of the role of AGE compounds mediated cellular effects in macrophages. The 
uptake and intra-cellular internalization of AGE compounds is not fully understood. The role of 
AGE-RAGE interaction in macrophage activation has not been described. This study was 
initiated to fill these gaps in our understanding of the role of AGEs in macrophage activation. 
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We hypothesized that AGE-RAGE interaction triggers cellular signaling leading macrophage 
activation and pro-inflammatory cytokine release.      
The uptake of the AGE compounds by macrophages was determined by fluorescence 
based uptake assay. A rapid uptake of the Rib-vH BSA was observed and the Rib-vH BSA 
internalized into the lysosomes after an hour of incubation. We tested the role of AGE receptors 
RAGE, galectin-3 and SR-A in AGE uptake however, the receptor responsible for Rib-vH BSA 
uptake could not be established by knockdown studies such as the SR-A knockdown or by using 
specific receptor inhibitors to inhibit the binding of AGE to RAGE and galectin-3 and requires 
further investigation. AGE treatment lead to the increase in pro-inflammatory gene expression, 
ROS production and NF-κB upregulation indicating that the Rib-vH BSA internalization led to 
the activation of the macrophages and polarized them into “M1-like” inflammatory 
macrophages. The role of RAGE in AGE mediated cellular effects could not elucidated and our 
results suggest a RAGE independent pathway for the AGE activity. Our results for the first time 
indicate the role of TLRs in certain AGE mediated cellular effects in the macrophages. These 
results provide a novel understanding of the role of AGE mediated macrophage activation and 
also emphasize the importance of targeting the AGE compounds to prevent the inflammation in 
diabetic complications. However, further studies are required to understand the AGE-receptor 
interactions leading to the AGE induced cellular effects which include the identification of the 
receptor responsible for the AGE mediated macrophage activation.   
Finally, the structural basis behind the RAGE-S100B interaction was determined. RAGE 
is an immunoglobulin type cell surface receptor sensing damage associated molecular patterns 
(DAMPs) in stressed and damaged tissues 21, 22. Despite the recognition of RAGE as a disease 
relevant receptor protein and as a potential pharmacological target, fundamental mechanistic 
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questions regarding ligand recognition and induction of ligand specific signaling by RAGE 
remain unanswered. In particular, it remains unknown how RAGE can on the one side recognize 
structurally unrelated ligands, such as S100 proteins, AGE compounds and amyloid beta peptide, 
and on the other side demonstrate exquisite ligand specificity. RAGE cannot only distinguish 
between individual members of the S100 protein family 448, but also activate distinct cellular 
signaling pathways as a function of ligand concentration. S100B is an alarmin detected in wide 
range of clinical conditions including inflammatory and neurodegenerative diseases  198, 504 and is 
also a well-established prognostic marker for melanoma 505. RAGE-S100B interaction has been 
reported to trigger inflammatory responses including the generation of oxidative stress and the 
upregulation of NF-κB in monocytes 33and human peripheral blood mononuclear cells 506. 
RAGE-S100B interaction can also trigger the release of pro-inflammatory cytokine and 
chemokine release 507. In order to develop more robust inhibitors to prevent RAGE-S100B 
interaction it is important to understand the structural basis behind the RAGE-S100B interaction. 
We hypothesize that the Trp residues in the V-domain of RAGE are necessary for ligand stability 
and S100B binding. It has been reported that the Trp residues are enriched in the binding 
hotspots of protein interfaces than any other amino acid indicating that Trp plays an important 
role in the stability of protein complexes 462. Trp is the largest of the naturally occurring amino 
acids, which has an indole ring that accounts for its hydrophobicity. Trp is fluorescent with high 
a quantum yield and more importantly its fluorescence properties like emission, quantum yield 
and quenching depends on its position in the protein and its surrounding environment, which 
makes it a good probe of the protein conformation 460, 461. Trp is the least abundant amino acid in 
proteins 462. However, the V-domain contains three Trp residues and these residues occur within 
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a stretch of 21 amino acids (Trp51, Trp61 and Trp72). These residues could function as 
hydrophobic anchor residues for the binding of S100B and other S100 proteins.  
Our fluorescence data show that the position of Trp51 is on the interior of the protein and 
Trp61is on the exterior, but the position of Trp72 is ambiguous indicating that this residue can 
shuttle between the interior and the exterior regions of the protein. These results are in agreement 
with known structures of the V-domain (PDB ID: 2L7U, 3CJJ, 3S58, 3S59, 3O3U, 2E5E, 
2M1K, 4LP4, 4LP5, 4OI7, 4OI8, 2MJW, 4OF5, 4OFV, 4P2Y, 2MOV) 455 197, 456, 497-500 508, 509. 
We expect RAGE to have a certain degree of flexibility that enables it to bind to several different 
ligands and the flexibility of Trp72 could add to the plasticity of the V-domain. Thermofluor data 
provide insights in the function of individual Trp residues for domain stability and show that 
Trp72 appears to destabilize the domain suggesting its role in plasticity. The different NMR and 
crystal structures also show that the region containing the W72 can adopt multiple confirmations, 
few of the structures report a short helix (PDB ID: 3O3U, 2E5E, 2M1K, 4LP4, 4LP5, 4OI7, 
4OI8, 2MOV)455, 456, 498-500 and others report random coils (PDB ID: 2L7U, 3CJJ, 2MJW, 4OF5, 
4OFV, 4P2Y) 197, 497, 508, 509. 
Interestingly, our fluorescence polarization results indicate tighter binding of the S100B 
to the Trp mutants than the wild type and the tightest binding was observed with the triple 
mutant. We suspect this mean that the RAGE V-domain mutants are able to refold owing to the 
smaller alanine side chains allowing them to more easily adopt a confirmation that would be 
complimentary to S100B hydrophobic groove and RAGE being a multiligand receptor capable of 
binding many different protein ligands and structural changes in the V-domain are probably 
necessary to bind different ligands. However, the presence of additional sites on the V-domain 
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that might further stabilize or even provide alternate binding sequences to interact with S100B 
cannot be ruled out.     
To obtain further insights into the role of Trp residues in S100B binding we studied the 
binding of Trp containing RAGE peptides to S100B. The mutation of the W51, 61 and 72 to 
alanine did not affect their binding to S100B. The W72 peptide has the least binding affinity 
when compared to the other two peptides. To investigate the atomic details of S100B ability to 
accommodate different modes of interaction with the RAGE V-domain we determined the 
structure of the two RAGE derived peptides (W61 and W72) in complex with S100B and 
compared the binding of these peptides to the TRTK-12:S100B model (PDB: 3IQQ) 492.  The 
presence of either the W61 or the W72 peptides did not alter the structure of S100B.  
Interestingly, the W72 peptide binds in the same S100B surface groove as the TRTK-12 peptide 
and the W61, but runs in the opposite direction, which results in the Trp being buried in a 
completely different pocket on the surface of S100B as opposed to the W61 where the Trp is 
solvent exposed partially 464 . This provides an interesting model whereby the structural stability 
of S100B may force flexible regions, such as those found on the RAGE V-domain, to adopt 
conformations that favor the interaction in this hydrophobic groove. These results provide novel 
understanding of the structural basis for RAGE:S100B interaction. However, to fully understand 
the RAGE:S100B interaction and to determine how different ligands mediate RAGE signaling 
further structural and biophysical investigation are necessary. 
Taken together, my thesis provides a better understanding of RAGE-ligand interactions 
and would assist in the discovery of new and efficient RAGE inhibitors in the near future.  
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